WE’VE COME SINCE MENDEL - AANEM

1

1

WE’VE COMEA LONG WAY

SINCE MENDELGene replacement therapy: A genetic evolution

See how genetic research has progressed from Mendel’s

work with pea plants to notable advancements in

medicine. Today, gene replacement therapy (GRT) is a

therapeutic approach that is being investigated for its

potential to treat monogenic diseases at their source.1,2

©2018 AveXis, Inc. All Rights Reserved. US-UNB-18-0057 10/18

References: 1. Gayon J. From Mendel to epigenetics: history of genetics. C R Biol. 2016;339(7-8):225-230. 2. Naldini L. Gene therapy returns to centre stage. Nature. 2015;526(7573):351-360.

Visit us at Booth #415 and atGRTzone.com/AANEM2018 to learn more

1

WELCOME TO THE AANEM ANNUAL MEETING

ERIC J. SORENSON, MD, AANEM PRESIDENT

Greetings from the Washington, DC area! I’m glad you’ve chosen to attend the premier event for health care professionals in NM and EDX medicine. Get ready for an outstanding meeting with plenty of sessions and workshops designed to enhance your medical knowledge and provide insight into the latest developments in our field. Ultimately, our goal with the 2018 AANEM Annual Meeting is to provide each of you with further expertise to help you better serve patients.

For our plenary sessions, I’ve invited speakers who are worldwide leaders in the development of novel NM therapeutics. Each speaker will share their expertise on how to translate these treatment approaches to NM diseases. Because of our fantastic meeting location, we were able to line up colleagues in regulatory roles who can address questions about regulatory processes enacted by the US Food and Drug Administration that impact NM and EDX medicine.

One of the things I enjoy most about the AANEM Annual Meeting is the opportunity to see the outstanding research submitted by our colleagues. I encourage all of you to walk around the Poster Hall, view the abstracts, and discuss the research findings with the poster presenters. And while you’re there, take a moment to congratulate AANEM’s 2018 recipients of the Golseth Young Investigator Award, Best Abstract Award, Technologist Member Recognition Award, President’s Research Initiative Award, and Residency and Fellowship Member Award.

It’s safe to say most, if not all, of you are here for the unparalleled educational content you’ll be receiving. But, I know many of you also come to this meeting for the collegiality and networking. It’s an important part of why I attend as well. To help facilitate that, we have built time into the schedule to allow for those important connections to occur. We have various social activities planned throughout the next several days. For instance, I encourage you to check out the new AANEM Lounge area and the Speed Networking event on Wednesday from 3:00 – 3:45 pm.

For those who haven’t yet joined the AANEM, I encourage you to become a member of this wonderful community of neurologists, physiatrists, technologists, researchers and collaborators dedicated to improving the lives of patients with NM diseases. Stop by the AANEM Booth to learn more about the benefits of AANEM membership.

I hope you have a wonderful time here in DC!

2

Table of ContentsNeed to Know InfoAnnual Meeting HoursSocial Event HoursCME InformationCEUs & CNCT Checkpoint InformationEnjoy Your StayLower Atrium Level MapBallroom Level MapNational Harbor MapSilent AuctionAnnual Meeting Collection & Workshop E-BundlePrecision Medicine PlenariesSchedule DescriptionsWednesday ScheduleThursday ScheduleFriday ScheduleSaturday Schedule2018 AANEM Achievement Awards2018 Abstract Award WinnersPoster Hall DiagramExhibitorsExhibit Hall DiagramAANEM Corporate SupportersAANEM Foundation ContributorsAANEM Advocacy ContributorsAcknowledgments & Appreciation2017-2018 Board of DirectorsInitialismsMeeting Objectives & PoliciesSpeaker Index

3456789

10111213

14151627364552546061697274757677787981

3

Need to Know InfoDownload Our Meeting App!Everything you need to know about the meeting (schedule, rooms, speakers, etc.) can be found on the AANEM Meeting App. The app is the most current source of information about the 2018 AANEM Annual Meeting. Any meeting changes and important messages will be sent via the app throughout the meeting. Use the app to customize your meeting by selecting the sessions and workshops you’re attending. Share photos of the meeting through the app as well! Sponsored by Biogen.

Just search for the AANEM 2018 Annual Meeting App in your app store and download it to your device!

Get Free WiFi!WiFi is FREE throughout the 2018 AANEM Annual Meeting event space compliments of Grifols USA, LLC. Use the user name AANEM and password Grifols2018.

Please note: Your WiFi connection in the Gaylord National Resort and Convention Center will be different outside of AANEM meeting spaces. You will receive further WiFi details upon hotel check-in. Claim Meeting CME, CEUs, and CNCT Checkpoints!Everything you need to know about claiming your CME, CEUs, and CNCT Checkpoints for the meeting can be found on pages 6 and 7.

View our Workshop Board!All workshops with open slots will be displayed on the Workshop Board near the Registration Booth. If you find a workshop you’d like to attend, please stop by the Registration Booth to sign up.

Residents/Fellows – Use Rush Tickets and Save!Workshops with openings are offered to residents and fellows at NO CHARGE. Residents and fellows can determine which workshops are available at the Registration Booth. Rush tickets will be handed out 15 minutes before the start of each workshop.

Share Your Experience on Social Media!Use social media? Have you liked and followed AANEM yet? Visit our pages and be sure to share your meeting updates and photos on your own social media pages throughout the week.

Facebook.com/AANEMorg | Twitter.com/AANEMorgUse this hashtag - #2018AANEMinDC

4

Registration Booth | Prince George FoyerVisit the Registration Booth to register for the meeting and add workshops to your registration.

AANEM Booth | Lower AtriumStop by the AANEM Booth and the staff there will be happy to assist you with any questions related to membership, ABEM certification, lab accreditation, coding, and more!

Speaker Ready Room | Potomac Registration DeskFaculty and Speakers: before delivering your presentations, please visit the Speaker Ready Room to make changes to your presentation and/or get it loaded appropriately. AV staff will be on hand to transfer your presentation to the appropriate session room. Please load your presentation at least 1 hour prior to your session start time to allow enough time for AV staff to transfer it to the proper location. If you would prefer to bring your presentation to the session room on your own flash drive, you may do so.

Exhibit Hall | Prince George DThe Exhibit Hall is a great place to meet and network with industry professionals including representatives from equipment, technology, and pharmaceutical companies.

Product Store | Prince George FoyerThe AANEM Product Store offers products that meet ABPN and ABPMR MOC requirements for both performance improvement and self-assessment CME. New this year, we will only have samples of certain products onsite and we will assist you with online ordering of the products you would like to purchase. More information is available at www.aanem.org/sale.

Silent Auction | Prince George FoyerVisit the Silent Auction to benefit the AANEM Foundation. All money raised will be used by the Foundation to fund scientific research on NM diseases.

Poster Hall | Prince George ETake time to stroll through the Poster Hall to view the research submitted for the annual meeting. Poster authors will be available on Thursday and Friday. See details to the right.

Annual Meeting Hours

TuesdayRegistration Booth: 6:00 – 9:00 pmAANEM Booth: 6:00 - 9:00 pmSpeaker Ready Room: 6:00 – 8:00 pm

WednesdayRegistration Booth: 6:30 am – 6:00 pm AANEM Booth: 7:00 am - 5:00 pmSpeaker Ready Room: 7:00 am – 4:00 pmExhibit Hall: 5:30 – 7:00 pm Product Store: 8:00 am – 6:00 pmSilent Auction: 8:00 am – 6:00 pmPoster Hall: 9:00 am – 7:00 pm

ThursdayRegistration Booth: 7:00 am – 6:00 pm AANEM Booth: 8:00 am – 5:00 pmSpeaker Ready Room: 7:00 am – 4:00 pmExhibit Hall: 9:00 am – 4:00 pmProduct Store: 8:00 am – 6:00 pm Silent Auction: 8:00 am – 4:00 pm Poster Hall: 9:00 am – 9:00 pm

FridayRegistration Booth: 7:00 am – 4:00 pm AANEM Booth: 8:00 am – 5:00 pm Speaker Ready Room: 7:00 am – 4:00 pm Exhibit Hall: 9:00 am – 4:00 pmProduct Store: 8:00 am – 4:00 pm Silent Auction Pickup: 10:00 am – 4:00 pm Poster Hall: 9:00 am – 4:00 pm

SaturdayRegistration Booth: 7:00 – 10:00 amSpeaker Ready Room: 7:00 – 11:30 am

5

Social Event HoursCoffee Breaks | Various locations. See schedule.Enjoy free coffee and use break time to network and socialize with your colleagues.

Speed Networking | Next to Lounge on Potomac LevelBuild connections with peers, leaders, and other professionals in NM and EDX medicine by attending our speed networking event (space is limited). Don’t forget your business cards! Sponsored by Grifols USA, LLC.

President’s Reception | Prince George DThis is the official kickoff event of the meeting each year. Socialize with attendees and exhibitors while enjoying complimentary appetizers, wine, and refreshments. Sponsored by Biogen.

Abstract Poster Sessions | Prince George EStop by the Poster Hall after the Thursday and Friday plenary sessions to meet abstract authors and discuss their research.

Abstract Award Reception | Potomac FoyerEnjoy an evening celebrating research! Socialize with abstract authors while enjoying complimentary pasta and salad bar, wine, and refreshments. Golseth, Best Abstract, Technologist, and President’s Research award-winning authors will be available to discuss their research.

EMG Tonight | Potomac AEMG Tonight is an interactive, entertaining event meant to be a lighthearted look at EMG with lots of laughs. A variety of guests will share their wisdom on EMG-related topics. Join the fun and camaraderie! Drinks and sweet treats will be available. Sponsored by Natus Neuro.

AANEM Lounge | Outside of Potomac A and BLooking for a fun, laid-back place to relax and hang out with your colleagues? Visit the AANEM Lounge. This new social area was created to be a fun, comfortable, congregational space for meeting attendees. Inside you’ll find a charging station and a media wall featuring social media postings and meeting photos. Caricature artists and musicians will provide entertainment during some coffee breaks and the reception. Media wall sponsored by Grifols USA, LLC.

WednesdayCoffee Break: 9:30 – 10:30 amPotomac Foyer

Speed Networking: 3:00 – 3:45 pm

Coffee Break: 3:00 – 4:00 pmPotomac Foyer

President’s Reception: 5:30 – 7:00 pm

AANEM Lounge: 8:00 am – 5:30 pm

ThursdayCoffee Break: 9:30 – 10:00 amPrince George D

Abstract Poster Session I: 11:30 am – 12:30 pm | Posters: 1-105

Coffee Break: 3:00 – 4:00 pmPrince George D

Abstract Award Reception: 5:45 – 6:45 pm

EMG Tonight: 7:00 – 9:00 pm


FridayCoffee Break: 9:30 – 10:00 amPrince George DAbstract Poster Session II: 11:30 am – 12:30 pm | Posters: 106-207

Coffee Break: 3:00 – 4:00 pmPrince George D


SaturdayCoffee Break: 9:30 – 10:00 amPotomac Foyer


6

CME Information

CME CreditsYou may earn up to 22.5 CME credits by attending sessions at this meeting. Credits are listed in this program. Record your CME hours via www.aanem.org/cmeform or the meeting app after each session or do it all at once after the meeting before December 15.

Self-Assessment CMEPhysicians can earn up to 27 Self-Assessment (SA) CME at this meeting (these sessions are free for members and $50 per session for nonmembers).

Credit for this Maintenance of Certification (MOC) activity will only be awarded to those who attend the live session and receive a passing score of 70% on the post-test after 3 attempts. Good news - no pre-tests this year!

The following sessions are designated for Part II SA credit toward MOC. All 5 sessions are eligible for 9 SA CME. AANEM will report completion of each SA activity to ABPN and ABPMR. Physicians may only attend 1 SA session per day. Post-tests will appear on www.aanem.org/mtg-sa at the end of the session and must be completed by December 15, 2018.

Basics With the Experts – Wednesday, 8:00 am Demyelinating Neuropathies – Thursday, 1:30 pm Interactive Case Based Approach to Genetics and Neuropathology – Thursday, 1:30 pm Entrapment Neuropathies – Friday, 1:30 pm Emerging Therapies and Controversies – Friday, 1:30 pm

CME Recording Form Info For all hours of participation in general sessions, record your CME via the recording form (www.aanem.org/cmeform) or via the meeting app.

Credit for workshops will be automatically recorded for you by AANEM. You will be responsible for recording all other credit from the meeting on your own using the CME Recording Form.

In order to receive SA CME credit, registered attendees must complete a post-test with a 70% passing rate at www.aanem.org/mtg-sa.

The CME Recording Form may be submitted until December 15, 2018. Credit submitted after this date will incur a $25 late fee and will not be reported to ABPN or ABPMR.

7

CEUs & CNCT Checkpoint Information

CEU CreditsYou may earn up to 22.5 CEU credits by attending sessions at this meeting. Credits are listed in this program. Record your CEU hours via www.aanem.org/cmeform or the meeting app after each session or do it all at once after the meeting before December 15.

CNCT Checkpoints for TechnologistsYou can receive a total of 4 Checkpoint credits at this meeting (these sessions are free for members and $50 per session for nonmembers). One Checkpoint credit is given just for registering for the meeting! No action is required for this credit.

To receive Checkpoint credits for the sessions below, you must attend the live session and receive a passing score of 70% on the post-test after 3 attempts. Good news - no pre-tests this year! Post-tests will appear on www.aanem.org/mtg-checkpoints at the end of the session and must be completed by December 15, 2018.

Basics With the Experts – Wednesday, 8:00 amDemyelinating Neuropathies – Thursday, 1:30 pmEntrapment Neuropathies – Friday, 1:30 pm

CEU Recording Form InfoFor all hours of participation in general sessions, record your CEU via the recording form (www.aanem.org/cmeform) or via the meeting app.

Credit for workshops will be automatically recorded for you by AANEM. You will be responsible for recording all other credit from the meeting on your own using the CME Recording Form.

In order for technologists to receive Checkpoint credit, registered attendees must complete a post-test with a 70% passing rate must be completed at www.aanem.org/mtg-checkpoints.

The CEU Recording Form may be submitted until December 15, 2018. Credit submitted after this date will incur a $25 late fee.

© 2018 Alnylam Pharmaceuticals, Inc.

Visit www.alnylam.com to learn more

To those who say “impossible, impractical, unrealistic, ” we say:

CHALLENGE ACCEPTED

We are relentless in our pursuit of new treatments. Because patients shouldn’t have to wait for hope.

8

What are the highlights of the Gaylord National Resort and Convention Center?You will find top-notch amenities at this resort:• Only waterfront hotel in the DC area (located on

the Potomac River)• 7 restaurants, including a rooftop lounge• Indoor pool and whirlpool• 24-hour indoor fitness center• Run, walk, or cycle on the Woodrow Wilson

Bridge Pedestrian Path• Onsite shopping• Full-service spa• 19-story glass atrium with fountain shows in the

evening• Free bus transportation throughout National

Harbor, 11 am – 4 pm daily

What is included as part of the AANEM attendee room rate?• Unlimited local and domestic long-distance• Complimentary high-speed Internet access• Daily newspaper at elevator landings• Designated complimentary in-room beverages• Complimentary fitness center access• Coupon book with a valued savings of $100

What restaurants are available in this resort?There are 7 restaurants to choose from!• Old Hickory Steakhouse (Open for dinner.

Reservations required.)• Pienza Marketplace (Open for breakfast)• National Pastime Sports Bar and Grill (Open for

lunch and dinner)• Pose Rooftop Lounge• Belvedere Lobby Bar• The Cocoa Bean (Open for breakfast, lunch,

and dinner. Coffee house serving Starbucks beverages, baked goods, and gourmet sandwiches.)

• Harbor Marketplace

Is smoking allowed at the hotel?No. This hotel is smoke-free.

Outside of the AANEM Annual Meeting, what else can I do in the Washington, DC area?• MGM National Harbor• The Capital Wheel• Washington Monument• Thomas Jefferson Memorial• Potomac Riverboat Company• George Washington’s Mount Vernon

Visit Washington.org for more attractions.

Enjoy Your Stay

9

Lower Atrium Level

Registration Booth

AANEM Booth Silent Auction

Product Store Exhibit Hall

Poster Hall

D

E

PRINCE G

EORG

E’S EXH

IBITION

HA

LL

Thurs. & Fri. Coffee Breaks

10

Ballroom Level

Sessions

AANEM Lounge

Industry Forums

Wed. & Sat. Coffee Breaks

Potomac Ballroom

BD

AC

654321

56

4

32

1

98

7

DE

F IH

1112

10

G

11

WednesdayIndustry Forums

National Harbor

32

12

Silent AuctionStop by on Wednesday & Thursday!

Play the AANEM Challenge and Win a $100 Amazon Gift Card!

View all the donations and make bids on items you like!

Instructions• To make a bid, write down the number

found on your badge along with the dollar amount of your bid.

• Bids must be in by 4:00 pm on Thursday.• You need to check the Silent Auction lists to

see if you won.• Winners can pay for their items between

10:00 am and 4:00 pm on Friday at the Registration Booth.

All money raised from the Silent Auction goes to the AANEM Foundation for Research & Education to provide funds for scientific research on NM diseases.

How to Play:

• Visit these booths: BioCure RX, Biogen, Biohaven Pharmaceuticals, GeneDX, Grifols, and KabaFusion.

• Take a photo/selfie at each of these booths (you must visit all 6 booths to qualify for the drawing).

• Upload your 6 photos to the AANEM Challenge section of the meeting app.

Once you meet these requirements, you will be entered into a random drawing for a $100 Amazon gift card. One winner will be chosen Thursday evening and a second winner will be chosen Friday evening. Winners will be notified via email.

We’re looking forward to seeing your photos! Good luck!

13

Bring the Meeting Home!2018 Annual Meeting Collection Want to bring the 2018 AANEM Annual Meeting session presentations home with you? Miss a few sessions and need to catch up on what you missed? AANEM has a solution for you – the 2018 AANEM Annual Meeting Collection – a digital download of session presentations. The download will include many presentations and presenters’ commentary (as audio of most presentations will be recorded live).

Purchasers of the 2018 AANEM Annual Meeting Collection will receive CME/CEUs for sessions in which CME/CEU was offered. The link to the digital download will be available approximately 2 weeks after the meeting.

The 2018 Annual Meeting Collection does not contain “Ask the Expert” session presentations nor workshop materials.

Buy Now

$300(through October 13)

Price after the meeting:$450 (members)

$780 (nonmembers)

2018 Workshop E-BundleWant to capture the teaching points from the majority of workshops held at the 2018 AANEM Annual Meeting? Miss a workshop or two and want to find out what you missed? Then purchase the 2018 Workshop E-Bundle.

Purchasers of this bundle will receive handouts from the workshops that use handouts (40 or more) via a single, downloadable PDF. These handouts contain the teaching points.

Workshop CME/CEUs are only available for in-person attendance. Workshop CME/CEUs cannot be obtained by purchasing the 2018 Workshop E-Bundle.

Buy Now

$75(through October 13)

Price after the meeting:$100 (members)

$250 (nonmembers)

14

Wilson W. Bryan, MD

FDA Regulation of Cell Therapy

Steven D. Pearson, MD, MSc, FRCP

From Assessing Evidence to Determining a “Fair” Price: How Should the Value of New Treatments for NM Disorders be Evaluated?

Reiner Lecture

Craig M.McDonald, MD

Precision Medicine Therapeutics in

Duchenne Muscular Dystrophy: Dystrophin

Restoration and Exercise Mimetics

FRIDAY | 10:00 AM - 12:00 PM

SATURDAY | 10:00 AM - 12:00 PM

Precision Medicine Plenaries

A. Gordon Smith, MD

Orphan Drug Pricing – A View from the

Trenches

Timothy M. Miller, MD, PhD

RNA-targeted Mechanisms and

Therapeutics for ALS Olney Lecture

WEDNESDAY | 3:45 PM - 5:30 PM

THURSDAY | 10:00 AM - 12:00 PM

The following speakers will be sharing their expertise as it relates to the plenary theme: Precision Medicine in Neuromuscular and Musculoskeletal Medicine. “These individuals are worldwide leaders in the development of novel NM therapeutics and will explain how to translate this into clinical practice,” said Eric J. Sorenson, MD, AANEM President.

Matthew B. Harms, MD

ALS and Related NM Diseases in the

Precision Medicine Era Lambert Lecture

THURSDAY | 10:00 AM - 12:00 PM FRIDAY | 10:00 AM - 12:00 PM

15

Sessions are included with your AANEM Annual Meeting registration.

Your registration gives you access to a wide variety of educational sessions related to NM, MSK, and EDX medicine. We have a diverse group of meeting attendees each year whose learning needs are different. To cover the spectrum, we have sessions on the basics for those in the early stages of their career (or those who just need a refresher!) as well as advanced sessions for seasoned professionals. There is something for everyone! Each attendee can tailor their learning by choosing the offerings most applicable to their practice. Most sessions offer CME and CEUs.SE

SSIO

NS

WO

RKSH

OPS

SOC

IAL

EVEN

TSCustomize Your Experience

Social events are included with your AANEM Annual Meeting registration.

All registered attendees are invited to the meeting’s social events which include Speed Networking, President’s Reception, Exhibit Hall, Abstract Poster Sessions, Abstract Award Winners’ Reception, Coffee Breaks, and EMG Tonight. These events do not offer CME/CEUs. Registered guests are welcome at all social events (except Speed Networking).

Enhance your learning experience by adding workshops to your registration.

To customize your meeting experience, you may choose to add workshops to your registration. Workshops are designed for hands-on learning in small groups and are led by experts in the field. Workshops typically feature a specific subject with participants gathered around while the expert teaches a technique or concept. Almost all of our workshops offer CME and some offer CEUs. To keep general registration costs lower, workshops are not included with the general registration fee.

NOTE: Workshops are held throughout the day on Wednesday and Saturday. They have limited seating and require advance registration. Workshop locations are found on registered attendees’ tickets. All workshops are open to physicians. Technologists may attend workshops where CEUs are being offered. Workshops with openings will be noted on the Workshop Board near the Registration Booth. Residents and fellows, ask about free workshop tickets at the Registration Booth (see page 3 for details).

IND

UST

RYFO

RUM

S Industry Forums are included with your AANEM Annual Meeting registration.

Each Industry Forum is comprised of a 60-minute presentation on a topic related to a disease state, research findings, products, or services. Registered meeting attendees may attend Industry Forums free of charge and breakfast, lunch, and/or light appetizers will be provided by AANEM. Industry Forums have limited seating, so if you’d like to attend one or all of them, be sure to arrive early to secure a spot. Please note that Industry Forums are sponsored and not part of the official scientific program of AANEM. CME is not provided.

16Wednesday | October 10

Share Your AANEM Annual Meeting Experience on Social Media!

Use the Hashtag: #2018AANEMinDC

6:45 am - 8:00 am

IndustryForum

Industry ForumNational Harbor 2-3

Diagnosis Beyond the Symptoms: Bridging the Gap Between Neuropathy and Cardiomyopathy in hATTR Amyloidosis

Sponsored by: AKCEA Therapeutics

The aspects of hereditary transthyretin (hATTR) amyloidosis that set it apart from other peripheral and autonomic neuropathies also present a myriad of challenges for the neurologist. This industry forum will acknowledge those challenges and provide guidance on how to improve diagnosis and management of patients with hATTR amyloidosis, a multisystemic disease. Topics to be discussed include red-flag symptom clusters that should raise suspicion of hATTR amyloidosis, how to make a differential diagnosis, and the importance of multidisciplinary care and management of patients with this progressive and debilitating disease.

Target Audience: Neuromuscular specialists with an interest in peripheral neuropathy and/or autonomic neuropathy

Learning Objectives:• Identify red-flag symptoms that should lead to suspicion of hATTR amyloidosis• Use recommended diagnostic testing when hATTR amyloidosis is suspected• Consider multidisciplinary approaches and collaboration with other specialists when diagnosing and managing this multisystemic disease

This activity is sponsored by AKCEA Therapeutics and is not part of the official scientific program of AANEM.

Food will be provided by AANEM for session attendees. Seating is limited.

6:45 am: Registration

No CME/CEU 7:00 am: Presentation

8:00 am - 12:00 pm

Session

Basics With the ExpertsPotomac 3-4

(1) Explain the basic concepts underlying nerve conduction and approach to the study. (2) Conduct and interpret NCSs in the upper and lower extremities. (3) Use specialized studies including repetitive nerve stimulation, cranial nerve studies, blink reflex, short and prolonged exercise studies in channelopathies. (4) Apply needle EMG for the diagnosis of NM disorders. (5) Identify anomalous innervations and common pitfalls when performing nerve conduction studies. (6) Explain technical factors and important safety considerations affecting the study.

This is a Self-Assessment (SA) CME/CNCT Checkpoint session. To receive the SA CME/CNCT Checkpoint credit(s), a post-test must be completed with a 70% passing rate. Post-tests are free to members and $50 for nonmembers.

8:00 am: Introduction Mohammad K. Salajegheh, MD

8:10 am: Basics of Nerve Conduction and Approach to Study Mohammad K. Salajegheh, MD

8:40 am: Upper and Lower Extremity NCSs Kelly G. Gwathmey, MD

9:30 am: Break

10:30 am: Specialized Studies and Needle EMG Basics Aaron Izenberg, MD

11:20 am: Study Pitfalls and Troubleshooting Joseph M. Choi, MD

3.0 CME/CEU 11:50 am: Discussion and Q & A

17 Wednesday | October 10

8:00 am - 12:00 pm

Session

Hot Topics in NM LiteraturePotomac B

(1) Appraise several of the most impactful findings in NM literature over the past year. (2) Recognize the clinical value of these studies and their impact in NM patients including: clinical neurophysiology applications, myopathy evaluation, peripheral neuropathy workup, motor neuron disease understanding and NM junction disorders. (3) Discuss hot topics and groundbreaking work within these different areas of NM medicine. (4) Integrate this emerging knowledge within clinical practice.

8:00 am: Introduction Ruple S. Laughlin, MD

8:05 am: Hot Topics in Clinical Neurophysiology Ruple S. Laughlin, MD

8:35 am: Highlights in Peripheral Nerve Literature A. Gordon Smith, MD

9:05 am: Breakthroughs in Myopathy - Genetics and Autoimmune/Inflammatory Margherita Milone, MD, PhD

9:30 am: Break

10:30 am: Breakthroughs in Myopathy-Inflammatory Margherita Milone, MD, PhD

10:50 am: Highlights in Motor Neuron Disease Literature Katharine Nicholson, MD

11:20 am: The Latest in Neuromuscular Junction Disorders Zachary N. London, MD


8:00 am - 9:30 am

Session

Torsional and Altered NM Anatomy in EDXPotomac D

(1) Recognize changes in normal anatomy with limb torsion using MSK US. (2) Discuss strategies for assessing post-surgical/traumatic anatomy with high frequency US.

8:00 am: Introduction Elizabeth G. Forrest, MD

8:10 am: Systematic Approach to Altered Anatomy Jeffrey A. Strakowski, MD

8:45 am: Torsional Anatomic Changes With Internal Rotation Faye Y. Tan, MD


8:00 am - 12:00 pm

Session

EDX NM Challenging CasesPotomac 1-2

Participants will acquire skills to apply and refine the process of diagnostic formulation in NM medicine and clinical EMG and improve patient care. This symposium relies on attendees to provide challenging cases.

8:00 am: EDX NM Challenging Cases Bashar Katirji, MD

9:30 am: Break

3.0 CME/CEU10:30 am: EDX NM Challenging Cases Bashar Katirji, MD

8:00 am - 9:30 am

Workshop

W11A EMG and US Respiratory

(1) Perform phrenic NCSs. (2) Utilize techniques for safe needle EMG of the diaphragm (including US assisted). (3) Localize and perform needle EMG of chest wall muscles, which are helpful in the diagnosis of respiratory failure. (4) Utilize US for evaluating thickness and contractility of the diaphragm.

1.5 CME Andrea J. Boon, MD

8:00 am - 9:30 am

Workshop

W18A NM US

(1) Obtain images with transverse and longitudinal transducer positions. (2) Describe how to manipulate basic US instrumentation to include focal depth, Doppler flow, and transducer frequency. (3) Describe how muscle, nerve, and tendon appear with US. (4) Discuss the principle of anisotropy.

1.5 CME/CEU Michael S. Cartwright, MD


8:00 am - 9:30 am

Workshop

W20A Office-Based Injection Procedures

(1) Describe the principles underlying the safe and effective performance of office-based procedures. (2) Identify contraindications to select office-based injection procedures, identify appropriate patients, prepare and instruct them on what to expect during and after a procedure. (3) Describe and demonstrate commonly performed office-based injection procedures, including trigger-point injections, shoulder and knee injections, bursal injections, carpal tunnel injections, and botulinum toxin injections for migraine and cervical dystonia. (4) Become aware of the complications that may result from office-based injection procedures, how to minimize the chance of complications, and manage complications if they arise. (5) Describe how the use of US to guide needle placement can enhance accuracy and understand when it is most appropriately used as well as its limitations.

1.5 CME Ashish Khanna, MD

8:00 am - 9:30 am

Workshop

W27A Repetitive Nerve Stimulation

(1) Perform RNS to shoulder, upper arm, hand, and facial muscles. (2) Discuss sequential examination for detecting NM transmission defects, such as artifacts.

1.5 CME/CEU Vettaikorumakankav Vedanarayanan, MD, FRCPC

8:00 am - 12:00 pm

Workshop

W33A-B You Make the Call: An Interactive Approach to the Skills of EMG Waveform Recognition

(1) Identify the firing patterns of different types of EMG waveforms. (2) Identify the characteristics of a variety of normal and abnormal spontaneous waveforms. (3) Recognize normal and abnormal patterns of recruitment of MUAPs. (4) Recognize and understand the significance of the changes in morphology of MUAPs in diseases. Includes audience participation and videos of EMG waveforms.

3.5 CME Devon I. Rubin, MD

8:00 am - 9:30 am

Workshop

W37A Hands-On Practical Instrumentation

(1) Explain the implications of amplifiers and filters on the biologic waveform. (2) Describe interference in the work environment. (3) Determine how to eliminate stimulus artifact. (4) Discuss the implications of stimulation with both the cathode and anode.

1.5 CME/CEU Daniel Dumitru, MD, PhD

8:00 am - 9:30 am

Workshop

W46A Paraspinal Mapping and the Evaluation of Lumbosacral Plexopathy/Radiculopathy

(1) Establish a clinical and EDX approach to disorders affecting the lumbosacral roots and plexus. (2) Identify and distinguish findings between lumbar radiculopathies versus disorders affecting the lumbosacral plexus.

1.5 CME Andrew J. Haig, MD

8:00 am - 9:30 am

Workshop

W61A US Lower Extremity Nerves and Muscles

(1) Explain optimal transducer frequencies for imaging lower extremity nerves. (2) Identify the tibial nerve at the ankle and knee, the fibular nerve at the knee, and the sciatic and sural nerves using US. (3) Describe the branching patterns of tibial, fibular, and sural nerves in the lower extremities. (4) List expected findings of nerve entrapment as may be seen on US and findings in structures other than the nerve that may be significant.

1.5 CME/CEU Steven J. Shook, MD


8:00 am - 12:00 pm

Workshop

W62W1 NCS Workshop/NCS Case Studies

(1) Perform basic NCSs in the upper extremity andlower extremity. (2) Perform repetitive stimulation.(3) Describe common pitfalls of NCSs. (4) Identifythe most common mononeuropathies in the upperand lower extremities. (5) Work through a case andcome up with the correct diagnosis. [The session istaught by technologist and physician teams withemphasis on hands-on learning and actual casepresentations.]

Teresa Spiegelberg, CNCT, R.NCS.T, R.EEG.T, BS

James W. Teener, MD

3.5 CME/CEU Ann A. Little, MD

8:00 am - 9:30 am

Workshop

W65A Quantifying the NM Exam: QST and Dynamometers

(1) Identify the different types of sensory nervefibers and sensations they medicate. (2) Discussapplications of QST to the diagnosis of focal andgeneralized neuropathies.

1.5 CME/CEU P James B. Dyck, MD

8:00 am - 9:30 am

Workshop

W67A US-Guided Treatment of Peripheral Mononeuropathies

(1) Describe the technical aspects of US-guidedneedle placement. (2) Utilize US-guided proceduresto treat common peripheral neuropathies. (3)Demonstrate the ability to track a needle under real-time US guidance in order to quickly and accuratelytarget a structure through a hands-on approach.

1.5 CME/CEU John W. Norbury, MD

8:00 am - 9:30 am

Workshop

W76A NM US Basic Upper Extremity

(1) Describe basic principles of US imaging andequipment requirement. (2) Demonstrate scanningtechnique of the median and ulnar nerves, dynamictesting and measurements. (3) Discuss sonographicfindings of common entrapment neuropathies.

Elena Shanina, MD

1.5 CME/CEU Shawn Jorgensen, MD

8:00 am - 9:30 am

Workshop

W80A Tarsal Tunnel

(1) Identify the contents of the tarsal tunnel. (2)Distinguish the symptoms between plantar fasciitisand tarsal tunnel syndrome (TTS). (3) Compare thepotential areas of entrapment in TTS and interpretthe symptoms associated with it. (4) Contrast TTSfrom Baxter’s nerve entrapment and its influence onclinical management. (5) Formulate a strategy onneedle examination of key muscles in TTS andBaxter’s nerve entrapment.

1.5 CME/CEU William L. Doss, MD

8:00 am - 6:00 pm

Social Event

Silent AuctionPrefunction area outside Prince George D-E


9:00 am -7:00 pm

Social Event

Poster HallPrince George Exhibit Hall E

Take time to stroll through the Poster Hall to view research submitted for the annual meeting. Poster authors will be available at specified times to discuss their research.

8:00 am - 12:45 pm

Session

MGFA SessionPotomac C

The Myasthenia Gravis Foundation of America (MGFA) Medical/Scientific Advisory Board presents a scientific session highlighting research in the area of MG and myasthenic disorders. This session is the premier annual event around the U.S. and world related to the pathogenesis, immunology, diagnosis, and treatment of MG and related disorders of the NM junction. Included in the program will be leaders in MG research from the scientific and clinical areas.

8:00 am: Welcome Nancy Law

8:00 am: Welcome Edward Walsh, CPA

8:15 am: Keynote Anna R. Punga, MD, PhD


8:45 am: Isolating and Investigating Rare Autoantibody-Producing B Cells in MG Kevin O'Connor, MD

9:00 am: MuSK MG is Associated With an Imbalance in Tfh17 Cell Subsets Yingkai Li, MD

9:15 am: Highly Purified Staphylococcal Protein A Decreases Disease Activity in the Mouse Model of MG Linda L. Kusner, MD

9:30 am: Myasterix: A Phase 1B Clinical Trial of CV-MG01, Acetylcholine Receptor Mimetic Rudolf Mercelis, MD, PhD

9:45 am: Break (during the break, poster authors will stand by their posters for questions)

10:45 am: Thymectomy is Not Associated With Clinical Improvement in a Multi-Center Cohort of Patients With MuSK MG Katherine Clifford, BA

10:50 am: Validation of the Triple Timed Up-and-Go Test for Clinical Assessment in Lambert-Eaton Myasthenia Patients Shruti Raja, MD

10:55 am: Disease Burden and Treatment History in the MGFA Patient Registry Henry J. Kaminski, MD

11:00 am: Baseline Decrement in Patients With Mild MG Predicts Immunomodulation Treatment Alon Abraham, MD

11:05 am: Retrospective Analysis of Outcomes and Safety After Rituximab Use For MG in Patients ≥ 65 Years Old Christopher Doughty, MD

11:10 am: Imbalance of Two Main Circulating Dendritic Cell Subsets in Patients With MG Weibin Liu, MD, PhD

11:15 am: Results From the MGTX Extension Study of Thymectomy in MG Gil I. Wolfe, MD

11:30 am: Long-Term Effectiveness and Safety of Eculizumab in Generalized MG: Beyond MG-ADL and QMG Srikanth Muppidi, MD

11:45 am: Break

11:55 am: Overlap Syndrome of MG and Myositis is a Common Etiology of NM Weakness Associated With Immune Checkpoint Inhibitor Therapy in a Multicenter Retrospective Study of 15 Patients Amanda C. Guidon, MD

12:10 pm: The Risk of Serious Infections and Fractures in MG Charles D. Kassardjian, MD

No CME/CEU

12:25 pm: Subcutaneous Immunoglobulin in MG: a North American Open Label Study Mazen M. Dimachkie, MD

9:30 am - 10:30 am

Social Event

Caricature Artist in the AANEM LoungePotomac Foyer

Visit the AANEM Lounge to get a cartoon likeness created of yourself or just watch caricatures emerge of other meeting attendees.

9:30 am - 10:30 am

Social Event

Coffee BreakPotomac Foyer

Enjoy free coffee and use break time to network and socialize with your colleagues.

10:30 am - 12:00 pm

Session

Using Technology in Health Care: Sensors and Arm Support Systems for Upper Extremity FunctionPotomac D

(1) Describe examples of currently used upper extremity functional outcome measures in NM conditions. (2) Explain the fundamental technological basis for 3D motion reconstruction for upper extremity reachable workspace measure. (3) Summarize the application and utility of kinect-based reachable workspace as outcome measure in NM conditions. (4) Identify future applications of sensor and robotics technology in NM conditions.

10:30 am: Kinect Sensor for Upper Extremity Function Assessment in NM Conditions Jay J. Han, MD

11:00 am: Current and Future Technologies for Remote Assessment and Monitoring Jay J. Han, MD

1.5 CME/CEU

11:30 am: Upper Extremity Assessment and Development of Wearable Arms Supports for People With NM Disorders Mariska Janssen, PhD

10:30 am - 12:00 pm

Workshop

W02B Autonomic Testing Using EMG Equipment

(1) Perform the two quantitative tests for autonomic function, quantitative sudomotor axon reflex testing and heart rate variability studies. (2) Apply this technique to standard EDX practice where appropriate.

1.5 CME Jasvinder P. Chawla, MBBS, MD, MBA


10:30 am - 12:00 pm

Workshop

W06B Intraoperative Monitoring

Discuss the indications, utility, and limitations of somatosensory, motor, and brain stem evoked potentials EEG, EMG, and NCSs as monitors of brain stem, spinal cord, cranial nerve, and peripheral nerve function during posterior fossa, spinal, peripheral, and vascular surgery.

1.5 CME E. Matthew Hoffman, DO, PhD

10:30 am - 12:00 pm

Workshop

W16B MUAP Quantitation

(1) Discuss the basic composition of the motor unit potential. (2) Identify how the motor unit remodels in NM disorders are reflected in the motor unit potential. (3) Discuss the basics in acquisition and analysis of motor unit potentials.

1.5 CME Paul E. Barkhaus, MD

10:30 am - 12:00 pm

Workshop

W31B SFEMG Basic/Advanced

Acquire skills in SFEMG recordings using volitional and axonal microstimulation techniques, using a SFEMG needle. Must be familiar with the basic concepts of SFEMG techniques.

1.5 CME James M. Gilchrist, MD

10:30 am - 12:00 pm

Workshop

W45B Cervical Radiculopathy/Brachial Plexopathy

(1) Discuss the anatomy of the cervical roots and the brachial plexus. (2) Describe the role of the sensory NCS in the initial localization of axon loss processes to preganglionic versus ganglionic/postganglionic. (3) Illustrate the role of the sensory NCS in localizing focal lesions to specific regions of the brachial plexus (root, trunk, division, cord, terminal nerve). (4) Discuss the role of motor NCS in further localizing the lesion and in defining its severity. (5) Describe the role of the needle EMG in confirming the NCS findings and in defining the temporal features of the disorder (slowly progressive, rapidly progressive, acute, subacute, chronic). (6) Demonstrate this information using illustrative cases.

1.5 CME Ghazala R. Hayat, MD

10:30 am - 12:00 pm

Workshop

W53B Most Reliable Techniques for CTS EDX

(1) Perform the NCS techniques required for the CTS Sensory Index. (2) Design an EDX study for a patient with possible CTS. (3) Recite the most common pitfalls in EDX testing for CTS.

1.5 CME/CEU William S. Pease, MD

10:30 am - 12:00 pm

Workshop

W55B Myopathies: EDX Approach

(1) Discuss the role of EDX testing in myopathies. (2) Identify EDX findings in muscle disorders. (3) Determine muscle selection criteria for EDX in patients with suspected myopathy. (4) Use the EDX findings to generate a differential diagnosis.

1.5 CME Elie Naddaf, MD

10:30 am - 12:00 pm

Workshop

W57B US MSK Lower Extremity

(1) Explain which transducer frequencies are typically used for imaging lower extremity joints in adults. (2) Override a differential diagnosis of lower extremity joint pain. (3) Identify key landmarks in lower extremity joints using US. (4) Describe the pathologic changes of tendon rupture, tear, and inflammation.

1.5 CME/CEU Jeffrey A. Strakowski, MD

10:30 am - 12:00 pm

Workshop

W59B US Guidance for Neurotoxins

(1) Discuss the pros and cons of using in-plane and out-of-plane US views to guide needle placement. (2) Compare and contrast the use of EMG needle guidance, nerve stimulation, and US for identifying neurotoxin targets in patients. (3) Identify common targets for needle-guided injections using US. (4) List the technical challenges of using US for needle guidance.

1.5 CME Michael C. Munin, MD


10:30 am - 12:00 pm

Workshop

W60B US MSK Upper Extremity

(1) Explain which transducer frequencies are optimal for imaging upper extremity joints in adults. (2) Provide a differential diagnosis of joint pain in the upper extremity. (3) Identify key landmarks in upper extremity joints using US. (4) Describe the pathologic changes of tendon rupture, tear, and inflammation.

1.5 CME/CEU John W. Norbury, MD

10:30 am - 12:00 pm

Workshop

W68B You Make the Call-NM Edition

(1) Distinguish the typical nerve, muscle, or skin pathologic patterns of common NM disorders. (2) Demonstrate the clinical, electrophysiologic, and pathologic correlations in different disease processes. (3) Recognize the role of pathology in confirming the final diagnosis through presenting a series of interactive clinical vignettes where audience participation is encouraged.

1.5 CME/CEU Mohamed Kazamel, MD

10:30 am - 12:00 pm

Workshop

W72B Blink Reflex

(1) Discuss the principles and practice of eliciting the blink reflex with electric stimulation or by mechanical taps. (2) Identify the clinical values and limitations of the blink reflex as an EDX study.

1.5 CME/CEU Jun Kimura, MD

10:30 am - 12:00 pm

Workshop

W81B NM US Basic Lower Extremity

(1) Explain optimal transducer frequencies for imaging lower extremity nerves and appropriate choice of transducers. (2) Describe echogenicity and methods of demonstrating Morton’s neuroma in the foot. (3) Identify and trace the sciatic nerve from the ischiofemoral outlet into the posterior thigh. (4) Identify common muscles for EMG and chemodenervation and methods of safe approaches with needle. (5) Describe and demonstrate the branching patterns of sciatic, tibial, fibular, and sural nerves in the lower extremities. (6) List expected findings of nerve entrapment as may be seen on US and findings in structures other than nerve that may be significant.

Lester S. Duplechan, MD

1.5 CME/CEU Sarada Sakamuri, MD

12:00 pm - 1:30 pm

Social Event

Caricature Artist in the AANEM LoungePotomac Foyer

Visit the AANEM Lounge to get a cartoon likeness created of yourself or just watch caricatures emerge of other meeting attendees.

12:00 pm - 1:15 pm

IndustryForum

Industry ForumNational Harbor 2-3

Considerations for Patients With Later-onset SMA and Intrathecal Access

Sponsored by: Biogen

This session will review principles of intrathecal access in complicated spines. It will provide an overview of nusinersen clinical data in a broad range of patients and will include a patient ambassador sharing his story about living with SMA.

Target Audience: Physicians

Learning Objectives: • Discuss principles of intrathecal access in complicated spines in patients with SMA• Summarize the clinical result data of nusinersen in patients with later-onset SMA

Faculty: Arun Varadhachary, MDCameron Kersey, MD Bill H., Patient Ambassador

This activity is sponsored by Biogen and is not part of the official scientific program of AANEM.


12:00 pm: Registration

No CME/CEU 12:15 pm: Presentation


1:30 pm - 3:00 pm

Session

History of EDX and NM DiseasesPotomac 3

(1) Identify the historical discoveries and the development landmarks of some the currently available electrophysiologic techniques. (2) Relate some of the currently well described NM disease conditions to their original descriptions. (3) Demonstrate the historical evolution of our understanding of the etiology and pathology of certain NM disorders.

1:30 pm: The Early History of NCSs and EMG Mohamed Kazamel, MD

1:55 pm: The Early Years of AANEM John C. Kincaid, MD

2:20 pm: The History of Amyotrophic Lateral Sclerosis Jose David Avila, MD

1.5 CME/CEU 2:45 pm: Discussion and Q & A

1:30 pm - 3:00 pm

Session

Ethical Implications in NM MedicinePotomac 4

(1) Describe the current state of ethics in the workplace. (2) Identify resources for teaching and assessing ethics and professionalism. (3) Summarize two ethical aspects presently being debated.

1:30 pm: Introduction Eduardo A. De Sousa, MD

1:35 pm: Conduct Issues by an EDX Coordinator (Tech Perspective) Jerry Morris, CNCT, MS, R.NCS.T.

1:55 pm: Conduct Issues by an EDX Coordinator (Physician Perspective) Diana Mnatsakanova, MD

2:15 pm: Informed Consent After the Supreme Court of PA Case, Shinal v. Toms Segun T. Dawodu, MD, JD, MBA, LL.M, MS

2:35 pm: Ethical Issues Surrounding Treatment of SMA Jason M. Edinger, DO


1:30 pm - 3:00 pm

Session

Cutting Edge USPotomac C

(1) Explain the most recent advances in NM US. (2) Apply US skills to diagnose relevant NM conditions.

1:30 pm: Cutting Edge Ultrasound Michael S. Cartwright, MD

1:40 pm: Shear Wave Elastography Lisa D. Hobson-Webb, MD

2:15 pm: Ultrasound for Assessment of CIDP David C. Preston, MD


1:30 pm - 3:00 pm

Session

Effective Strategy in a Multidiscipline ClinicPotomac 5-6

(1) Explain the benefits and challenges in developing and maintaining a multidisciplinary care program for NM disease. (2) Summarize various financial and staffing models to support a multidisciplinary program in NM disease. (3) Relate the challenges and opportunities in designing appropriate outcome measures to support the maintenance of a multidisciplinary program in NM disease.

1:30 pm: Why Multidisciplinary Care? Justifying and Building the Mission of the Program. Jeffrey Rosenfeld, MD, PhD

2:10 pm: How to Start a Multidisciplinary Program. Funding and Maintaining the Program. Terry Heiman-Patterson, MD


1:30 pm - 3:00 pm

Workshop

W10C EMG Needle Basics

(1) Utilize electrophysiologic techniques related to needle EMG. (2) Apply a problem-directed approach to the study. (3) Identify insertional and spontaneous activity. (4) Identify the characterization of MUAP morphology and recruitment in normal and diseased states.

1.5 CME Atul T. Patel, MD


1:30 pm - 3:00 pm

Workshop

W13C Entrapment Lower Limb

Familiarize participants with techniques needed to evaluate and diagnose entrapments in lower limbs. Acquire skills to (1) perform NCSs for peroneal, tibial, medial, and lateral plantar nerves; and (2) identify the appropriate muscles for evaluating lower limb nerve entrapments and appropriate needle placement for EMG examination.

1.5 CME Michael T. Andary, MD, MS

1:30 pm - 3:00 pm

Workshop

W18C NM US


1.5 CME/CEU Francis O. Walker, MD

1:30 pm - 3:00 pm

Workshop

W22C Skin Biopsy Technique & Applications

(1) Discuss the development of skin biopsy as a clinical technique. (2) Describe its current applications and limitations in clinical practice. (3) Discuss the technique involved in obtaining skin specimens to increase providers’ comfort level in performing this billable procedure in their own office.

1.5 CME David W. Polston, MD

1:30 pm - 3:00 pm

Workshop

W24C Pelvic Floor EMG

This workshop will demonstrate a common pelvic floor EDX procedure on a male subject in a small group setting. The limited size allows all participants to view the demonstration and ask questions. There will be a discussion session regarding female and male pelvic floor clinical neurophysiology and anatomy. Participants will acquire skills to perform (1) common pelvic floor EDX studies in men; (2) apply their technical ability to perform male pelvic floor EDX studies; and (3) perform pelvic floor neurophysiology.

1.5 CME Andrew H. Dubin, MD, MS

1:30 pm - 3:00 pm

Workshop

W38C Physical Exam of the Athlete: Cervical Spine and Upper Extremity

Examine an individual and determine if the pain is from the cervical spine, shoulder, elbow, wrist, hand or a muscle and identify the typical athletic injuries to these regions. Participants will (1) determine which structure of the cervical spine is the pain generator, i.e., nerve root, facet joint or muscle; (2) distinguish which shoulder structures are pain generators; (3) determine a diagnostic and therapeutic plan; (4) identify the key elements in a history and physical exam to make a diagnosis and discuss a proper diagnostic workup and treatment plan for the injured athlete; and (5) discuss the differential diagnosis for cervical spine and upper extremity injuries in the athlete. Physical examination maneuvers useful in the diagnosis of radiculopathy and common nerve entrapment syndromes will be determined.

1.5 CME/CEU Francis P. Lagattuta, MD

1:30 pm - 3:00 pm

Workshop

W44C Anatomy & Kinesiology of the Shoulder/Upper Limb

(1) Identify the normal anatomy and the normal and abnormal kinesiology resulting from paralysis of key upper limb muscles. (2) Perform the neurological examination on each other to localize root from peripheral nerve lesions. (3) Differentiate winging from serratus anterior versus trapezius muscle weakness. (4) Localize lesions to specific peripheral nerve sites based on the motor and key components of the sensory and reflex examination and integrate with EDX and US findings. Participants are requested to wear short sleeve shirts to facilitate examining each other.

1.5 CME John W. Norbury, MD

1:30 pm - 3:00 pm

Workshop

W50C Advanced Autonomic Testing

Familiarize participants with 3 quantitative tests of autonomic function using specialized equipment designed for autonomic reflex function testing: (1) sudomotor testing; (2) cardiovagal testing with heart-rate response to deep breathing; and (3) Valsalva maneuver testing to evaluate cardiovagal and adrenergic function.

1.5 CME Amanda C. Peltier, MD, MS


1:30 pm - 3:00 pm

Workshop

W58C US Upper Extremity Nerves and Plexus

(1) Explain the optimal transducer frequency for imaging upper extremity nerves. (2) Identify the median nerve at the wrist, ulnar nerve at the elbow, and brachial plexus using US. (3) Describe normal median nerve mobility and the appearance of ulnar nerve dislocation on real-time US. (4) List the findings of nerve entrapment as may be seen on US and findings in structures other than nerves that may be relevant.

1.5 CME/CEU Vanessa Baute, MD

1:30 pm - 5:30 pm

Workshop

W64D Resident and Fellow Inclusive JumpStart

Designed for residents and fellows who already have proficiency in basic techniques. Participants will learn more advanced techniques from national experts who have over 20 years of experience in their area. They will (1) demonstrate less commonly used NCSs; (2) discuss pitfalls associated with common NCSs; and (3) identify which tests (NCS and EMG) constitute the optimal EDX evaluation of the foot as well as how to perform needle EMG in the foot and interpret these findings. These sessions are small group venues designed to be interactive so that trainees can learn from experts in EMG.

Sponsored by Grifols USA, LLC

David R. Del Toro, MD

Lawrence R. Robinson, MD

No CME/CEU Bassam A. Bassam, MD

1:30 pm - 3:00 pm

Workshop

W70C Expert US

Demonstrate advanced US practices involving challenging and complicated nerves. Workshop also includes measurement techniques of the peripheral nerve in the upper and lower limbs.


1:30 pm - 3:00 pm

Workshop

W73C Sonographic Needle Guidance for Carpal Tunnel Injections

(1) Explain sono-anatomy of the carpal tunnel and adjacent structures. (2) Discuss approaches for sonographic needle imaging. (3) Compare US-guided and “blind method” injections for treatment of CTS. (4) Distinguish structural abnormalities and common anatomic variations that may affect the procedure. (5) Demonstrate technique of US-guided carpal tunnel injection.

1.5 CME Elena Shanina, MD

1:30 pm - 3:00 pm

Workshop

W75C Chemodenervation Guidance Techniques-EMG, Nerve Stimulation and US

(1) Discuss how to use US, needle EMG and nerve stimulation to guide chemodenervation injections using botulinum toxin. (2) Describe the benefits and limitations of each localization technique for chemodenervation procedures. (3) Discuss ways to combine US with EMG/nerve stimulation to maximize ability to target and select muscles for chemodenervation.

1.5 CME Michael C. Munin, MD

1:30 pm - 3:00 pm

Workshop

W82C NCS Basics

This workshop is designed to address techniques of performing NCSs of commonly-studied nerves. Participants will acquire skills to (1) place the stimulating and recording electrodes for optimal recordings; (2) adjust the stimulation intensity and duration; (3) adjust machine settings for appropriate recordings; and (4) discuss common technical issues regarding basic NCSs.

1.5 CME/CEU Ghazala R. Hayat, MD


1:30 pm - 3:00 pm

Session

Active Peripheral Nerve Research Presented by PNSPotomac 1-2

The Peripheral Nerve Society (PNS) is an international organization of physicians and scientists working together to develop and provide the best treatments for people who have peripheral nerve diseases. The PNS encompasses all aspects of the peripheral nervous system, both clinical and scientific, and ranges from electrophysiologic tools for diagnosis to molecular mechanisms of disease and nerve fiber regeneration. Participants will acquire skills to (1) summarize the latest research in genetic neuropathy; (2) discuss mechanisms for recovering from neuropathy; and (3) apply new treatments in neuropathy as they are developed.

1:30 pm: Introduction Eric Lancaster, MD, PhD

1:35 pm: Amyloid Neuropathy Michael J. Polydefkis, MD

2:00 pm: Update on Hereditary Motor Neuropathy Charlotte J. Sumner, MD

2:25 pm: CIPD Eric Lancaster, MD, PhD

No CME/CEU 2:50 pm: Discussion and Q & A

3:00 pm - 3:45 pm

Social Event

Speed NetworkingPotomac Foyer

Looking for a fun, easy way to network at the AANEM Annual Meeting? Want to build connections with peers, leaders, and other professionals in NM and EDX medicine? Speed networkers will make approximately 10-11 connections during the session. Don’t forget your business cards!

Sponsored by Grifols USA, LLC

3:00 pm - 4:00 pm

Social Event

Guitarist in the AANEM LoungePotomac Foyer

Relax in the AANEM Lounge while listening to the music of guitarist, Rich Barry. Rich is a versatile guitarist whose repertoire includes classical, Spanish, jazz, basso nova, and acoustic popular music.

3:00 pm - 4:00 pm

Social Event



3:45 pm - 5:30 pm

Session

Plenary 1: Precision Medicine in NM and MSK MedicinePotomac B

3:45 pm: Introduction Robert W. Irwin, MD

3:50 pm: Presidential Address Eric J. Sorenson, MD

4:10 pm: Annual Business Meeting: Election of Officers Eric J. Sorenson, MD

4:15 pm: Activities and Financial Overview Eric J. Sorenson, MD

4:20 pm: Recognize Outgoing Members Eric J. Sorenson, MD

4:25 pm: Introduction Eric J. Sorenson, MD

4:30 pm: Orphan Drug Pricing – a View from the Trenches A. Gordon Smith, MD

5:10 pm: Awards: Golseth, Golseth Runner-up, Best Abstract, Best Runner-up, Technologist, Technologist Runner-up Eric J. Sorenson, MD

1.5 CME/CEU5:25 pm: Closing Eric J. Sorenson, MD

5:30 pm - 7:00 pm

Social Event

Exhibit HallPrince George Exhibit Hall D

Want to learn more about the products that make our industry unique? Take the opportunity to stop by and see the latest innovations in our industry.

5:30 pm - 7:00 pm

Social Event

President's ReceptionPrince George Exhibit Hall D

The President’s Reception is the official kickoff event of the meeting each year. Socialize with attendees and exhibitors while enjoying appetizers, wine, and refreshments.

Sponsored by Biogen

27 Thursday | October 11

6:45 am - 8:00 am

IndustryForum

Industry ForumPotomac A

hATTR Amyloidosis: Understanding the Multisystem Manifestations of the Disease

Sponsored by: Alnylam Pharmaceuticals

Please join our expert faculty panel during this educational symposium to learn about hereditary transthyretin-mediated (hATTR) amyloidosis and the challenges in diagnosing this multisystem disease. The faculty will take a deep dive into not only the neuropathy symptoms commonly associated with the disease, but also the other affected organ systems and “red-flag” signs and symptoms to look for in your patients. We hope you attend and are able to learn about the importance of earlier identification and diagnosis of these patients.

Faculty: • Chair: Dr. Alejandra González-Duarte (Department of Neurology, Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, Mexico)• Dr. Amanda Peltier (Department of Neurology, Vanderbilt University, US)• Dr. Mazen Hanna (Department of Cardiovascular Medicine, Cleveland Clinic, US)

This activity is sponsored by Alnylam Pharmaceuticals and is not part of the official scientific program of AANEM.




8:00 am - 9:30 am

Session

How to Incorporate Genetic Testing/How to Pay for ItChesapeake 1

Describe how to utilize an algorithmic approach to ordering genetic tests for patients with suspected hereditary NM disorders.

This is an “Ask the Experts” session. There will be an interactive discussion designed around audience participation. There are no handouts nor a planned presentation and this session will not be included in the Annual Meeting Collection.

1.5 CME/CEU Anthony A. Amato, MD

8:00 am - 9:30 am

Session

MACRAChesapeake 2

(1) Describe an overview of the Quality Payment Program. (2) Identify the four categories under the Merit-Based Incentive Program (MIPs). (3) Identify how EDX and NM physicians can succeed in MIPs. (4) Describe Advanced Alternative Payment Models.


1.5 CME/CEU Millie Suk, JD, MPP

8:00 am - 9:30 am

Session

ChemodenervationChesapeake 3

(1) Explain the principles and practical aspects of chemodenervation with the botulinum toxins in focal dystonia and spasticity. (2) Identify the role of EMG guidance in the recognition of dystonic EMG patterns and choice of candidate muscles for injection. (3) Discuss dosing differences/relationships among available toxins.


1.5 CME/CEU Janice M. Massey, MD

8:00 am - 9:30 am

Session

NM USChesapeake 4

(1) Explain how NM US is incorporated into an EDX laboratory. (2) Discuss NM conditions in which US can improve the diagnosis and treatment. (3) Identify the general aspects of billing for NM US.


1.5 CME/CEU Francis O. Walker, MD

28Thursday | October 11

8:00 am - 9:30 am

Session

EDX Evaluation of CIDP and MMNChesapeake 5

An algorithmic approach for the diagnosis of CIDP or MMN: (1) define the clinical phenotype in the context of the clinical history; (2) identify the EDX findings of acquired demyelination; (3) utilize the validated EDX criteria to ascertain the diagnosis [EFNS PNS]; (4) resort to supportive criteria if #3 is not met. Based on 1-4, CIDP can be diagnosed as typical or atypical [based on the phenotype], and either can be definite, probable or possible [based on the EDX criteria and supportive criteria]. Based on 1-4, MMN classification can be definite, probable or possible [based on the EDX criteria and supportive criteria]. (5) Identify that although the phenotype #1 such as in CIDP is used to classify CIDP as typical or atypical, certainty of the diagnosis, i.e. definite, probable or possible in either CIDP or MMN depends on the EDX criteria #3 with help from the supportive criteria #4 if needed.


1.5 CME/CEU Said R. Beydoun, MD

8:00 am - 9:30 am

Session

Diabetic NeuropathyChesapeake 6

(1) Explain the many faces of diabetic neuropathy. (2) Differentiate the treatments for the NM complications of diabetes. (3) Summarize diabetic small fiber and autonomic neuropathies.


1.5 CME/CEU Jau-Shin Lou, MD, PhD, MBA

8:00 am - 9:30 am

Session

Evidence-Based MedicineChesapeake 7

Participants will get an introduction to evidence-based medicine and its application in routine clinical care.


1.5 CME/CEU Gary S. Gronseth, MD

8:00 am - 9:30 am

Session

RadiculopathyChesapeake 9

(1) Discuss pertinent historical features of lumbosacral and cervical radiculopathies. (2) Explain pertinent physical exam and PE findings in lumbosacral and cervical radiculopathies. (3) Identify optimal EDX examination for lumbosacral and cervical radiculopathies that ensures high diagnostic accuracy. (4) Discuss other diagnostic testing for lumbosacral and cervical radiculopathies. (5) Describe treatment options for lumbosacral and cervical radiculopathies.


1.5 CME/CEU Peter A. Grant, MD

8:00 am - 9:30 am

Session

Small Fiber NeuropathyChesapeake 10

(1) Describe the clinical features and compare the diagnostic tests available (QST, skin biopsy, QSART, and cardiovascular reflex test). (2) Discuss the etiology, prognosis, and therapy of small fiber neuropathy. (3) Identify the role of skin biopsy in evaluating treatment efficacy in small fiber neuropathy.


1.5 CME/CEU Lan Zhou, MD, PhD


8:00 am - 9:30 am

Session

Botulinum Toxin for PainChesapeake 11

(1) Discuss the various painful conditions that have been treated with botulinum toxin. (2) Summarize literature support and limitations for treatment of painful conditions using botulinum toxin. (3) Discuss some of the proposed mechanisms of action of botulinum toxins in painful conditions. (4) Discuss the various techniques used to treat pain with botulinum toxins.


1.5 CME/CEU Atul T. Patel, MD

8:00 am - 9:30 am

Session

What Reference Values and NCS Techniques Should I Use in My PracticeChesapeake 8

(1) Discuss how high quality normative data (reference values) are derived. (2) Discuss the normative data taskforce and the results of that effort that identified techniques and reference values for common NCSs that are useful resources for EDX physicians. (3) Demonstrate how easy it is to incorporate these NCS techniques into your practice.


1.5 CME/CEU Timothy R. Dillingham, MD, MS

8:00 am - 9:30 am

Session

EMG ReportsPotomac 4

Discuss how to improve patient care by providing a concise interpretation of EMG data and assessment of their clinical significance for the referring physician.

8:00 am: Introduction Winfried A. Raabe, MD

8:05 am: Do Referring Physicians Understand our EMG Reports? Devon I. Rubin, MD

8:30 am: Is a Clinical Interpretation (Beyond EDX Interpretation) Helpful or Harmful to the Referring Physician? Devon I. Rubin, MD

8:55 am: EMG Report Formulation Kerry H. Levin, MD


8:00 am - 9:30 am

Session

Complementary/Alternative MedicinePotomac 3

(1) Discuss how to integrate complementary and/or alternative medicine treatments for symptoms of NM diseases. (2) Distinguish which treatments have been scientifically studied and which have benefits that are anecdotally noted.

1.5 CME/CEU Loretta M. VanEvery, MD


8:00 am - 9:30 am

Session

US Controversial TopicsPotomac C

(1) Discuss the utility of diagnostic US in CTS. (2) Discuss the utility of diagnostic US in the diagnosis of ALS. (3) Identify a scientific and rational approach when using diagnostic US in the EDX lab.

8:00 am: Introduction Shawn Jorgensen, MD

8:05 am: Ultrasound in the Diagnosis of ALS: PRO Lisa D. Hobson-Webb, MD

8:20 am: Ultrasound Alone Cannot be Used to Diagnose ALS Zachary Simmons, MD

8:35 am: Discussion and Q & A

8:45 am: Introduction Shawn Jorgensen, MD

8:50 am: Should Ultrasound Be Done First for CTS: PRO Michael S. Cartwright, MD

9:05 am: Should Ultrasound Be Done First for CTS? Lawrence R. Robinson, MD


8:00 am - 9:30 am

Session

NM Pathology as a Diagnostic Tool in Challenging NM Cases: Taking it to the Next LevelPotomac 5-6

(1) Integrate the findings from nerve and muscle biopsies with clinical evaluation for diagnosis complex NM cases. (2) Identify the usefulness of nerve and muscle biopsies in era of genetics testing. (3) Formulate the treatment of unusual NM disorders based on nerve and muscle biopsy results.

8:00 am: Introduction Justin Y. Kwan, MD

8:05 am: Advanced Nerve and Muscle Pathology Justin Y. Kwan, MD

8:30 am: Advanced Muscle Pathology Part I, Unusual Inflammatory and Hereditary Muscle Disorders Suur Biliciler, MD

8:55 am: Advanced Muscle Pathology Part II Cecile L. Phan, MD


8:00 am - 9:30 am

Session

NM Video CasesPotomac 1-2

(1) Discuss significant physical signs of different NM disorders from video presentations. (2) Describe how to guide your laboratory investigations based on accurate identification of leading findings on video cases. (3) Analyze how to use EDX tests as an extension of clinical examination. (4) Assess how longitudinally follows the progress of NM diseases via temporally spaced video clips. (5) Differentiate between functional and organic NM disorders via video case demonstration.

1.5 CME/CEU Aziz Shaibani, MD

8:00 am - 4:00 pm

Social Event

Silent AuctionPrefunction area outside Prince George D-E


9:00 am - 9:00 pm

Social Event



9:00 am - 4:00 pm

Social Event



9:30 am - 10:00 am

Social Event

Coffee BreakPrince George Exhibit Hall D



9:40 am - 10:00 am

Session

Presentation by Alexion Presentation Stage - Exhibit Hall

A Treatment for Patients with Anti-Acetylcholine Receptor (AchR) Antibody Positive Generalized Myasthenia Gravis (gMG)

Presenter: Dr. Levine• Director of Phoenix Neurological ALS Clinic• Phoenix Neurological Institute, Phoenix, AZ

No CME/CEU

10:00 am - 12:00 pm

Session


10:00 am: Welcome Eric J. Sorenson, MD

10:05 am: President's Research Initiative Awards Eric J. Sorenson, MD

10:20 am: Introduction Eric J. Sorenson, MD

10:25 am: ALS and Related NM Diseases in the Precision Medicine Era Matthew B. Harms, MD


11:10 am: RNA-targeted Mechanisms and Therapeutics for ALS Timothy M. Miller, MD, PhD

2.0 CME/CEU11:40 am: Closing Eric J. Sorenson, MD

11:30 am - 12:30 pm

Social Event

Abstract Poster Session IPrince George Exhibit Hall E

Authors for posters 1 - 105 will be available to discuss their research. Review the information from this year’s abstracts and meet the authors.

12:00 pm - 1:15 pm

IndustryForum


A New Treatment for Patients With Anti-Acetylcholine Receptor (AchR) Antibody Positive Generalized Myasthenia Gravis (gMG) - gMG Expert Forum

Sponsored by: Alexion Pharmaceuticals, Inc.

This forum will discuss the ongoing disease burden in patients with anti-AChR antibody-positive generalized myasthenia gravis, and the role of the complement system in disruption of neuromuscular transmission.

Faculty: James F. Howard Jr., MDDistinguished Professor of Neuromuscular DiseaseProfessor of Neurology, Medicine, and Allied HealthChief, Neuromuscular DisordersUniversity of North Carolina at Chapel Hill

Jeffrey Guptill, MDAssociate Professor of Neurology,Duke University School of Medicine

This activity is sponsored by Alexion Pharmaceuticals, Inc., and is not part of the official scientific program of AANEM.





1:30 pm - 5:30 pm

Session

Interactive Case Based Approach to Genetics and NeuropathologyPotomac B

(1) Recognize the importance of correlating clinical, electrophysiological and pathological findings in the diagnosis of NM diseases. (2) Illustrate the usefulness of NM pathology findings in patient care. (3) Analyze available treatments in hereditary NM diseases.

This is a Self-Assessment (SA) CME session. To receive the SA CME credits, a post-test must be completed with a 70% passing rate. Post-tests are free to members and $50 for non-members.

1:30 pm: Introduction Margherita Milone, MD, PhD

1:35 pm: Muscle Disorders: Hereditary Myopathies Cases Teerin Liewluck, MD

1:35 pm: Muscle Disorders: Acquired Myopathies Cases Suur Biliciler, MD

3:00 pm: Break

4:00 pm: Introduction Justin Y. Kwan, MD

4:05 pm: Nerve Disorders: Hereditary Neuropathies Cases Christopher J. Klein, MD

3.0 CME/CEU4:45 pm: Nerve Disorders: Acquired Neuropathies Cases Mohamed Kazamel, MD

1:30 pm - 5:30 pm

Session

Demyelinating NeuropathiesPotomac 1-2

(1) Describe criteria used for identifying demyelination on NCS. (2) Identify technical pitfalls in identifying demyelination. (3) Describe the presentation, diagnosis, and treatment of GBS and CIDP. (4) Recognize select paraproteins associated with demyelinating neuropathies. (5) Identify inherited forms of demyelinating neuropathy.

This is a Self-Assessment (SA) CME/CNCT Checkpoint session. To receive the SA CME/CNCT Checkpoint credit(s), a post-test must be completed with a 70% passing rate. Post-tests are free to members and $50 for non-members.

1:30 pm: Introduction Shawn J. Bird, MD

1:35 pm: EDX Criteria of Demyelination Mark B. Bromberg, MD, PhD

2:05 pm: Techniques and Pitfalls in Demyelinating Neuropathies Candise Dolan, CNCT, R.EEG.T, R.NCS.T

2:30 pm: CMT1 and Other Inherited Demyelinating Neuropathies Nicholas E. Johnson, MD

3:00 pm: Break

4:00 pm: Guillain-Barré Syndrome Christyn Edmundson, MD

4:25 pm: Chronic Inflammatory Demyelinating Polyneuropathy Shawn J. Bird, MD

4:50 pm: Paraprotein-Associated Demyelinating Neuropathies Noah A. Kolb, MD


Just search for theAANEM 2018 Annual Meeting App

in your app store and download it to your device!

Download our Annual Meeting App Today!


1:30 pm - 5:30 pm

Session

Use of EDX and US for Evaluation of Focal Neuropathies of the Upper LimbPotomac C

(1) Review the capabilities of high frequency US to image the peripheral nervous system. (2) Review the important components of the EDX evaluation for assessment of focal neuropathies. (3) Review potential contributions of US and EDX for assessment of focal neuropathies including the relative strengths and weaknesses of each. (4) Discuss case examples of challenging focal neuropathies with improved management decisions provided by the information gained from the use of both US and EDX techniques.

1:30 pm: Introduction Jeffrey A. Strakowski, MD

1:35 pm: Live US Demonstration of Upper Limb Peripheral Nerves Jeffrey A. Strakowski, MD

2:15 pm: EDX of Upper Limb Focal Neuropathies Jun Kimura, MD

3:00 pm: Break

4:00 pm: NMUs for Upper Limb Focal Neuropathies Michael S. Cartwright, MD

4:45 pm: Case Discussions Integrating EDX and US Jeffrey A. Strakowski, MD


1:30 pm - 5:30 pm

Session

Brain Computer Interface/Functional RecoveryPotomac D

Participants will (1) identity and discuss brain-computer interfaces; and (2) explain and summarize ongoing trials of intracortically-based brain-computer interfaces for people with paralysis.

1:30 pm: Introduction Leigh R. Hochberg, MD, PhD

1:35 pm: Brain-Computer Interfaces (BCIs) for Communication and Mobility Leigh R. Hochberg, MD, PhD

3:00 pm: Break

3.0 CME/CEU

4:00 pm: Tailoring BCIs to Interface With the Post-Stroke Brain Karunesh Ganguly, MD, PhD

1:30 pm - 3:00 pm

Session

Developing EducationPotomac 4

(1) Discuss EMG report writing. (2) Discuss GME for the EMG clinician-educator.

1:30 pm: Introduction Dianna Quan, MD

1:35 pm: How to Teach EMG Report Writing Kerry H. Levin, MD

2:10 pm: Overview of GME for the EMG Clinician-Educator Wendy M. Helkowski, MD

1.5 CME/CEU2:45 pm: Discussion Q & A Taylor B. Harrison, MD

1:30 pm - 3:00 pm

Session

How to Build a Successful Private or Academic EDX PracticePotomac 5-6

(1) Identify opportunities for practice building in your academic and/or private practice medical community. (2) Implement strategies to align your EDX practice with the needs of patients and referring providers. (3) Identify the educational needs of referring providers and leverage this to improve patient care and build a successful EDX practice.

1:30 pm: How to Build a Successful Academic EDX Practice John W. Norbury, MD

2:00 pm: How to Build a Successful Private EDX Practice Shawn Jorgensen, MD



1:30 pm - 5:30 pm

Session

Bedside Evidence-Based MedicineChesapeake 8-9

Identify study design characteristics and learn basic biostatistics skills to evaluate a study critically: “How valid are the results and how applicable are they to my patient?” Limited to 50 - registration is required.

1:30 pm: Introduction Pushpa Narayanaswami, MBBS, DM

1:45 pm: Developing the Question and Performing the Literature Search Raghav Govindarajan, MD

2:30 pm: Internal and External Validity Gary S. Gronseth, MD

3:15 pm: Break

4:00 pm: Precision and Evidence Synthesis Gary S. Gronseth, MD

4:30 pm: Meta-analysis and Conclusions Pushpa Narayanaswami, MBBS, DM


3:00 pm - 4:00 pm

Social Event



3:10 pm - 3:30 pm

Session

Presentation by MT PharmaPresentation Stage - Exhibit Hall

Can We Build a New Paradigm of Diagnosis to Treatment? The Role of the Latest ALS Therapy.

No CME/CEU

4:00 pm - 5:30 pm

Session

Genomic Testing of the NM Patient:Ethical & Clinical ConsiderationsPotomac 4

(1) Determine indications for genetic testing in the NM patient. (2) Implement patient and family counseling that encompasses both the pre- and post-testing period and beyond. (3) Identify potential collaborations with clinical and research entities to support coordinated care and discovery.

4:00 pm: Indications for Genomic Testing and the Pre- and Post-Test Considerations Ericka P. Simpson, MD

4:30 pm: Next Generation Sequencing: Opportunities, Challenges and Limitations. Mario Saporta, MD, PhD

1.5 CME/CEU

5:00 pm: Bridging the Divide Between Research Exploration and Clinical Destination Matthew B. Harms, MD

4:00 pm - 5:30 pm

Session

Exercise for NM DiseasePotomac 3

(1) Explain benefits of exercise in NM and autonomic disorders. (2) Identify types of exercise used to benefit NM/autonomic disorders and how to prescribe.

4:00 pm: Exercise in Neuropathy and Autonomic Disorders Amanda C. Peltier, MD, MS

4:05 pm: Exercise in Painful Diabetic Neuropathy Mamatha Pasnoor, MD

4:30 pm: Exercise and Metabolic Neuropathy John R. Singleton, MD

4:55 pm: Exercise in POTS Amanda C. Peltier, MD, MS


4:00 pm - 5:30 pm

Session

Member Practice Issues Open ForumChesapeake 11

The Professional Practice Committee (PPC) will be hosting an open forum for members to discuss any current issues or trends they are seeing in their practices and that the PPC may be able address either with advice, or potentially, through the creation of a new position statement.

No CME/CEU Members of the Professional Practice Committee


Special Discount on AANEM Products

Save up to 50% off AANEM education products while supplies last!

We’ve discounted over 30 of our DVDs, books, and self-assessments and as an Annual Meeting attendee, you are the first to hear of this

one-time only sale.

Supply is limited so don’t wait! Visit www.aanem.org/sale or come talk with us at the AANEM Product Store in the Prince George Foyer.

5:30 pm - 6:30 pm

Social Event



5:45 pm - 6:45 pm

Social Event

Abstract Award Winners' ReceptionPotomac Foyer

Enjoy an evening celebrating research! Socialize with abstract authors while enjoying a pasta and salad bar, wine and refreshments. Poster authors will be available for discussion of their industry-leading research.

Abstract award winners include Golseth Young Investigator, Golseth Young Investigator Runner-up, Best Abstract, Best Abstract Runner-up, Technologist and Technologist Runner-up.

7:00 pm - 9:00 pm

Social Event

EMG TonightPotomac A

EMG Tonight is an interactive, entertaining session formatted like the old Tonight Show with Johnny Carson. This session is meant to be a lighthearted look at EMG with lots of laughs. A variety of “guests” will appear through the duration of the “show” to share their wisdom on various EMG topics.

Sponsored by Natus Neuro

Erik R. Ensrud, MD


Amanda C. Peltier, MD, MS

John W. Norbury, MD

Jun Kimura, MD

Ileana Howard, MD

Millie Suk, JD, MPP

5:30 pm - 6:30 pm

Social Event



5:45 pm - 6:45 pm

Social Event

Abstract Award Winners' ReceptionPotomac Foyer

Enjoy an evening celebrating research! Socialize with abstract authors while enjoying a pasta and salad bar, wine and refreshments. Poster authors will be available for discussion of their industry-leading research.

Abstract award winners include Golseth Young Investigator, Golseth Young Investigator Runner-up, Best Abstract, Best Abstract Runner-up, Technologist and Technologist Runner-up.

7:00 pm - 9:00 pm

Social Event

EMG TonightPotomac A

EMG Tonight is an interactive, entertaining session formatted like the old Tonight Show with Johnny Carson. This session is meant to be a lighthearted look at EMG with lots of laughs. A variety of “guests” will appear through the duration of the “show” to share their wisdom on various EMG topics.

Sponsored by Natus Neuro

Erik R. Ensrud, MD


Amanda C. Peltier, MD, MS

John W. Norbury, MD

Jun Kimura, MD

Ileana Howard, MD

Millie Suk, JD, MPP

36Friday | October 12

6:45 am - 8:00 am

IndustryForum


Clinical Utility of Genetic Testing in the Diagnosis of Proximal (Limb-Girdle) Muscle WeaknessSponsored by: Sanofi Genzyme

It is the position of the AANEM that genetic testing plays a vital role in the diagnosis, appropriate investigation, and monitoring of NM disease. Proximal muscle weakness is a feature of many overlapping NM disorders including muscular dystrophies, myopathies, and Pompe disease, which can make determining the specific underlying etiology challenging. This forum will review the differential diagnosis of proximal muscle weakness and the role of genetic testing in the diagnosis and management of patients with proximal, limb-girdle muscle weakness.

This forum will review methods of genetic testing used in clinical practice and discuss interpretation of results as highlighted through case presentations. The goal of this forum is for clinicians to appreciate the increasing role of genetic testing in the evaluation and management of NM disorders and how to best use genetic testing in their clinical practice.

Target Audience: Physicians, advanced practice providers, genetic counselors and other health care providers

Learning Objectives: • Highlight the differential diagnosis of proximal, limb-girdle muscle weakness (LGMW)• Identify the various genes involved in the underlying etiology of LGMW• Describe the clinical/diagnostic evaluation used in the evaluation of LGMW• Understand the importance of genetic testing for this group of disorders• Understand genetic testing methods, interpretation of results and limitations

Faculty:Matthew Harms, MDColumbia University

Livija Medne, MS, LCGCChildren’s Hospital of Philadelphia

This activity is sponsored by Sanofi Genzyme and is not part of the official scientific program of AANEM.




8:00 am - 9:30 am

Session

Entrapment NeuropathiesChesapeake 8

(1) Demonstrate how to use the Robinson Index for diagnosis of CTS. (2) Identify the best approaches for diagnosing ulnar neuropathy at the elbow. (3) Discuss how to formulate prognostic statements in focal neuropathies.


1.5 CME/CEU Lawrence R. Robinson, MD

8:00 am - 9:30 am

Session

EDX Evaluation of the FootChesapeake 1

(1) Describe which tests (NCS & EMG) constitute the optimal EDX evaluation of the foot. (2) Assess the role of needle EMG in EDX of the foot. (3) Assess the differential diagnosis for neuropathic foot pain, including entrapment neuropathies in the foot/ankle. (4) Compare the electrophysiologic findings and clinical presentation in TTS vs peripheral neuropathy.


1.5 CME/CEU David R. Del Toro, MD

37 Friday | October 12

8:00 am - 9:30 am

Session

Peripheral NeuropathyChesapeake 2

(1) Discuss a differential diagnosis of peripheral neuropathy and further divide the neuropathies into motor, sensory, and mixed types as well as into demyelinating and axon loss types. (2) Discuss the EDX approach to evaluating patients with diffuse polyneuropathies. (3) Describe treatment options for neuropathies from immunosuppression to neuropathic pain management.


1.5 CME/CEU Peter D. Donofrio, MD

8:00 am - 9:30 am

Session

Role of Placebo in Clinical Trials and NM TherapiesChesapeake 3

(1) Explain the factors that lead to the placebo response in the placebo arm of the clinical trials. (2) Convey the neurobiology of the placebo effect in clinical trials. (3) Evaluate the impact of placebo on pain and fatigue and project that on other NM disorders. (4) Identify methods to minimize impact of placebo on outcome in clinical trials. (5) Summarize the positive impact of placebo in treatment of NM diseases.


1.5 CME/CEU Aziz Shaibani, MD

8:00 am - 9:30 am

Session

Setting Up Your NM US LabChesapeake 6

(1) Describe the US equipment needed to perform NM US. (2) Address barriers to implementation of US into an EMG laboratory. (3) Discuss appropriate coding for NM US. (4) Provide guidance on obtaining appropriate training for performing NM US.


1.5 CME/CEU Lisa D. Hobson-Webb, MD

8:00 am - 9:30 am

Session

Brachial PlexopathiesChesapeake 7

(1) Describe the anatomy of the brachial plexus. (2) Describe the role of the sensory NCS in initial localization of focal lesions within specific brachial plexus regions. (3) Analyze the role of motor NCS in further localizing and characterizing the lesion (pathophysiology, severity, prognosis). (4) Identify the role of needle EMG in confirming the NCS findings and further localizing and characterizing the lesion, especially its temporal features (slowly progressive, rapidly progressive, acute, subacute, chronic). (5) Demonstrate this approach using illustrative cases.


1.5 CME/CEU Mark A. Ferrante, MD

The No. 1 place for your PMR andNM/EDX job search!

Explore the career center today atwww.healthecareers.com/aanem


8:00 am - 9:30 am

Session

NM Junction TechniquesChesapeake 5

(1) Describe NM junction physiology. (2) Discuss RNS testing technique, quality control, and findings in disease. (3) Discuss jitter assessment with single-fiber and concentric needles. (4) Identify EDX assessment strategies for patients with NM transmission disorders.


1.5 CME/CEU Amanda C. Guidon, MD

8:00 am - 9:30 am

Session

Autoimmune Demyelinating PolyneuropathiesChesapeake 9

(1) Discuss how to use clinical and laboratory features to identify and classify autoimmune neuropathies. (2) Discuss management of this group of disorders.


1.5 CME/CEU Jeffrey A. Allen, MD

8:00 am - 9:30 am

Session

Basic NervePotomac 3

(1) Interpret what you see on the screen with nerve conductions, some pitfalls and how to correct them. (2) Classify repetitive stimulation and what you see in different NMJ disorders. (3) Summarize information and host Q & A discussion.


1.5 CME/CEU Teresa Spiegelberg, CNCT, R.NCS.T, R.EEG.T, BS

8:00 am - 9:30 am

Session

Cranial Nerve TestingPotomac 4

(1) Describe the basic physiology which underlies the impulse propagation along the nerve axons and generation of muscle action potentials. (2) Outline the current approach in evaluating neuropathies affecting the accessory, trigeminal, and facial nerves. (3) Identify features of NCS abnormalities found in disorders affecting these nerves. (4) Recognize EDX techniques used for this evaluation. (5) Describe the use of blink reflex for assessing the trigeminal and facial nerves. (6) Discuss repetitive stimulation of the facial and accessory nerves for evaluation of NM junction. (7) Discuss the merit and demerit of commonly used methods and the technical pitfalls that may lead to an erroneous interpretation of the acquired results.


1.5 CME/CEU Jun Kimura, MD

8:00 am - 9:30 am

Session

Prosthetics and OrthoticsChesapeake G

(1) Describe tips for successful prescription of commonly useful orthotics and prosthetics of the upper extremity that are helpful in NM disease. (2) Describe pitfalls in prescription of lower extremity orthotics and prosthetics and how to overcome them to maximize patient utilization. (3) Describe how to communicate with your patients about economic factors involved in prescription and utilization of orthotics and prosthetics, including how you both can advocate for the best selection for them.


1.5 CME/CEU Erik R. Ensrud, MD


8:00 am - 9:30 am

Session

Women in NM MedicinePotomac 1-2

(1) Discuss challenges and opportunities that face women today as they manage multiple roles. (2) Relate the experiences of women leaders in medicine. (3) Explore methods of addressing gender bias in the workplace/resources to address gender bias in the workplace.

8:00 am: Introduction Dianna Quan, MD

8:05 am: Say what? Gender Bias and the Language We Choose Bonnie J. Weigert, MD

8:35 am: Women of the AANEM-Progress or Plateau? Janice M. Massey, MD


8:00 am - 9:30 am

Session

New NM Therapies: Integrative MedicinePotomac 5-6

(1) Evaluate the current evidence for integrative medicine approaches to neuropathy, neuropathic pain, myalgias, cramps and fatigue. (2) Use nutrition, exercise, supplementation and an “anti-inflammatory treatment approach” in the care of common NM conditions. (3) Identify and manage potential nutrient depletion from common pharmaceuticals. (4) Summarize the current evidence for acupuncture in the treatment of peripheral neuropathy. (5) Differentiate various acupuncture modalities such as manual acupuncture, electroacupuncture and moxibustion. (6) Identify which patients with peripheral neuropathy may benefit from acupuncture and educate them as to what a typical acupuncture treatment course would entail.

8:00 am: Introduction Julie Rowin, MD

8:05 am: The Case for the Integrative Management of Neuropathy and Neuropathic Pain Julie Rowin, MD

8:30 am: Acupuncture for the Treatment of Peripheral Neuropathy – Conceptual Framework and Summary of the Evidence Alexandra K. Dimitrova, MD, MA

8:55 am: Integrative Holistic Approach to Myalgias, Cramps and Fatigue Jinny Tavee, MD


8:00 am - 9:30 am

Session

Hereditary Neuropathy Foundation Session: CMT/IN Patient OutcomesPotomac D

(1) Identify key characteristics and phenotypes of CMT patients, apply appropriate methods of testing for diagnosis including genetic testing and evaluation to determine the use of additional clinical testing scales and PRO instruments to enhance treatment options. HCPs will be provided with genetic testing options, patient cost assistance programs, insight from experts on CMT current and future natural history studies, observational real-world data studies, and clinical trial information.

(2) Identify, organize and produce relevant referral resources for the CMT Medical Community - “The CMT Dream Teams.” An integrated approach will be discussed to allow attendees to understand HNF’s programs such as CMT Centers of Excellence, HCP Directory, “Peer to Peer” Education Program, and CMT SAE in collaboration with AANEM.

8:00 am: Introduction and Video (The Patient Journey of the Warren Family) Estela Lugo, HNF

8:15 am: The Impact of Patient Reported Outcomes (PROs) on Diagnosis, Functional Outcome Measures, and Research Support for Accelerated CMT Therapies

Panel: Allison Moore, CEO-HNF; Andrea Pal, MS, CGC; Florian Thomas, MD; and Mark Larkin, PhD

8:45 am: Introduction to Topic Discussion Estela Lugo, HNF

8:50 am: The 'CMT Dream Teams' the Importance of Incorporating Referral Resources to CMT Clinicians for Improving Patient Treatment Options and Transitional Care Practices

Panel: James Nussbaum, PT, PhD, SCS; Jahannaz Dastgir, DO; and Estela Lugo, HNF

No CME/CEU 9:20 am: Discussion and Q & A

9:00 am - 4:00 pm

Social Event



40

9:00 am - 4:00 pm

Social Event



9:30 am - 10:00 am

Social Event



9:40 am - 10:00 am

Session

Presentation by MT PharmaPresentation Stage - Exhibit Hall

Can We Build a New Paradigm of Diagnosis to Treatment? The Role of the Latest ALS Therapy.

No CME/CEU

10:00 am - 12:00 pm

Session



10:05 am: Awards: Lifetime Achievement, Distinguished Physician, Distinguished Researcher, Distinguished Service, and Advocacy Eric J. Sorenson, MD


10:25 am: From Assessing Evidence to Determining a 'Fair' Price: How Should the Value of New Treatments for NMD be Evaluated? Steven D. Pearson, MD, MSc, FRCP


11:05 am: FDA Regulation of Cell Therapy Wilson W. Bryan, MD


10:00 am - 4:00 pm

Social Event

Silent Auction Winner Pick-upPrefunction area outside Prince George D-E

Silent Auction Winners, pick-up your items at the Registration Booth.

11:30 am - 12:30 pm

Social Event

Abstract Poster Session IIPrince George Exhibit Hall E

Authors for posters 106 - 207 will be available to discuss their research. Review the information from this year’s abstracts and meet the authors.

Friday | October 12

Training Program

Partnership

Join the TPP for just $253!Free AANEM membership for

residents/fellows

Exclusive educational materialsDeep discounts on the AANEM

Annual Meeting

Access to all the services of AANEM


12:00 pm - 1:15 pm

IndustryForum


Primary Periodic Paralysis— Patient Pathways in Care

Sponsored by: Strongbridge Biopharma

The presentation is designed to provide insight into patients' journeys toward an appropriate diagnosis of primary periodic paralysis—or PPP—as well as treatment options. Many of these patients go through long journey searching for the right healthcare professional that can provide them with an accurate diagnosis. Specialists who are knowledgeable about PPP obtain detailed medical and family histories and may perform a number of tests—including genetic testing—to confirm an accurate PPP diagnosis. The presentation will examine the immediate and long-term burden of this disease, how distressing and unpredictable PPP symptoms may be to patients, and how beneficial therapies can help to achieve symptom control.

Target Audience: Health care professionals attending the AANEM Annual Meeting who treat patients with NM conditions

Learning Objectives: • Have a deeper understanding of the complex algorithm for diagnosing PPP in order to shorten the diagnostic journey for patients• Understand immediate consequences of PPP as well as long-term disease progression• Learn about the first and only FDA approved treatment option for PPP

This activity is sponsored by Strongbridge Biopharma and is not part of the official scientific program of AANEM.




1:30 pm - 5:30 pm

Session

Emerging Therapies and ControversiesPotomac B

(1) Identify current, recently approved and in the pipeline ALS therapies. (2) Discuss newly emerging novel therapy in SMA. (3) Assess additional treatment options and thymectomy outcomes in MG. (4) Discuss various current and emerging therapies in immune mediate neuropathy. (5) Implement current and newly emerging NM patients chronic management.

This is a Self-Assessment (SA) CME session. To receive the SA CME credits, a post-test must be completed with a 70% passing rate. Post-tests are free to members and $50 for nonmembers.

1:30 pm: Introduction Bassam A. Bassam, MD

1:35 pm: ALS Emerging Therapies Bassam A. Bassam, MD

2:00 pm: Emerging Therapeutics in Autonomic Disorders Mohamed Kazamel, MD

2:25 pm: MG Eculizumab and Thymectomy Todd D. Levine, MD

2:50 pm: Discussion and Q & A

3:00 pm: Break

4:00 pm: Introduction Todd D. Levine, MD

4:05 pm: Emerging Therapies in Immune Mediate Neuropathy Said R. Beydoun, MD

4:30 pm: NM Patient Chronic Management Amanda L. Witt, MD

4:55 pm: Emerging Therapies in SMA Perry B. Shieh, MD, PhD



1:30 pm - 5:30 pm

Session

Diagnosis and Treatment Breakthroughs in Genetic TestingPotomac 5-6

(1) Discuss how to integrate current testing platforms in your neuropathy practice. (2) Discuss the technical strengths and limitations of the next generation sequencing testing for various forms of neuropathy. (3) Explain new treatment and research approaches afforded by genetic testing. (4) Illustrate the importance of correlating molecular findings with clinical and other laboratory data. (5) Convey the relevance of a genetic diagnosis for proper treatment. (6) Summarize hereditary myopathies and neurogenic processes sharing the same defective gene. (7) Assess the genetic technical analysis strategies, and genetic counseling. (8) Generate comprehensive and helpful genetic testing reports by applying evidence-based gene variant classification guidelines. (9) Summarize latest advances in population genomic-driven drug discovery.

1:30 pm: NGS Testing Easing Diagnosis and Affording True Individualized Medicine Christopher J. Klein, MD

2:15 pm: Genetic Testing in the Lab-From Order to Diagnosis and Beyond Zhiyv (Neal) Niu, PhD

3:00 pm: Break

4:00 pm: Diagnosis of Hereditary Myopathies in the NGS Era Margherita Milone, MD, PhD


1:30 pm - 5:30 pm

Session

US Assessment of MSK MimicsPotomac C

(1) Discuss some common MSK conditions that could clinically mimic focal neuropathies. (2) Describe methods of distinguishing peripheral nerve and MSK pathology. (3) Identify cases of clinical presentations using US and EDX to distinguish potential MSK abnormalities from focal neuropathies.

1:30 pm: US Assessment of MSK Mimics Jeffrey A. Strakowski, MD

3:00 pm: Break

3.0 CME/CEU4:00 pm: US Assessment of MSK Mimics Jeffrey A. Strakowski, MD

1:30 pm - 5:30 pm

Session

Entrapment NeuropathiesPotomac D

(1) Discuss the clinical and EDX approach to uncommon upper extremity entrapment neuropathies including ulnar neuropathy at the wrist, dorsal ulnar cutaneous neuropathy, proximal median neuropathy, suprascapular neuropathy and axillary neuropathy. (2) Discuss the clinical and EDX approach to uncommon lower extremity entrapment neuropathies including sciatic neuropathy, femoral neuropathy, obturator neuropathy, pudendal neuropathy and lateral femoral cutaneous neuropathy. (3) Identify the key distinguishing EDX features to differentiate uncommon entrapment neuropathies from their common mimickers. (4) Review anatomy and physiology of the radial motor and sensory nerves. (5) Explain sites of entrapment of the radial nerve and their nerve conduction abnormalities.

This is a Self-Assessment (SA) CME/CNCT Checkpoint session. To receive the SA CME/CNCT Checkpoint credit(s), a post-test must be completed with a 70% passing rate. Post-tests are free to members and $50 for nonmembers.

1:30 pm: Introduction Samuel M. Bierner, MD

1:35 pm: Less Common Entrapment Neuropathies Thiru M. Annaswamy, MD, MA

3:00 pm: Break

4:00 pm: Introduction Samuel M. Bierner, MD

4:05 pm: Radial Neuropathies With Relevant Case Examples Jerry Morris, CNCT, MS, R.NCS.T.



1:30 pm - 3:00 pm

Session

Respiratory Management of the NM PatientChesapeake 8-9

(1) Assess and evaluate the respiratory status, including airway clearance, of the adult NM patient. (2) Identify and manage sleep related breathing disorders of adult NM patients. (3) Utilize devices to evaluate pulmonary function and devices to manage airway clearance and ventilation.

1:30 pm: Introduction Ericka P. Simpson, MD

1:35 pm: The Evaluation and Management of Respiration in Your NM Patient: Why, How, and What? Ericka P. Simpson, MD

2:00 pm: Pulmonology 101 for the NM Specialist Venessa Holland, MD

2:25 pm: Sleep Related Breathing Dysfunction in the NM Patient Aparajitha K. Verma, MD


1:30 pm - 3:00 pm

Session

SMA Therapy in the Age of Nusinersen: Experience at Three Academic Medical CentersPotomac 1-2

Explain the major logistical challenges posed by this therapy, including institutional hurdles to start-up, the prior authorization process, scheduling patients, and administering the drug.

1:30 pm: Introduction Edward C. Smith, MD

1:35 pm: The Duke Experience Edward C. Smith, MD

1:55 pm: The UCLA Experience Perry B. Shieh, MD, PhD

2:15 pm: The John Hopkins Experience Thomas O. Crawford, MD


1:30 pm - 3:00 pm

Session

NeuroprostheticsPotomac 3-4

(1) Explain the underlying physiology and recording techniques utilized in the electromyographic control of prosthetic limbs. (2) Recognize opportunities for engineering solutions to solve challenges faced by amputees, including intent recognition, haptic feedback, and degrees of freedom.

1:30 pm: Introduction William Filer, MD

1:40 pm: Motor Control of Neuroprosthetic Devices Paul F. Pasquina, MD

2:15 pm: Haptic Feedback: Closing the Loop Dustin Tyler, PhD


1:30 pm - 3:00 pm

Session

Challenging Cases RoundtableChesapeake 1-2

Meeting attendees are invited to participate in a new and exciting roundtable of EDX NM Challenging Cases. Attendees will confer with experts who will recommend a wide array of principles, including performance and interpretation of their clinical studies and add clinical input in a smaller one-on-one setting. This session will provide positive feedback to stimulate use of quality EDX studies in the diagnosis and treatment of patients. Participants are encouraged to bring their own cases to the session. Limited to 60 - registration is required.

Erik R. Ensrud, MD

Bashar Katirji, MD

Bryan E. Tsao, MD

1.5 CME/CEU Mark A. Ferrante, MD

3:00 pm - 4:00 pm

Social Event




4:00 pm - 5:30 pm

Session

Respiratory Management of the NM Patient Part IIChesapeake 7

Demonstrations and hands-on learning stations.

Ericka P. Simpson, MD

Aparajitha K. Verma, MD

No CME/CEU Venessa Holland, MD

4:00 pm - 5:30 pm

Session

Axial WeaknessPotomac 3-4

(1) Discuss the clinical approach to patients with axial postural disorders, and the differentiation of NM causes from dystonia or skeletal problems. (2) Diagnose the various NM causes of axial weakness, including muscle, NM junction, peripheral nerve and motor neuron etiologies. (3) Discuss the association of camptocormia with NM disease. (4) Recognize factors that may predict response to immunomodulating therapy in axial weakness.

4:00 pm: Approach to Patients With Suspected Axial Myopathy: Diagnosis and Treatment Challenges Elie Naddaf, MD

4:35 pm: Neurogenic Causes of Axial Weakness Mohammad Abu Rub

5:10 pm: Axial Weakness Perry K. Richardson, MD


4:00 pm - 5:30 pm

Session

Channelopathies in NM DiseasesPotomac 1-2

(1) Explain the primary periodic paralyses. (2) Discuss the management and treatment of periodic paralysis. (3) Summarize conditions associated with sodium channelopathies.

4:00 pm: Introduction Jau-Shin Lou, MD, PhD, MBA

4:05 pm: Periodic Paralysis: Review and Update Mohammad K. Salajegheh, MD

4:45 pm: Discussion and Q & A

4:55 pm: A Tale of Three Maladies: Congenital Insensitivity to Pain, Inherited Erythromelagia, and Small Fiber Neuropathy Jau-Shin Lou, MD, PhD, MBA


5:30 pm - 6:30 pm

Social Event

Violinist in the AANEM LoungePotomac Foyer

Unwind in the AANEM Lounge while listening to the beautiful sounds of the violin.

5:30 pm - 6:45 pm

IndustryForum


Can We Build a New Paradigm of Diagnosis to Treatment? The Role of the Latest ALS Therapy

Sponsored by: Mitsubishi Tanabe Pharma America, Inc.

This presentation will review the latest ALS therapy, with a live Q&A following the program. Attendees will hear how this therapy may be able to fit into their current treatment and/or management paradigm for people with ALS.

Target Audience: Neurologists, physical medicine and rehabilitation specialists, and other health care professionals. Intended for US audiences only.

Faculty: Said R. Beydoun, MDProfessor of Clinical NeurologyProgram Director, Clinical Neurophysiology FellowshipDivision Chief, Neuromuscular DisordersKeck Medical Center of USCUniversity of Southern CaliforniaLos Angeles, CA

This activity is sponsored by Mitsubishi Tanabe Pharma America, Inc., and is not part of the official scientific program of AANEM.




45 Saturday | October 13

6:45 am - 8:00 am

IndustryForum


Evolving CIDP Treatment: Patients, Practicalities, and Perspectives

Sponsored by: CSL Behring

This educational forum aims to raise awareness of CIDP and update the audience on diagnosis and treatment options, including subcutaneous immunoglobulin (SCIG) as an alternative option for maintenance therapy. SCIG is now FDA-approved for the maintenance treatment of CIDP in adults, based on the results from the Polyneuropathy and Treatment with Hizentra (PATH) study. The session will cover the evolution of CIDP treatment and best practice, including a review of the PATH study results and their implications for CIDP treatment management. A short interview session will follow devoted to the patient perspective and the impact of SCIG on patient autonomy and daily life. The forum will conclude with a session on practicalities and insights for real-world practice, including: identifying suitable patients, transitioning patients from intravenous immunoglobulin (IVIG), and challenges in CIDP maintenance therapy management.

Learning objectives: • Identify patient factors for selection of maintenance therapy for patients with CIDP • Apply learnings and insights from the PATH study into real-world practice • Initiate conversations with patients surrounding their treatment options and transitioning from IVIG

Faculty:• Jeffrey A. Allen, MD• Tuan H. Vu, MD• Appolos L.• Melody Bullock, BS, BSN, MS, IgCN, CRNI

This activity is sponsored by CSL Behring and is not part of the official scientific program of AANEM.




8:00 am - 9:30 am

Session

Intraoperative MonitoringPotomac C

(1) Employ optimization techniques to improve the quality of baseline intraoperative somatosensory evoked potentials and motor evoked potentials. (2) Recognize technical issues with intraoperative evoked potentials and implement effective troubleshooting strategies to resolve. (3) Interpret evoked potential changes to localize the site of neurologic injury and provide a differential diagnosis.

8:00 am: Introduction E. Matthew Hoffman, DO, PhD

8:05 am: Intraoperative Evoked Potential Optimization Techniques E. Matthew Hoffman, DO, PhD

8:40 am: Localizing and Troubleshooting Intraoperative Evoked Potential Changes Jeffrey A. Strommen, MD


8:00 am - 9:30 am

Session

AdvocacyPotomac 5-6

(1) Discuss what’s going on in Washington, DC and how it affects AANEM members. (2) Identify how to successfully advocate for your interests. (3) Discuss AANEM’s advocacy efforts and how you can assist.

8:00 am: Introduction Millie Suk, JD, MPP

8:05 am: Capitol Hill: Understand What’s Going on in Washington, D.C. and How it Affects AANEM Members Dane Christiansen

8:35 am: Learn How to Successfully Advocate For Your Interests Millie Suk, JD, MPP

9:00 am: AANEM Advocacy Efforts: What is the Organization Doing and How Can I Help? Millie Suk, JD, MPP


46Saturday | October 13

Thank you for your service and dedication to the pursuit of quality patient care.

American Board of Electrodiagnostic Medicine(ABEM)

2017-2018Board of DirectorsJohn D. England, MD, ChairMichael T. Andary, MD, MS, Vice ChairFrancis O. Walker, MD, SecretaryChristina M. Marciniak, MD, Treasurer

MembersTimothy R. Dillingham, MD, MS Peter A. Grant, MDKathleen D. Kennelly, MD, PhDJanice M. Massey, MD

8:00 am - 9:30 am

Session

Traumatic Brachial PlexopathyPotomac 3-4

(1) Describe the anatomy of the brachial plexus and clinical presentations of traumatic brachial plexopathies. (2) Discuss the use of EDX studies in localization, quantification of the degree of injury and prognosis. (3) Distinguish the imaging studies including MRI neurography, CT myelogram, US and its limitations. (4) Discuss the Seddon and Sunderland grading systems and how MRI neurography can help predict pre-operative injury grade. (5) Describe intraoperative modalities (CMAP, NAP) employed for brachial plexus surgeries and how IOM helps guide the surgical options. (6) Identify the cutting edge surgical options, including neurolysis, nerve grafting and transfer.

8:00 am: Introduction Vita G. Kesner, MD, PhD

8:05 am: Clinical Manifestations of Traumatic Brachial Plexopathies: Utility of EDX Studies and Intraoperative Modalities Vita G. Kesner, MD, PhD

8:25 am: Multimodality Imaging of Brachial Plexus Trauma Adam Singer, MD

8:50 am: Traumatic Brachial Plexus Imaging Techniques With an Emphasis on MRI Neurography Nicholas M. Boulis, MD


8:00 am - 9:30 am

Session

Small Fiber Neuropathy/AutonomicsPotomac 1-2

(1) Describe the presenting symptoms and review the evaluation and management of orthostatic hypotension. (2) Identify a step wise approach for the diagnosis of amyloidosis and discuss current treatments and drugs in pipeline for ATTR. (3) To evaluate the etiology and impact of ED and present a practical clinical approach to diagnosing and investigating common and treatable causes in men with ED.

8:00 am: Introduction Divisha Raheja, MD

8:05 am: Orthostatic Hypotension Steven Vernino, MD, PhD

8:30 am: Amyloid Neuropathy Kourosh Rezania, MD

8:55 am: Parasympathetic Failure and ED Jasvinder P. Chawla, MBBS, MD, MBA


8:00 am - 9:30 am

Workshop

W05AS Cranial NCS and EMG Testing

(1) Perform neurophysiological testing of the cranial nerves including blink reflexes and jaw jerk; seventh NCSs; and eleventh nerve testing. (2) Discuss EMG of key muscles that complement the cranial NCS.

1.5 CME Jun Kimura, MD

8:00 am - 9:30 am

Workshop

W18AS NM US


1.5 CME/CEU Vanessa Baute, MD

47 Saturday | October 13

8:00 am - 9:30 am

Workshop

W21AS NCS Pitfalls

(1) Identify common instrumentation, physiologic, and operator errors. (2) Alter recording electrode montages and use the instrument’s filters to help optimize the recording of motor and sensory potentials. (3) Minimize stimulus artifact interference with waveform recording.

1.5 CME/CEU Bassam A. Bassam, MD

8:00 am - 9:30 am

Workshop

W39AS Physical Exam of the Athlete: Lumbar Spine and Lower Extremity

(1) Distinguish different pain generators in the lumbar spine and how specific sports cause overuse injuries. (2) Describe a specific diagnostic workups and treatment plans for a specific sports related spine injuries.

1.5 CME/CEU Francis P. Lagattuta, MD

8:00 am - 9:30 am

Workshop

W45AS Cervical Radiculopathy/Brachial Plexopathy

(1) Discuss the anatomy of the cervical roots and the brachial plexus. (2) Describe the role of the sensory NCS in the initial localization of axon loss processes to preganglionic versus ganglionic/postganglionic. (3) Illustrate the role of the sensory NCS in localizing focal lesions to specific regions of the brachial plexus (root, trunk, division, cord, terminal nerve). (4) Discuss the role of motor NCS in further localizing the lesion and in defining its severity. (5) Describe the role of the needle EMG in confirming the NCS findings and in defining the temporal features of the disorder (slowly progressive, rapidly progressive, acute, subacute, chronic). (6) Demonstrate this information using illustrative cases.

1.5 CME Mark A. Ferrante, MD

8:00 am - 9:30 am

Workshop

W58AS US Upper Extremity Nerves and Plexus

(1) Explain the optimal transducer frequency for imaging upper extremity nerves. (2) Identify the median nerve at the wrist, ulnar nerve at the elbow, and brachial plexus using US. (3) Describe normal median nerve mobility and the appearance of ulnar nerve dislocation on real-time US. (4) List the findings of nerve entrapment as may be seen on US and findings in structures other than nerve that may be relevant.

1.5 CME/CEU Monika Krzesniak-Swinarska, MD

8:00 am - 9:30 am

Workshop

W61AS US Lower Extremity Nerves and Muscles

(1) Explain optimal transducer frequencies for imaging lower extremity nerves. (2) Identify the tibial nerve at the ankle and knee, the fibular nerve at the knee, and the sciatic and sural nerves using US. (3) Describe the branching patterns of tibial, fibular, and sural nerves in the lower extremities. (4) List expected findings of nerve entrapment as may be seen on US and findings in structures other than the nerve that may be significant.

1.5 CME/CEU Steven J. Shook, MD

8:00 am - 9:30 am

Workshop

W77AS US-Guided Peripheral Nerve Interventions-Hydrodissection

(1) Discuss important principles of peripheral nerve identification. (2) Identify the anatomy and sonographic appearance for some common peripheral nerve procedure locations. (3) Describe the methods and techniques for performing peripheral nerve needle-guided procedures. (4) Discuss the methods and techniques for performing hydrodissection procedures for entrapment neuropathies.


48Saturday | October 13

2019Don’t miss next year’s

AANEM Annual MeetingAustin, Texas | Oct. 16-19, 2019

8:00 am - 9:30 am

Workshop

W78AS Chemodenervation for Head and Neck Conditions: Dystonia, Sialorrhea, Migraine

(1) Recognize the various conditions of the head and neck that can be treated with botulinum neurotoxins (BoNT). (2) Identify the commonly involved muscles in cervical dystonia. (3) Localize the BoNT injection sites for the various conditions involving the face (dystonias, sialorrhea, migraine headaches. (4) Discuss how to use needle EMG and US to help guide BoNT injections for head and neck conditions.

1.5 CME Atul T. Patel, MD

8:00 am - 9:30 am

Workshop

W79AS Optimizing the Evaluation/Management of Peripheral Nerve Trauma: Multidisciplinary Approach

(1) Identify the indications for and the importance of early multidisciplinary evaluation of peripheral nerve trauma. (2) Describe potential limitations and pitfalls in the EDX assessment of these patients. (3) Describe the indications and advantages of utilizing US in conjunction with EDX evaluation. (4) Identify the typical surgical approaches utilized in peripheral nerve trauma. Faculty will discuss and share complex cases with the group.

David Reece, DO

Matthew E. Miller, MD

1.5 CME/CEU Jonathan K. Smith, MD

9:30 am - 10:00 am

Social Event



10:00 am - 12:00 pm

Session

Plenary 4: Precision Medicine in NM and MSK MedicinePotomac C


10:05 am: Awards: IFCN & Foundation Certificates Eric J. Sorenson, MD


10:25 am: Precision Medicine Therapeutics in Duchenne Muscular Dystrophy: Dystrophin Restoration and Exercise Mimetics Craig M. McDonald, MD


11:05 am: Annual Meeting 2019 Vision Anthony E. Chiodo, MD, MBA


49

Actor portrayals.In the treatment of amyotrophic lateral sclerosis (ALS), every move matters.As you decide the next move for your patients, consider Radicava® (edaravone), the only FDA-approved treatment option for patients with ALS in the last 20 years.1,2

Overall shift in point loss between treatment groups at 6 months1,3

Discover more at Radicava.com/move

Shown to slow the decline of physical function in patients with ALS1

33% less change in total ALS Functional Rating Scale–Revised (ALSFRS-R) scores vs placebo1,*

Safety profile established with 300+ patients in 3 clinical trials1

Product access programs from Searchlight Support™

*In a 6-month study of 137 participants.1 Individual results may vary.

IndicationRadicava® (edaravone) is indicated for the treatment of amyotrophic lateral sclerosis (ALS).

Important Safety InformationHypersensitivity Reactions Radicava® is contraindicated in patients with a history of hypersensitivity to edaravone or any of the inactive ingredients in Radicava®. Hypersensitivity reactions (redness, wheals, and erythema multiforme) and cases of anaphylaxis (urticaria, decreased blood pressure, and dyspnea) have been reported. Patients should be monitored carefully for hypersensitivity reactions, and if they occur, discontinue Radicava®, treat per standard of care, and monitor until the condition resolves.

Sulfite Allergic Reactions Radicava® contains sodium bisulfite, and may cause allergic type reactions, including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown, but occurs more frequently in asthmatic people.

Most Common Adverse Reactions Most common adverse reactions (at least 10% and greater than placebo) are contusion, gait disturbance, and headache.

Pregnancy Based on animal data, Radicava® may cause fetal harm.

Geriatric Use No overall differences in safety or effectiveness were observed between patients 65 years of age and older and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

To report suspected adverse reactions or product complaints, contact Mitsubishi Tanabe Pharma America, Inc., at 1-888-292-0058. You may also report suspected adverse reactions to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see brief summary of the full Prescribing Information on the next page.

References: 1. Radicava Prescribing Information. Jersey City, NJ: Mitsubishi Tanabe Pharma America; 2017. 2. Rilutek Prescribing Information. Cary, NC: Covis Pharmaceuticals Inc.; 2016. 3. Takei K, Takahashi F, Liu S, Tsuda K, Palumbo J. Post-hoc analysis of randomised, placebo-controlled, double-blind study (MCI186-19) of edaravone (MCI-186) in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(sup 1):49-54.

Radicava, the Radicava logo, and the corporate symbol of Mitsubishi Tanabe Pharma America are registered trademarks of Mitsubishi Tanabe Pharma Corporation. Searchlight Support is a trademark of Mitsubishi Tanabe Pharma America, Inc. For US audiences only.© 2018 Mitsubishi Tanabe Pharma America, Inc. All rights reserved. CP-RC-US-0503 06/18

≤2points

Lost

points

Lost

3-10points

Lost

≥11

1 –1 –2 –3 –4 –5 –6 –7 –8 –9 –10 –11 –12 –13 –14 –15 –16 –17 –18 –19 –200

≤2 pointsLost pointsLost 3-10 pointsLost≥11

39.1%

(n=27)

53.6%

(n=37)

7.2%

(n=5)

Perc

ent o

f Pat

ient

s

0

50

100

63.2%

(n=43)

23.5%

(n=16)13.2%

(n=9)

Radicava (n=69) Placebo (n=68)

Number of Radicava patients (n=69) who1,2:

Point Change in ALSFRS-R Score

≤2points

Lost

points

Lost

3-10points

Lost

≥11

1 –1 –2 –3 –4 –5 –6 –7 –8 –9 –10 –11 –12 –13 –14 –15 –16 –17 –18 –19 –200


= one patient = one patient

Num

ber o

f Pat

ient

s

10

5

0 0

15

Number of placebo patients (n=68) who1,2:

Num

ber o

f Pat

ient

s

10

5

15

Change in ALSFRS-R scores over 24 weeks Patients who1,3:

≤2points

Lost

points

Lost

3-10points

Lost

≥11

1 –1 –2 –3 –4 –5 –6 –7 –8 –9 –10 –11 –12 –13 –14 –15 –16 –17 –18 –19 –200


39.1%

(n=27)

53.6%

(n=37)

7.2%

(n=5)

Perc

ent o

f Pat

ient

s

0

50

100

63.2%

(n=43)

23.5%

(n=16)13.2%

(n=9)




≤2points

Lost

points

Lost

3-10points

Lost

≥11

1 –1 –2 –3 –4 –5 –6 –7 –8 –9 –10 –11 –12 –13 –14 –15 –16 –17 –18 –19 –200



Num

ber o

f Pat

ient

s

10

5

0 0

15


Num

ber o

f Pat

ient

s

10

5

15


3X as many patients given Radicava® lost ≤2 points vs those given placebo

3X as many patients given placebo lost ≥11 points vs those given Radicava®

This shift in distribution demonstrates that a majority of patients responded to treatment—not a specific subtype of patient.3

Give Patients with ALS a Chance.Help Slow the Decline in Functional Loss.

Treated With Radicava® PATIENTS2000+

In the US as of March 1, 2018

Trim7.5”

Trim7.5”

Trim10”

50

Actor portrayals.In the treatment of amyotrophic lateral sclerosis (ALS), every move matters.As you decide the next move for your patients, consider Radicava® (edaravone), the only FDA-approved treatment option for patients with ALS in the last 20 years.1,2

Overall shift in point loss between treatment groups at 6 months1,3

Discover more at Radicava.com/move

Shown to slow the decline of physical function in patients with ALS1

33% less change in total ALS Functional Rating Scale–Revised (ALSFRS-R) scores vs placebo1,*

Safety profile established with 300+ patients in 3 clinical trials1

Product access programs from Searchlight Support™

*In a 6-month study of 137 participants.1 Individual results may vary.

IndicationRadicava® (edaravone) is indicated for the treatment of amyotrophic lateral sclerosis (ALS).

Important Safety InformationHypersensitivity Reactions Radicava® is contraindicated in patients with a history of hypersensitivity to edaravone or any of the inactive ingredients in Radicava®. Hypersensitivity reactions (redness, wheals, and erythema multiforme) and cases of anaphylaxis (urticaria, decreased blood pressure, and dyspnea) have been reported. Patients should be monitored carefully for hypersensitivity reactions, and if they occur, discontinue Radicava®, treat per standard of care, and monitor until the condition resolves.

Sulfite Allergic Reactions Radicava® contains sodium bisulfite, and may cause allergic type reactions, including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown, but occurs more frequently in asthmatic people.

Most Common Adverse Reactions Most common adverse reactions (at least 10% and greater than placebo) are contusion, gait disturbance, and headache.

Pregnancy Based on animal data, Radicava® may cause fetal harm.

Geriatric Use No overall differences in safety or effectiveness were observed between patients 65 years of age and older and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

To report suspected adverse reactions or product complaints, contact Mitsubishi Tanabe Pharma America, Inc., at 1-888-292-0058. You may also report suspected adverse reactions to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see brief summary of the full Prescribing Information on the next page.

References: 1. Radicava Prescribing Information. Jersey City, NJ: Mitsubishi Tanabe Pharma America; 2017. 2. Rilutek Prescribing Information. Cary, NC: Covis Pharmaceuticals Inc.; 2016. 3. Takei K, Takahashi F, Liu S, Tsuda K, Palumbo J. Post-hoc analysis of randomised, placebo-controlled, double-blind study (MCI186-19) of edaravone (MCI-186) in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(sup 1):49-54.

Radicava, the Radicava logo, and the corporate symbol of Mitsubishi Tanabe Pharma America are registered trademarks of Mitsubishi Tanabe Pharma Corporation. Searchlight Support is a trademark of Mitsubishi Tanabe Pharma America, Inc. For US audiences only.© 2018 Mitsubishi Tanabe Pharma America, Inc. All rights reserved. CP-RC-US-0503 06/18

≤2points

Lost

points

Lost

3-10points

Lost

≥11

1 –1 –2 –3 –4 –5 –6 –7 –8 –9 –10 –11 –12 –13 –14 –15 –16 –17 –18 –19 –200


39.1%

(n=27)

53.6%

(n=37)

7.2%

(n=5)

Perc

ent o

f Pat

ient

s

0

50

100

63.2%

(n=43)

23.5%

(n=16)13.2%

(n=9)




≤2points

Lost

points

Lost

3-10points

Lost

≥11

1 –1 –2 –3 –4 –5 –6 –7 –8 –9 –10 –11 –12 –13 –14 –15 –16 –17 –18 –19 –200


= one patient = one patientNu

mbe

r of P

atie

nts

10

5

0 0

15


Num

ber o

f Pat

ient

s

10

5

15


≤2points

Lost

points

Lost

3-10points

Lost

≥11

1 –1 –2 –3 –4 –5 –6 –7 –8 –9 –10 –11 –12 –13 –14 –15 –16 –17 –18 –19 –200


39.1%

(n=27)

53.6%

(n=37)

7.2%

(n=5)

Perc

ent o

f Pat

ient

s

0

50

100

63.2%

(n=43)

23.5%

(n=16)13.2%

(n=9)




≤2points

Lost

points

Lost

3-10points

Lost

≥11

1 –1 –2 –3 –4 –5 –6 –7 –8 –9 –10 –11 –12 –13 –14 –15 –16 –17 –18 –19 –200



Num

ber o

f Pat

ient

s

10

5

0 0

15


Num

ber o

f Pat

ient

s

10

5

15


3X as many patients given Radicava® lost ≤2 points vs those given placebo

3X as many patients given placebo lost ≥11 points vs those given Radicava®

This shift in distribution demonstrates that a majority of patients responded to treatment—not a specific subtype of patient.3

Give Patients with ALS a Chance.Help Slow the Decline in Functional Loss.

Treated With Radicava® PATIENTS2000+

In the US as of March 1, 2018

Trim7.5”

Trim7.5”

Trim10”

51

Brief Summary of Full Prescribing Information

INDICATIONS AND USAGE

RADICAVA (edaravone injection) is indicated for the treatment of amyotrophic lateral sclerosis (ALS).

CONTRAINDICATIONS

RADICAVA is contraindicated in patients with a history of hypersensitivity to edaravone or any of the inactive ingredients of this product. Hypersensitivity reactions and anaphylactic reactions have occurred [see Warnings and Precautions].

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions Hypersensitivity reactions (redness, wheals, and erythema multiforme) and cases of anaphylaxis (urticaria, decreased blood pressure, and dyspnea) have been reported in spontaneous postmarketing reports with RADICAVA.Patients should be monitored carefully for hypersensitivity reactions. If hypersensitivity reactions occur, discontinue RADICAVA, treat per standard of care, and monitor until the condition resolves [see Contraindications].

Sulfite Allergic ReactionsRADICAVA contains sodium bisulfite, a sulfite that may cause allergic type reactions, including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown. Sulfite sensitivity occurs more frequently in asthmatic people.

ADVERSE REACTIONS

The following serious adverse reactions are described elsewhere in the labeling: • Hypersensitivity Reactions [see Warnings and Precautions] • Sulfite Allergic Reactions [see Warnings and Precautions]

Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. In randomized, placebo-controlled trials, 184 ALS patients were administered RADICAVA 60 mg in treatment cycles for 6 months. The population consisted of Japanese patients who had a median age of 60 years (range 29-75) and were 59% male. Most (93%) of these patients were living independently at the time of screening.

Most Common Adverse Reactions Observed During Clinical StudiesAdverse reactions that occurred in ≥ 2% of patients in the RADICAVA-treated group and that occurred at least 2% more frequently than in the placebo-treated group in randomized placebo-controlled ALS trials were as follows for RADICAVA (N=184) versus Placebo (N=184), respectively: Contusion (15% versus 9%), Gait disturbance (13% versus 9%), Headache (10% versus 6%), Dermatitis (8% versus 5%), Eczema (7% versus 4%), Respiratory failure, respiratory disorder, hypoxia (6% versus 4%), Glycosuria (4% versus 2%), Tinea infection (4% versus 2%). Results are from pooled placebo-controlled studies including two additional studies with 231 additional patients, all using the same treatment regimen. The most common adverse reactions that occurred in ≥10% of RADICAVA-treated patients were contusion, gait disturbance, and headache.

Postmarketing Experience

The following adverse reactions have been identified during postapproval use of RADICAVA outside of the United States. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Skin and subcutaneous tissue disorders: Hypersensitivity reactions and anaphylaxis.

USE IN SPECIFIC POPULATIONS

Pregnancy

Risk SummaryThere are no adequate data on the developmental risk associated with the use of RADICAVA in pregnant women. In animal studies, administration of edaravone to pregnant rats and rabbits resulted in adverse developmental effects (increased mortality, decreased growth, delayed sexual development, and altered behavior) at clinically relevant doses. Most of these effects occurred at doses that were also associated with maternal toxicity [see Animal Data].

In the US general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. The background risk for major birth defects and miscarriage in patients with ALS is unknown.

Data

Animal DataIn rats, intravenous administration of edaravone (0, 3, 30, or 300 mg/kg/day) throughout the period of organogenesis resulted in reduced fetal weight at all doses. In dams allowed to deliver naturally, offspring weight was reduced at the highest dose tested. Maternal toxicity was also observed at the highest dose tested. There were no adverse effects on reproductive function in the offspring. A no-effect dose for embryofetal developmental toxicity was not identified; the low dose is less than the recommended human dose of 60 mg, on a body surface area (mg/m2) basis.In rabbits, intravenous administration of edaravone (0, 3, 20, or 100 mg/kg/day) throughout the period of organogenesis resulted in embryofetal death at the highest dose tested, which was associated with maternal toxicity. The higher no-effect dose for embryofetal developmental toxicity is approximately 6 times the recommended human dose (RHD) on a body surface area (mg/m2) basis.The effects on offspring of edaravone (0, 3, 20, or 200 mg/kg/day), administered by intravenous injection to rats from GD 17 throughout lactation, were assessed in two studies. In the first study, offspring mortality was observed at the high dose and increased activity was observed at the mid and high doses. In the second study, there was an increase in stillbirths, offspring mortality, and delayed physical development (vaginal opening) at the highest dose tested. Reproduction function in offspring was not affected in either study. Maternal toxicity was evident in both studies at all but the lowest dose tested. The no-effect dose for developmental toxicity (3 mg/kg/day) is less than the RHD on an mg/m2 basis.

Lactation

Risk SummaryThere are no data on the presence of edaravone in human milk, the effects on the breastfed infant, or the effects of the drug on milk production. Edaravone and its metabolites are excreted in the milk of lactating rats. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for RADICAVA and any potential adverse effects on the breastfed infant from RADICAVA or from the underlying maternal condition.

Pediatric Use

Safety and effectiveness of RADICAVA in pediatric patients have not been established.

Geriatric Use

Of the 184 patients with ALS who received RADICAVA in 3 placebo-controlled clinical trials, a total of 53 patients were 65 years of age and older, including 2 patients 75 years of age and older. No overall differences in safety or effectiveness were observed between these patients and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

NONCLINICAL TOXICOLOGY

Carcinogenesis, Mutagenesis, Impairment of Fertility

CarcinogenesisThe carcinogenic potential of edaravone has not been adequately assessed.

MutagenesisEdaravone was negative in in vitro (bacterial reverse mutation and Chinese hamster lung chromosomal aberration) and in vivo (mouse micronucleus) assays.

Impairment of FertilityIntravenous administration of edaravone (0, 3, 20, or 200 mg/kg) prior to and throughout mating in males and females and continuing in females to gestation day 7 had no effect on fertility; however, disruption of the estrus cycle and mating behavior was observed at the highest dose tested. No effects on reproductive function were observed at the lower doses, which are up to 3 times the RHD of 60 mg, on a body surface area (mg/m2) basis.

Marketed and distributed by:Mitsubishi Tanabe Pharma America, Inc., a US subsidiary of Mitsubishi Tanabe Pharma Corporation 525 Washington Blvd., Suite 400, Jersey City, NJ 07310

RADICAVA is a registered trademark of Mitsubishi Tanabe Pharma Corporation.CNP-RC-US-0080 04/18

Trim7.5”

Trim10”

52

Lifetime Achievement Award Recipient: James A. Leonard, Jr., MD The Lifetime Achievement Award is AANEM’s highest honor, and for 2018, AANEM is proud to announce James A. Leonard, Jr., MD, as its recipient. This award recognizes an AANEM member who has been a major contributor in the fields of NM and EDX medicine.

Working with patients has been and continues to be what Dr. Leonard enjoys most about his job. “I have always thought of PMR as primary care for a special population of patients – individuals that often other colleagues feel uncomfortable working with because of their impairments. I have been privileged to be able to provide care to many of my patients for the entirety or much of their lives, and in the process, have gotten to know their families, children, grandchildren, and great grandchildren,” noted Dr. Leonard.

Distinguished Physician Award Recipient: Yuen T. So, MD, PhDAANEM is honored to present Yuen T. So, MD, PhD, as the recipient of the 2018 AANEM Distinguished Physician Award due to his contributions as a clinician and educator as well as his overall support of AANEM activities.

Dr. So says finding out he won the 2018 AANEM Distinguished Physician Award came as a “complete surprise.” “Receiving this award is, without question, the most memorable career moment for me. I am deeply grateful to the AANEM Awards Committee and all of the years of support from the AANEM,” he said.

Distinguished Researcher Award Recipient: Ted M. Burns, MDAANEM selected Ted M. Burns, MD, as the recipient of the 2018 Distinguished Researcher Award. Each year, this award is given to an AANEM member who has made significant research contributions in clinical neurophysiology and NM disease.

Clinical research – particularly research in the assessment and treatment of myasthenia gravis (MG) – has been a central part of Dr. Burns’ career. This focus led Dr. Burns to develop the MG Composite and MG Quality of Life scales which are recognized worldwide as the standard end-points for ongoing clinical trials. “I especially like having an efficient, easy-to-use tool for estimating and understanding the quality of life of the MG patient … one that can parse out the different aspects of the patient’s struggle. It’s personally rewarding to know that others also find the outcome measures we created useful,” said Dr. Burns.

2018 AANEM Achievement AwardsThe 2018 AANEM Achievement Awards will be presented during the Friday plenary session. Join us as we recognize the following individuals for their significant contributions to NM and EDX medicine. Read their full stories at www.aanem.org/AANEMAchievementAwards.

53

Advocacy Award Recipient: Raghav Govindarajan, MDDue to his longstanding work advocating on behalf of EDX medicine, AANEM selected Raghav Govindarajan, MD, as the recipient of the 2018 AANEM Advocacy Award.

Dr. Govindarajan sees advocacy as a continuum. “It involves teaching and exposing learners to the fascinating world of EDX medicine, providing quality EDX care to patients, serving as a resource to referral providers, advocating at a grassroots level, and finally, advocating nationally,” said Dr. Govindarajan.

Distinguished Service Award Recipient: Shirlyn A. Adkins, JDMs. Adkins was chosen as the recipient of the 2018 AANEM Distinguished Service Award based on her past, current, and future contributions to the missions of AANEM and the AANEM Foundation.

Ms. Adkins has helped AANEM grow and evolve through a number of achievements over the past 2 decades; however, she is most proud of adding advocacy to the AANEM. “It was important for us to add this vital piece to our organization. As part of our mission, we need to advocate on behalf of our patients,” said Ms. Adkins.

JOIN US!

Physical Medicine and Rehabilitation congratulates Dr. James A. Leonard on receiving the Life Time Achievement Award from the American Association of Neuromuscular & Electrodiagnostic Medicine.

Physical Medicine and Rehabilitation at Michigan Medicine is a leader in rehabilitation training, research, and clinical care. Michigan Medicine has been the site of many groundbreaking medical and technological advancements since the Medical School first opened in 1850. Visit pmr.med.umich.edu and learn about exciting new developments in the department.

THELEADERSANDBEST!

October 25, 2018

All-Michigan Physiatry Reception at AAPM&R2018Hyatt Regency, Orlando

Fall, 2019James Rae Alumni Day and Football TailgateAnn Arbor

Leadership in EducationTraining the Leaders of Tomorrow

Leadership in Innovation #4 in NIH Funding for PM&R

Leadership in Interdisciplinary RehabilitationTranslating Innovation to Patient Care

For information:pmr.med.umich.eduor 734-936-8178

James A. Leonard, MD Clinical Professor 1975 - 2017

Professor and Chair 1994 - 2006Emeritus Professor 2017 -

54

Golseth Young Investigator Award Recipient - Katherine Clifford, BAThymectomy is Not Associated With Clinical Improvement in a Multi-Center Cohort of Patients With Anti-MuSK Myasthenia Gravis (Abstract #1)

“My project investigates the impact of thymectomy as a treatment in anti-muscle-specific kinase (MuSK) myasthenia gravis (MG). I analyzed data from a pre-existing dataset from a multi-center cohort of patients with anti-MuSK MG in order to evaluate clinical outcomes in patients treated with thymectomy compared to those not treated with thymectomy. We did not find thymectomy

to be associated with a greater likelihood of a favorable clinical outcome in anti-MuSK MG,” explained Clifford.

Clifford says she hopes her research will have an impact on guiding clinical decision-making and therapeutic management for patients with this rare subtype of MG.

Clifford is a fourth year medical student at the University of Vermont Larner College of Medicine and will graduate in May 2019. She is applying into a neurology residency program and will be pursuing a clinical and research career in neurology.

Golseth Young Investigator Award Runner-up - Long Davalos, MDErythromelalgia and Sensory Neuropathy in Autoimmune Hepatitis: A Case Study(Abstract #2)

“This case was about a patient who was diagnosed with autoimmune hepatitis and concomitantly presented sensory neuropathic symptoms and eryhtromelalgia. Based on the progression of the disease, and further testing, it seemed that the neurological findings had an autoimmune component,” explained Dr. Davalos. “We submitted this case because, to my knowledge, it was not previously reported. Additionally, we wanted to make physicians aware of this potential association, so treatment can be directed into controlling this autoimmune response.”

Dr. Davalos is Peruvian and graduated from medical school at Universidad Peruana Cayetano Heredia. He is currently a neurology resident at the University of Cincinnati and plans to start his NM fellowship in July 2019.

2018 Abstract Award WinnersAANEM is proud to announce abstract award winners in a number of categories: Golseth Young Investigator Award, Best Abstract Award, Technologist Member Recognition Award, President’s Research Initiative Awards, Residency and Fellowship Member Recognition Awards, AANEM Foundation International Fellowship Awards, and IFCN Awards.

Abstract numbers are listed beside each winner’s name. We encourage you to congratulate these individuals and visit with them during the following times:• Posters 1-105: Thursday, 11:30 am - 12:30 pm• Posters 106-207: Friday, 11:30 am - 12:30 pm

Golseth Young Investigator AwardThe Golseth Young Investigator Award, honoring AANEM Founding Member, Dr. James Golseth, is presented annually to a medical student or physician in the early stages of his/her career for original research in NM and EDX medicine. For 2018, a Golseth award winner and a runner-up were selected.

55

Best Abstract Award Recipient - Goran Rakocevic, MDQuantitative Clinical and Autoimmune Assessments in Stiff Person Syndrome: Evidence for a Progressive Disorder(Abstract #3)

“Stiff Person Syndrome is a rare yet fascinating neurological disorder rich in symptomatology and manifestations, a challenge to study in a systematic and longitudinal fashion in one center because of its disabling nature over time,” Dr. Rakocevic explained. “The highlight of our abstract is the evidence for faster progression of disablement than originally reported and believed.”

Dr. Rakocevic works at Thomas Jefferson University in Philadelphia, Pennsylvania as an Associate Professor of Neurology, Director of the Neuromuscular Electrodiagnostic Laboratory, Clinical Director of the Jefferson Weinberg ALS Center, and Director of the Neuromuscular Medicine Fellowship Program.

Best Abstract Award Runner-up - Shruti Raja, MDValidation of the Triple Timed Up-and-Go Test for Clinical Assessment in Lambert-Eaton Myasthenia Patients(Abstract #4)

Dr. Raja’s research focused on assessment of Lambert-Eaton Myasthenic Syndrome (LEMS) and was sponsored by the AANEM Foundation through a Clinical Research Fellowship Award.

“The abstract and project overall sought to validate a variant of the functional mobility ‘get up and go’ test that has been used in geriatrics, orthopedics, and in some neurologic conditions but not in NM conditions. I wanted establish that the 3TUG, a variant of this test, can be used to assess LEMS patients.

I looked at several different aspects of the 3TUG—reproducibility in LEMS patients, construct validity and correlation with patient and physician assessments of disease severity using data from the recently published DAPPER trial of 3,4-diaminopyridine free base in LEMS patients. Overall, the findings indicate the 3TUG is a valid tool for assessing disease severity in LEMS patients. The 3TUG also requires little additional equipment, making it a very practical tool for assessing LEMS patients.” Dr. Raja works at Duke University as an Assistant Professor in the Neuromuscular Division of the Department of Neurology.

Best Abstract AwardThe Best Abstract Award is given to the best research paper submitted to the AANEM Annual Meeting. All abstracts submitted are considered for this award unless the authors indicate that they do not wish to be considered. For 2018, a Best Abstract Award winner and a runner-up were selected.

We are committed to innovation to improve the lives of people with neurological, immunological, and bone disorders, finding solutions to meet their unique needs.

Creating valuefor patients

To learn more, visit

www.ucb-usa.com© 2018 UCB, Inc. All rights reserved.

Neil, UCB

56

Technologist Member Recognition Award RecipientsThe AANEM Technologist Member Recognition Award encourages technologists to take a leading role in conducting research in NM and EDX medicine. Technologists can receive this award for being the first and presenting author of an accepted abstract at the AANEM Annual Meeting. For 2018, 2 individuals were selected to receive this award (one as a runner-up).

Technologist Member Recognition Award Recipient - Favio C. Bumanlag, BAClinical, Laboratory and Electrodiagnostic Features of Zinc Deficiency-induced Peripheral Neuropathy(Abstract #12)

“Zinc, an essential trace element, plays a critical role in maintaining normal structural and functional conditions in the body. Peripheral nerves are susceptible to damage when zinc deficiency occurs. There isn’t much literature written about zinc deficiency induced peripheral neuropathy and recognition of it will help physicians and technologists effectively manage patients,” Bumanlag said.

Bumanlag works in the Department of Neurology as the chief technologist at the Lewis Katz School of Medicine at Temple University in Philadelphia, Pennsylvania.

Technologist Member Recognition Award Runner-up - Ali Arvantaj, CAPAgarose Based Acetylcholine Reduces Quantitative Sudomotor Axon Reflex Test’s (QSART) False Positives(Abstract #13)

“There are two ways to perform QSART. The first way involves using liquid acetylcholine (ACh); the second involves using agarose gel based ACh. Most labs use liquid ACh, as it is easier to make. Making agarose gel based ACh is more difficult as it requires special lab equipment and training. However, when an autonomic laboratory is equipped with the technology to make agarose gel based ACh, it not only makes the technical aspect of performing the QSART easier for the technologists (no leaks, possibility of placing the capsules very distal on the limbs) but also reduces

the false positives of the test. In our study, we showed that using agarose gel reduced the technical difficulties of performing the test and therefore significantly reduced the number of false positives,” Arvantaj explained.

Arvantaj currently works as a lead autonomic technologist at University Hospitals Cleveland Medical Center in Cleveland, Ohio.

Foundation International Fellowship & IFCN Award Recipients

The AANEM Foundation International Fellowship Award provides an opportunity for physicians who practice in economically developing countries to apply for funds to support their education through attendance at the AANEM Annual Meeting. Approximately 5 International Fellowship Awards are granted annually (there are 6 winners in 2018). All applicants are also automatically considered for awards funded by the North American Chapter of the International Federation of Clinical Neurophysiology (IFCN).

Fabio Barroso, MD (Abstract #43)

Otto J. Hernandez Fustes, MD, MSc(Abstract #57, #119, #126, #148, #149)

Naglaa A. Gadallah, MD(Abstract #6)

Nino Khizanishvili, MD (Abstract #123)

Mrinal Kumar Acharya, MBBS, MD(Abstract #131)

Pradnya Dhargave, MD(Abstract #93)

Foundation International Fellowship Award Winners

57

José M. Crespo, MD(Abstract #132)

Juan Ignacio Lopez, MD(Abstracts #128, #129)

Sergio Morales, MD(Abstract #147)

Fatima Pantiu, MD(Abstract #20)

Wagner Cavalcante, MD(Abstract #40)

Dong Zhang, MD(Abstracts #33, #118)

Thomas Torres Cuenca, MD(Abstract #51)

Haiden Pérez, MD (Abstract #61)

Joel V. Gutierrez, MD, PhD(Abstracts #31, #38)

Hala Elhabashy, MD(Abstract #175)

Abeer K. El Zohiery, MD(Abstract #30)

Rajeev Ojha, MD, DM(Abstract #150)

Maha Emad Ibrahim, PhD(Abstract #68)

Sarah Siddiqui, MBBS, FCPS, MRCP(Abstract #160)

Ahmed Wali, MD, FCPS, DABCN(Abstract #167)

Ma Luisa Gwenn F. Pabellano-Tiongson, MD(Abstract #146)

Dong Hwee Kim, MD, PhD(Abstract #155)

Je-Sang Lee, MD, PhD(Abstract #79)

MinKyun Sohn, MD(Abstract #46)

Gehad Swilam, MSc(Abstract #64)

Oksana Haiko, MD, PhD(Abstracts #127, #152)

Albina Tretiakova, PhD, DSc(Abstract #158)

Myat Thura, MD, MRCP (Abstracts #81, #154)

IFCN Award Winners

For 2018, Eric J. Sorenson, MD, AANEM President, chose Precision Medicine in NM and MSK Medicine as his topic for research for the AANEM Annual Meeting. Abstracts submitted on this topic are automatically considered for the President’s Research Initiative Award; however, only 10 abstracts or fewer are chosen to receive this honor.

President’s Research Initiative Award Recipients

Ryan Castoro, DO, MS A Novel Compound Heterozygous Mutation in Titin Leads to Core Myopathy with Heart Disease(Abstract #11)

Naglaa A. Gadallah, MD Association between Plantar Fasciitis and Foot Entrapment Neuropathy: Musculoskeletal Ultrasound and Electrodiagnostic Study(Abstract #6)

Anza B. Memon, MD Suprascapular Neuropathy: A Review of 87 Cases(Abstract #8)

James Nussbaum, PT, PhD, SCS, EMT Novel Physical Therapy Intervention for Patients with Charcot-Marie-Tooth. A Retrospective Case Series(Abstract #10)

Bhaskar Roy, MD, MMST Correlation between Electrical Impedance Myography and Two Quantitative Ultrasound Parameters in Duchenne Muscular Dystrophy(Abstract #9)

Hui Yang, PhD How Often is Molecular Therapy an Option for Duchenne Muscular Dystrophy Patients(Abstract #7)

President’s Research Initiative Award Winners

58

Samah Aburahma, MD (Abstract #138)

Yasir Al-Khalili, MD (Abstracts #124, #125)

Tristin Allen-Jouaibi, MD (Abstract #141)

Bethany A. Calabrese, DO (Abstract #176)

Bei Cao, MD (Abstract #53)

Ryan Castoro, DO, MS (Abstract #11)

Cesar A. Colasante, MD (Abstract #50)

Mathieu Cuchanski, DO (Abstracts #45, #172)Long Davalos, MD (Abstract #2)

Marine Dididze, MD, PhD (Abstracts #17, #91, #92)

Behzad Elahi, MD, PhD (Abstract #192)

Obehioya Irumudomon, MD (Abstract #37)

William Jens, DO (Abstract #135)

Stacy Jordan, DO (Abstract #161)

Ehtesham Khalid, MD, MRCP, FCPS (Abstracts #113, #166)

Nikolai Khromouchkine, MD (Abstract #39)

Tiffany Lee, MD (Abstract #206)

Mary McClanahan, MD(Abstract #168)

Gabrielle Nguyen, MD(Abstract #60)

Shruti Raja, MD(Abstract #4)

Gregory Robbins, MD(Abstract #143)

Conor Ryan, MD(Abstract #32)

Nirav Sanghani, MD, DM(Abstracts #184, #197, #200)

Shuja Sheikh, MD(Abstracts #153, #188, #189)

Adnan Solaiman, MD(Abstract #29)

Thomas Torres Cuenca, MD(Abstract #51)

Rocio Vazquez Do Campo, MD(Abstract #156)

Stefanie Wolf, MD(Abstract #151)

Chelsea Zale, DO(Abstract #185)

Residency and Fellowship Member Award Recipients

The AANEM Residency and Fellowship Member Award encourages young physician members to conduct research in NM and EDX medicine. The awards are given to AANEM members currently enrolled in residency or fellowship programs. Those who are the first and presenting author of an accepted abstract for the annual meeting receive the award.

2018 Residency and Fellowship Member Award Winners

Clinical Utility of Genetic Testing in the Diagnosis of Proximal (Limb-Girdle) Muscle Weakness

Friday, October 12, 2018 | Time: 7:00 - 8:00 AMLocation: Gaylord National, Room: Potomac A

Please join us for an Industry Forum held during the AANEM Annual Meeting.

DISCLAIMERThis activity will be held during the AANEM Annual Meeting. It is not part of the official scientific program of the AANEM and is not approved for CME.

Sanofi Genzyme (SGZ) may not provide meals to certain persons at this SGZ sponsored Industry Forum. By accepting a meal at this program, you represent that none of these descriptions apply to you: (1) Minnesota or New Jersey prescriber; (2) healthcare provider licensed in Vermont (physician, nurse, pharmacist, etc.); (3) anyone prohibited from accepting things of value such as the food or drink at this event by other state or federal laws, or by his or her employer’s policies. In accordance with the PhRMA Code on Interactions with Healthcare Professionals, attendance at this program is limited to healthcare professionals. Accordingly, attendance by guests or spouses is not permitted. Sanofi Genzyme thanks you for your understanding.

SGUSMA.PD.18.08.0446Expires: 10/14/18

Līvija Medne, MS, LCGCGenetic CounselorChildren’s Hospital of Philadelphia

Matthew Harms, MDAssociate Professor of NeurologyColumbia University Vagelos College of Physicians and Surgeons

59

FOR ADDITIONAL INFORMATION, PLEASE CONTACT: Patty Shipton, FASPR, Physician Recruiter, at

[email protected] or 717-531-4703.

The Penn State Health Milton S. Hershey Medical Center is committed to affirmative action, equal opportunity and the diversity of its workforce. EOE-AA-M/F/D/V. All individuals (including current employees) selected for a position will undergo a background check appropriate for the position’s responsibilities.

Clinical and research neurologists with expertise in Neuromuscular Neurology are invited to apply for an open position at The Pennsylvania State University College of Medicine and the Penn State Health Milton S. Hershey Medical Center. This search represents part of a major institutional commitment to expansion of the neurosciences. The successful candidate will join the collegial faculty of Penn State Neurology, which is poised for an exciting period of growth under the leadership of the new Chair, Krish Sathian, MBBS, PhD, FANA.

WHAT WE’RE SEEKING

• Medical degree – MD, DO, or foreign equivalent.• BC/BE in Neurology and Neuromuscular fellowship training or foreign equivalent.• Clinical interest and expertise in neuromuscular diseases and a strong background and training in EMG.• Excellent patient care abilities and interest in teaching, as well as participation in clinical research.• For research position, clinical and/or laboratory research interest relevant to neuromuscular neurology.

WHAT WE OFFER:

• Outstanding program with a national reputation. • Large MDA and Neuromuscular Outpatient Clinics, ALS Center of Excellence, EMG/Autonomic Laboratory.• Highly collaborative culture.• Cutting-edge basic and clinical neuroscience research and top-notch facilities at both the Hershey and the

University Park campuses.• Interaction with dynamic clinicians across all neuroscience-related departments and participation in innovative

educational approaches.• Faculty rank commensurate with experience.• Competitive salary and generous benefits.

Neuromuscular Neurologist

AREA HIGHLIGHTS:Located in a safe, family-friendly setting in Hershey, PA, our local neighborhoods boast a reasonable cost of living. Whether you prefer a suburban setting or a thriving city rich in theater, arts, and culture, you’ll find it all right here. Known as the home of the Hershey chocolate bar, Hershey’s community is rich in history and the greater metro area offers an abundant range of outdoor activities, arts, restaurants and diverse experiences. We’re also conveniently located within a short distance to major cities, including Philadelphia, Pittsburgh, NYC, Baltimore, and Washington DC.

60

Poster HallPoster Hall

Entrance Entrance

Abstract Poster Viewing Abstract Poster AwardsGolsethBest AbstractPresident's Research InitiativeResident/Fellow RecognitionTechnologist Recognition

AANEM Poster Presentation - Thursday, 11:30 am to 12:30 pm IFCNPosters 1 through 105 Foundation International

AANEM Poster Presentation - Friday, 11:30 am to 12:30 pm MGFA PostersPosters 106 through 207 999 Withdrawn

All abstract posters will be on display from Wednesday, October 10 at 8:00 am through Friday, October 12 at 1:00 pm. Stop by after the Thursday and Friday Plenary sessions to meet the authors and discuss their research.

207

206

146 153

145 154

116 123

115 124

99

64

52 65

66

50 67

114 125

176 183

175 184

179 180

178 181

177 182

149 150

148 151

147 152

85 92

84 93

119 120

118 121

117 122

88 89

87 90

86 91

113 126

112 127

49 68

111 128

110 12979

83 94

82 95

81 96

53

80 97

144 155

143 156

142 157

141 158

140 159

174 185

173 187

172 188

171 189

170 190

205

204

203

202

201

MG

FA

MG

FA

MG

FA

MG

FA

MG

FA

MG

FA

200

199

198

197

196

169 191

168 192

167 193

166 194

165 195

139 160

138 161

137 162

136 163

135 164

75 103

74 104

109 130

108 131

107 132

78 100

10177

76 102

106 133

105 134

58

57

56

55

54

59

60

61

62

63

48

47

46

45

44 73

72

71

70

6918

17

16

15

14

39

40

41

42

43

23

22

21

20

19

34

35

36

37

38

26

25

24

29

30

31

32

33

28

27

13 121

112

103

94

8 7 6

51

61

ExhibitorsAkceaBooth 301

Akcea Therapeutics is a development and commercialization company focused on helping patients with serious and rare diseases. The name “Akcea” is derived from the Greek word for value and worth.Something that has “akcea” is not common, but precious and rare. Our name supports the value we are creating for the healthcare provider community, patients, and their families. We are driven by knowing that patients depend on us.Wakefield, MA | https://akceatx.com

Alexion PharmaceuticalsBooth 109

Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare and ultra- rare diseases through the innovation, development and commercialization of life-changing therapies. Alexion has pioneered the complex field of complement biology and is committed to developing and delivering life-changing therapies to patients with devastating complement- mediated and metabolic disorders.Cheshire, CT | http://www.alexion.com

Allergan, IncBooth 309

Allergan plc (NYSE: AGN), is a bold, global pharmaceutical company focused on developing, manufacturing and commercializing branded pharmaceuticals, devices and biologic products for patients around the world. For more information, visit Allergan’s website at www.Allergan.com.Irvine, CA | http://www.allergan.com

Alnylam PharmaceuticalsBooth 315

In 2012, Alnylam entered into an exclusive alliance with Genzyme, a Sanofi company, to develop and commercialize RNAi therapeutics, including patisiran and ALN-TTRsc, for the treatment of ATTR in Japan and the broader Asian-Pacific region. In early 2014, this relationship was extended as a significantly broader alliance to advance RNAi therapeutics as genetic medicines. Under this new agreement, Alnylam will lead development and commercialization of patisiran in North America and Europe while Genzyme will develop

and commercialize the product in the rest of world.Developing patisiran (ALN-TTR02), an intravenously administered RNAi therapeutic, to treat the FAP form of the disease.Cambridge, MA | http://www.alnylam.com

Ambu Inc.Booth 223

Ambu manufactures and sells quality electrodes that optimize workflow, reduce costs and improve patient care. Our full line of neurodiagnostic electrodes includes reusable and disposable products to help meet your everyday needs. We specialize in needle and surface electrodes for IOM, EMG, NCS, EP, Sleep and EEG studies. Ambu designs our products with both the patient and physician in mind.Glen Burnie, MD | http://www.ambuUSA.com

American Board of Physical Medicine & RehabilitationBooth 129

ABPMR strives to serve the public by improving the quality of patient care in physical medicine and rehabilitation (PM&R). Visit our booth to learn about free resources available to those who are preparing to take exams; the innovative tools we offer to support our diplomates in maintaining their certification - including CertLinkTM and the subspecialty certifications offered.Rochester, MN | http://www.abpmr.org

American Board of Psychiatry and NeurologyBooth 428

The American Board of Psychiatry and Neurology serves the public interest and the professions of psychiatry and neurology by promoting excellence in practice through its certification and maintenance of certification processes.Deerfield, IL | https://www.abpn.com

ArgenxBooth 429

Argenx is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody- based therapies for the treatment of severe autoimmune diseases and cancer.Boston, MA | http://www.argenx.com

62

AvexisBooth 415

We are breaking barriers. AveXis is a clinical-stage gene therapy company relentlessly focused on bringing gene therapy out of the lab and into the clinical setting for patients and families devastated by rare and orphan neurological genetic diseases. For more information, please visit AveXis.com.Bannockburn, IL | https://www.avexis.com

B. Braun CeGaT, LLCBooth 230

B. Braun CeGaT provides genetic diagnostic testing for a broad range of diseases. Founded in 2009, our team has extensive experience with the development of next- generation sequencing based assays and clinical interpretation of genetic variations. We have developed hundreds of multi-gene diagnostic panels for various disease areas including our neuromuscular panel of over 330 genes.Bethlehem, PA | http://www.bbrauncegat.com

BioCure RXBooth 232

BIOCURE Specialty Pharmacy is a privately held company that specializes in high cost, high patient out-of- pocket, and clinically complex therapies that involve nursing care and/or training. BIOCURE is designed to provide solutions for the medical professionals, commercial payers, manufacturers, and most importantly the patient through the most advanced technologies.Atlanta, GA | http://www.biocurerx.com

BiogenBooth 110

At Biogen, our mission is clear: we are pioneers in neuroscience. Since our founding in 1978 as one of the world’s first global biotechnology companies, Biogen has led innovative scientific research with the goal over the last decade to defeat devastating neurological diseases.Weston, MA | https://www.biogen.com

VISIT US ON THE EXHIBIT FLOORPlease also join us at the Mitsubishi Tanabe Pharma America, Inc. booth and on the exhibit floor for an opportunity to discuss the ALS diagnosis with the speaker at the following times: Thursday, October 11 • 3:10 pm-3:30 pm | Friday, October 12 • 9:40 am-10:00 am

PRESENTED BY

Said R. Beydoun, MD, FAANProfessor of Clinical Neurology, Program Director, Clinical Neurophysiology Fellowship Division Chief, Neuromuscular DisordersKeck Medical Center of USC University of Southern California • Los Angeles, CA

New data on the latest ALS therapy will be presented.

This activity will be held during the AANEM Annual Meeting. It is not part of the official

scientific program of the AANEM.

© 2018 Mitsubishi Tanabe Pharma America, Inc. All rights reserved. CP-RC-US-0662 08/18 Intended for US audiences only.The Corporate Symbol of Mitsubishi Tanabe Pharma America is a registered trademark of Mitsubishi Tanabe Pharma Corporation.

Industry Forum from

Mitsubishi Tanabe Pharma America, Inc.Can We Build a New Paradigm of Diagnosis to Treatment?

The Role of the Latest ALS TherapyWHENFriday, October 12, 2018 • 5:30 pm-6:30 pmLight Refreshments and Presentation

WHEREGaylord National Resort and Convention Center – Potomac A201 Waterfront Street • National Harbor, Maryland 20745

This is a promotional presentation and is not certified for continuing medical education credit. If you are licensed in any state or other jurisdiction or are an employee or contractor of any organization that limits or prohibits meals from the pharmaceutical industry, please do not partake in the meal. Attendance by spouses or guests is prohibited.

REGISTRATION INFORMATIONTo register for this program, please visit www.intramedgroupmeetings.com/aanem or scan this QR code with your mobile device.Badges will be confirmed at sign-in.Preregistration is encouraged, but not required.

63

Biohaven PharmaceuticalsBooth 426

Biohaven is a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases, including rare disorders. Biohaven’s product candidates are small molecules based on two distinct mechanistic platforms: glutamate modulators and calcitonin gene-related peptide (CGRP) receptor antagonists. Biohaven is committed to addressing the high unmet need for new treatment options that target glutamate regulation and currently has three product candidates in development for multiple neurological indications including amyotrophic lateral sclerosis (ALS), spinocerebellar ataxia (SCA), obsessive compulsive disorder (OCD), Alzheimer’s disease, and neuropsychiatric indications such as Rett syndrome.New Haven, CT | http://biohavenpharma.com

BriovaRx Infusion ServicesBooth 322

BriovaRx Infusion Services is a home infusion care provider serving patients across the U.S. with a national network of pharmacies. We specialize in Immune globulin (IgG), Parenteral Nutrition (PN), Anti-infectives, Biologics, Inotropes and other specialty infusions. Our comprehensive services include specially trained on-staff nurses and pharmacists, around-the-clock clinical support, reimbursement specialists and on-going patient education for safety and comfort.Lenexa, KS | http://www.briovarxinfusion.com

Cadwell Laboratories, Inc.Booth 101

Cadwell has developed USA-made, innovative neurodiagnostic and neuromonitoring equipment since 1979. Our Arc EEG, Sierra EMG/EP, Cascade IONM, Easy III PSG and CadLink data management solutions help you manage efficient workflows, quality data, reliable performance and easy reporting. We are dedicated to helping you help your patients.Kennewick, WA | https://www.cadwell.com

Catalyst PharmaceuticalsBooth 228

Catalyst Pharmaceuticals, Inc., is advancing therapies targeting rare neuromuscular diseases with our lead candidate amifampridine phosphate being studied for Lambert - Eaton Myasthenic Syndrome (LEMS), Congenital Myasthenic Syndromes (PIII enrolling), MuSK Myasthenia Gravis (PIII enrolling), Spinal Muscular Atrophy (POC study), and additionally CP115

for Infantile Spasms. Catalyst has a PDUFA date for the LEMS indication on November 28.Coral Gables, FL | http://www.catalystpharma.com

Corinthian Reference LaboratoryBooth 128

CRL is a commercial diagnostic laboratory specializing in neurological disease detection. We specialize in epidermal nerve fiber density (ENFD) testing. ENFD testing offers patients objective evidence of a neuropathy which can hopefully lead to a more accurate diagnosis. For additional information, please contact Greg Davenport at 480-330-3684.Benbrook, TX | http://www.corinthianreferencelab.com

CSL BehringBooth 211

CSL Behring is a global biotherapeutics leader driven by our promise to save lives. We meet patients’ needs using the latest technologies to develop and deliver innovative biotherapies that are used to treat serious and rare conditions such as CIDP, coagulation disorders, primary immune deficiencies, hereditary angioedema and inherited respiratory disease.King of Prussia, PA | http://www.cslbehring.com

Diplomat Specialty Infusion GroupBooth 100

Diplomat Specialty Infusion Group is a national pharmacy and home infusion services provider specializing in the delivery of immune globulin therapy at home. We provide personalized support and attention to you and your patients, including post-infusion and trended reporting services for autoimmune neuropathies. Learn more atwww.diplomat.is/specialtyinfusion, or call 866.442.4679.Phoenix, AZ | https://www.diplomatpharmacy.com

Dysautonomia InternationalBooth 229

Dysautonomia International is a volunteer-led 501(c)(3) non-profit organization that advocates for dysautonomia patients through research, physician education, public awareness and patient empowerment programs. The Medical Advisory Board is comprised of leading experts in the field of autonomic neuroscience from Mayo Clinic, Harvard Medical School, Vanderbilt University, and beyond.East Moriches, NY | http://www.dysautonomiainternational.org

64

GeneDXBooth 226

GeneDx, a leader in genomics with expertise in rare genetic disorders, offers one of the broadest menus of sequencing services available. GeneDx provides testing to patients in more than 55 countries, and is a business unit of BioReference Laboratories, a wholly owned subsidiary of OPKO Health, Inc.Gaithersburg, MD | http://www.genedx.com

Grifols USA, LLCBooth 220

Grifols is a global healthcare company whose mission is to improve the health and well-being of people around the world. We have three primary divisions – Bioscience, Diagnostic and Hospital – that develop, produce and market our innovative products and services to medical professionals in more than 100 countries around the world.Los Angeles, CA | http://www.grifols.com

HealixBooth 327

Since 1989, Healix® has helped establish and manage hundreds of infusion centers nationwide. We offer simplified, custom solutions for neurologists who want to establish an in-office infusion center or are looking to expand a current operation. We currently provide care for more than 5,000 patients receiving biologic therapies.Learn more at Healix.net/neurologySugar Land, TX | http://www.healix.net

Hereditary Neuropathy FoundationBooth 328

Hereditary Neuropathy Foundation (HNF), an advocacy and research non-profit 501(c)3 dedicated to early and accurate diagnosis of Charcot-Marie-Tooth (CMT) and Inherited Neuropathies (IN). We support patients and families with critical information to improve quality of life, clinical research initiatives and trials to treat CMT/IN.New York, NY | http://www.hnf-cure.org

InfuCare RxBooth 124

InfuCare Rx is a national specialty infusion pharmacy dedicated to providing immunoglobulin therapy (IVIG/SCIG), as well as other infusion services to patients in the comfort of their home. Today, many chronic neuromuscular diseases require specialized infusion therapies to help patients lead a healthy and productive lifestyle. InfuCare Rx provides a consistent, coordinated, patient centric infusion experience through our team of dedicated pharmacists, nurses and other trained professionals. At InfuCare Rx, we strive to provide the optimal outcome with our cost-effective, patient centered approach.Aston, PA | http://www.infucarerx.com

InvitaeBooth 131Invitae’s mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. Our goal is to aggregate most of the world’s genetic tests into a single service with higher quality, faster turnaround time and lower prices. Visit www.invitae.com.San Francisco, CA | https://www.invitae.com

Jett FoundationBooth 425

Jett Foundation meets the needs of patients affected by Duchenne muscular dystrophy through educational programs that empower affected families with the knowledge, support, and resources needed to seek out the highest standard of care, the most cutting-edge and innovative treatments available, and promising clinical trials and scientific advancements.Kingston, MA | https://www.jettfoundation.org

KabaFusion, LLCBooth 433

KabaFusion is patient focused, pharmacist owned, home infusion provider. We are dedicated to working proactively with our patients, healthcare practitioners and payors to provide comprehensive support before, during, and after treatment. KabaFusion has years of experience providing home infusions and is recognized for excellence in the administration of Intravenous Immune Globulin (IVIG) nationwide.Cerritos, CA | http://www.kabafusion.com

65

Kedrion BiopharmaBooth 114

Kedrion Biopharma, an international biopharmaceutical company with corporate headquarters in Tuscany, Italy, specializes in the production of plasma-derived therapies for rare diseases and conditions such as hemophilia and primary immunodeficiency. Kedrion Biopharma’s US headquarters are in Fort Lee, New Jersey with a global presence in about 100 countries.Fort Lee, NJ | http://www.kedrionusa.com

KEGO CorporationBooth 430

KEGO is your one stop shop for all of your EMG, NVC, EEG and Sleep supplies. KEGO carries all major brands to simplify and enhance your shopping experience.Steedman, MO | http://www.kegocorp.com

Kroger Specialty InfusionBooth 121

Kroger Specialty Infusion provides superior service and care to patients requiring Ig Therapy as well as critical Home Infusion Therapy. Because of our superior clinical service, expertise, nursing and patient advocacy, we rapidly gained attention to become one of the leading specialty infusion companies in the nation.Torrance, CA | http://www.krogerspecialtyinfusion.com

Mayo Medical LaboratoriesBooth 231

Mayo Medical Laboratories (MML) is a global reference laboratory operating within Mayo Clinic’s Department

of Laboratory Medicine and Pathology. MML supports neurology practices through comprehensive testing services with specialization in autoimmune, biochemical, and genetic testing. MML also offers muscle and nerve pathology services. Learn more at MayoMedicalLaboratories.com/neurology.Rochester, MN | http://www.mayomedicallaboratories.com

Mitsubishi Tanabe Pharma AmericaBooth 115

At Mitsubishi Tanabe Pharma America, we are passionate about delivering treatment options as quickly as possible to the people who need them. We put patients first and go above and beyond to help those with life-threatening and rare diseases.Jersey City, NJ | https://www.mt-pharma-america.com

National Organization for Rare Disorders, IncBooth 427

NORD, a 501(c)(3) organization, is a patient advocacy organization dedicated to individuals with rare diseases and the organizations that serve them. NORD, along with its more than 280 patient organization members, is committed to the identification, treatment, and cure of rare disorders through programs of education, advocacy, research, and patient services.Danbury, CT | http://www.rarediseases.org

TTR-264 08/18

Industry Forum From Akcea Therapeutics:

Diagnosis Beyond the Symptoms: Bridging the Gap Between Neuropathy and Cardiomyopathy in hATTR AmyloidosisWednesday, October 10 | 7:00 – 8:00 amGaylord National Resort & Conference Center | National Harbor 2-3

Join our expert faculty panel at this industry forum for a discussion on aspects of hereditary transthyretin (hATTR) amyloidosis that set it apart from other peripheral and autonomic neuropathies. This symposium will explore the challenges of this multisystemic disease and provide guidance on how to improve diagnosis and management of patients with hATTR amyloidosis. Breakfast will be provided. We look forward to seeing you there!

Please note that this is a promotional, non-CME program, and no CME credits will be given for attendance. This activity is not part of the official scientific program of the AANEM.

66

Natus NeuroBooth 217

Natus Neuro provides leading solutions for the neurodiagnostic, neurosurgery, and neurocritical care markets. Neurodiagnostic solutions enhance the diagnosis and monitoring of various neurological conditions such as epilepsy, sleep disorders, and neuromuscular diseases. Neurosurgery and neurocritical care solutions limit uncertainty with advanced fluid drainage, shunts and intracranial pressure monitoring systems.Middleton, WI | http://www.natus.com

NeuroPath DxBooth 331

NeuroPath Diagnostics provides Epidermal Nerve Fiber Density Testing for the definitive diagnosis of small fiber neuropathy to help clinicians determine treatment options for their patients. All cases are read by David Saperstein, MD, Board Certified in Neurology, Neuromuscular Medicine, and Electrodiagnostic Medicine.Dallas, TX | www.neuropathdx.com

Nihon Kohden AmericaBooth 409

The MEB-2300 is latest and most innovative EMG/NCS/EP System from Nihon Kohden. Its scalable configuration offers either a six or twelve channel amplifier and up to two electrical stimulators. The MEB- 2300 is designed with advanced software packages and timesaving features to maximize workflow while ensuring data integrity.Irvine, CA | http://www.us.nihonkohden.com

Option CareBooth 127

Option Care offers industry-leading expertise, access, and support in IG home infusion therapy. Each year, we provide more than 80,000 IG home infusions across the country. We are contracted with more than 800 health plans and have a >96% success rate in overturning benefit denials.Bannockburn, IL | http://www.optioncare.com

Understanding the Role Complement Plays in the Disruption of Neuromuscular Transmission in Patients with anti-AChR antibody positive Generalized Myasthenia GravisDATE Thursday, October 11, 2018

LOCATION Potomac A Room Gaylord National Resort & Convention Washington, DC

TIME Registration and Lunch: 12:00pm - 12:15pm Forum: 12:15pm - 1:15pm

Please join us for an open forum discussing the ongoing disease burden in patients with anti-AChR antibody-positive generalized myasthenia gravis, and the role of the complement system in disruption of neuromuscular transmission

FACULTY PRESENTERSJames F. Howard Jr., MDDistinguished Professor of Neuromuscular DiseaseProfessor of Neurology, Medicine, and Allied Health Chief, Neuromuscular Disorders University of North Carolina at Chapel Hill

Jeffrey Guptill, MD, MA, MHSAssociate Professor of Neurology, Duke University School of Medicine

This activity is not part of the official scientific program of the AANEM Annual Meeting

Alexion® is a registered trademark of Alexion Pharmaceuticals, Inc. Copyright © 2018, Alexion Pharmaceuticals, Inc. All rights reserved. US/UNB-gMG/18/0044a

Alexion is committed to complying with all applicable laws and regulations and adhering to the highest standards in its interactions with healthcare professionals. Certain states and federal agencies have reg-ulations or policies that prohibit the receipt of meals at company sponsored events. You are accountable for understanding such restrictions and complying with them. Alexion may restrict your participation in this program. Please note, per industry guidelines, we are unable to accommodate spouses or guests at this event. In order to ensure accurate transparency reporting of meals, Alexion requires program attendees to sign in upon arrival. Subject to all applicable federal and/or state regulations Alexion will, at its discretion, disclose information related to food and beverage provided to you. In most cases, this information will be made public.

67

PharnextBooth 330

Pharnext is an innovative late stage biopharmaceutical company addressing unmet needs of patients living with rare or common neurological diseases. Pharnext is pioneering a new drug discovery paradigm based on big genomic data and artificial intelligence: PLEOTHERAPY™. PXT3003, Pharnext’s lead PLEODRUG™, is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A, results are expected by the end of 2018.Issy-Les-Moulineaux, France | https://www.pharnext.com

Safersonic US, Inc.Booth 326

Safersonic manufactures a family of sterile ultrasound probe covers designed especially for Ultrasound Guided Procedures. Safersonic is the only company offering a 1-foot long cover which is an ideal length for most injections. We eliminate the need for gel under the cover saving time and money. No gel under the cover reduces artifacts and gives better visualization. Additionally, no gel under the cover eliminates transducer damage from cleaning. Available in various lengths for different applications. Fits all transducers. Reduce Inventory. Faster Set-up time and Faster Clean-up. Upgrade your clinical practice, while upgrading patient care. SAVE TIME AND MONEY!Highland Park, IL | https://www.safersonic.com

Sanofi GenzymeBooth 122

Sanofi Genzyme focuses on developing specialty treatments for debilitating diseases that are often difficult to diagnose and treat, providing hope to patients and their families.Cambridge, MA | https://www.sanofigenzyme.com

Sarepta TherapeuticsBooth 423

Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular diseases. The company is primarily focused on rapidly advancing the development of its potentially disease-modifying Duchenne muscular dystrophy (DMD) drug candidates and is proud to support the 2018 AANEM Annual Meeting. For more information about Sarepta, please visit www.sarepta.com.Cambridge, MA | https://www.sarepta.com

ShireBooth 321

Shire is the global leader in serving patients with rare diseases. We strive to develop best-in-class therapies across a core of rare disease areas, supplemented by diversified capabilities in highly specialized conditions. We feel a strong sense of urgency to address the high unmet medical needs of these patient communities.Lexington, MA | https://www.shire.com

PRIMARY PERIODIC

PARALYSISPatient Pathways in Care

Location: Potomac A

Visit Strongbridge Biopharma at

to learn more about this rare

neuromuscular disease

Join us on Friday

For a review of Primary Periodic Paralysis

and a treatment option

Lunch will be provided by AANEM.

This activity is not part of the official scientific program of the AANEM.KEV-0442 08/2018

OCTOBER

12:00pm – 1:15pm

68

SpecialtyCareBooth 329

We hire Neurologists! Physicians and hospitals should always have the best possible means to ensure the most positive patient outcomes, while being able to maintain their own financial health and success. To help our customers achieve this, we are committed to delivering exceptional care outcomes, patient safety, and financial results in more than 1,000 hospitals and health systems, supporting 13,500 physicians during 400,000+ procedures annually. This makes us the market leader in perfusion and intraoperative neuromonitoring, and the industry’s choice for autotransfusion, sterile processing consulting, surgical assist, and minimally invasive surgical support.Brentwood, TN | http://www.specialtycare.net

Stealth BiotherapeuticsBooth 413

Stealth is an innovative biopharmaceutical company developing therapies to treat the mitochondrial dysfunction associated with genetic mitochondrial diseases and many common age-related diseases. Stealth’s mission is to lead the development of mitochondrial medicine to improve the lives of patients with diseases involving mitochondrial dysfunction, an area of high unmet clinical need.Newton, MA | http://www.StealthBT.com

StrongbridgeBooth 201

Strongbridge Biopharma is a global commercial-stage biopharmaceutical company focused on therapies for rare diseases. Strongbridge has the only FDA-approved treatment for hyperkalemic, hypokalemic, and related variants of Primary Periodic Paralysis (PPP). PPP is a group of rare hereditary disorders that causes potentially severe episodes of muscle weakness and/or paralysis.Trevose, PA | http://www.strongbridgebio.com

The Electrode StoreBooth 106

The Electrode Store is an ISO13485-certified manufacturer and distributor of the best supplies for EMG, EEG, and IONM. We offer monopolar and concentric needle electrodes, hypodermic needles for EMG-guided botulinum toxin injections, disposable and reusable surface electrodes, gels, pastes and more, with quick shipping, knowledgeable customer service, and low prices.Enumclaw, WA | https://www.electrodestore.com

Therapath NeuropathologyBooth 227

Provides comprehensive diagnostic and consultative neuropathology services.New York, NY | http://www.therapath.com

US WorldMedsBooth 133

Maker of MYOBLOC (rimabotulinum toxin B) for cervical dystonia.Louisville, KY | http://www.usworldmeds.com

WR Medical Electronics CompanyBooth 123

Autonomic Function Testing at its optimal best. Standardized and well established, WR Testworks systems perform cardiovagal, adrenergic, and sudomotor testing with scientifically validated equipment and exceptional support.Maplewood, MN | https://www.wrmed.com

69

Exhibit HallPresentation

Stage

| Entrance |

70

Visit Booth #315 to find out more about ONPATTRO, the first and only FDA-approved RNAi treatment for the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults.1

For the latest news and updates, sign up at www.onpattro.com/hcp

Reference: 1. ONPATTRO [package insert]. Cambridge, MA: Alnylam Pharmaceuticals, Inc; 2018.

NOW APPROVED

IndicationONPATTRO™ (patisiran) is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

Important Safety InformationInfusion-Related ReactionsInfusion-related reactions (IRRs) have been observed in patients treated with ONPATTRO. In a controlled clinical study, 19% of ONPATTRO-treated patients experienced IRRs, compared to 9% of placebo-treated patients. The most common symptoms of IRRs with ONPATTRO were flushing, back pain, nausea, abdominal pain, dyspnea, and headache.

To reduce the risk of IRRs, patients should receive premedication with a corticosteroid, acetaminophen, and antihistamines (H1 and H2 blockers) at least 60 minutes prior to ONPATTRO infusion. Monitor patients during the infusion for signs and symptoms of IRRs. If an IRR occurs, consider slowing or interrupting the infusion and instituting medical management as clinically indicated. If the infusion is interrupted, consider resuming at a slower infusion rate only if symptoms

have resolved. In the case of a serious or life-threatening IRR, the infusion should be discontinued and not resumed.

Reduced Serum Vitamin A Levels and Recommended SupplementationONPATTRO treatment leads to a decrease in serum vitamin A levels. Supplementation at the recommended daily allowance (RDA) of vitamin A is advised for patients taking ONPATTRO. Higher doses than the RDA should not be given to try to achieve normal serum vitamin A levels during treatment with ONPATTRO, as serum levels do not reflect the total vitamin A in the body.

Patients should be referred to an ophthalmologist if they develop ocular symptoms suggestive of vitamin A deficiency (e.g. night blindness).

Adverse ReactionsThe most common adverse reactions that occurred in patients treated with ONPATTRO were upper respiratory tract infections (29%) and infusion-related reactions (19%).

Please see Brief Summary of Full Prescribing Information on the adjacent page.

ONPATTRO is a trademark of Alnylam Pharmaceuticals, Inc. © 2018 Alnylam Pharmaceuticals, Inc. All rights reserved. TTR02-USA-00010-072018

71

Brief summary of Full Prescribing Information for ONPATTRO™ (patisiran) injection—Please consult Full Prescribing Information.

INDICATIONS AND USAGEONPATTRO is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

DOSAGE AND ADMINISTRATIONGeneral Dosing Information ONPATTRO should be administered by a healthcare professional. ONPATTRO is administered via intravenous (IV) infusion. Dosing is based on actual body weight. For patients weighing less than 100 kg, the recommended dosage is 0.3 mg/kg once every 3 weeks. For patients weighing 100 kg or more, the recommended dosage is 30 mg once every 3 weeks.Missed DoseIf a dose is missed, administer ONPATTRO as soon as possible.If ONPATTRO is administered within 3 days of the missed dose, continue dosing according to the patient’s original schedule. If ONPATTRO is administered more than 3 days after the missed dose, continue dosing every 3 weeks thereafter.Required Premedication All patients should receive premedication prior to ONPATTRO administration to reduce the risk of infusion-related reactions (IRRs) [see Warnings and Precautions (5.1)]. Each of the following premedications should be given on the day of ONPATTRO infusion at least 60 minutes prior to the start of infusion: intravenous corticosteroid (e.g., dexamethasone 10 mg, or equivalent); oral acetaminophen (500 mg); intravenous H1 blocker (e.g., diphenhydramine 50 mg, or equivalent); and intravenous H2 blocker (e.g., ranitidine 50 mg, or equivalent).For premedications not available or not tolerated intravenously, equivalents may be administered orally.For patients who are tolerating their ONPATTRO infusions but experiencing adverse reactions related to the corticosteroid premedication, the corticosteroid may be reduced by 2.5 mg increments to a minimum dose of 5 mg of dexamethasone (intravenous), or equivalent.Some patients may require additional or higher doses of one or more of the premedications to reduce the risk of IRRs [see Warnings and Precautions (5.1)].

CONTRAINDICATIONSNone.

WARNINGS AND PRECAUTIONSInfusion-Related Reactions Infusion-related reactions (IRRs) have been observed in patients treated with ONPATTRO. In clinical studies, all patients received premedication with a corticosteroid, acetaminophen, and antihistamines (H1 and H2 blockers) to reduce the risk of IRRs. In a controlled clinical study, 19% of ONPATTRO-treated patients experienced IRRs, compared to 9% of placebo-treated patients. Among ONPATTRO-treated patients who experienced an IRR, 79% experienced the first IRR within the first 2 infusions. The frequency of IRRs decreased over time. IRRs led to infusion interruption in 5% of patients. IRRs resulted in permanent discontinuation of ONPATTRO in less than 1% of patients in clinical studies. Across clinical studies, the most common symptoms (reported in greater than 2% of patients) of IRRs with ONPATTRO were flushing, back pain, nausea, abdominal pain, dyspnea, and headache [see Adverse Reactions (6.1)]. One patient in the ONPATTRO expanded access program had a severe adverse reaction of hypotension and syncope during an ONPATTRO infusion.Patients should receive premedications on the day of ONPATTRO infusion, at least 60 minutes prior to the start of infusion [see Dosage and Administration (2.2)]. Monitor patients during the infusion for signs and symptoms of IRRs. If an IRR occurs, consider slowing or interrupting the ONPATTRO infusion and instituting medical management (e.g., corticosteroids or other symptomatic treatment) as clinically indicated. If the infusion is interrupted, consider resuming at a slower infusion rate only if symptoms have resolved. In the case of a serious or life-threatening IRR, the infusion should be discontinued and not resumed.Some patients who experience IRRs may benefit from a slower infusion rate or additional or higher doses of one or more of the premedications with subsequent infusions to reduce the risk of IRRs. [see Dosage and Administration (2.2)].Reduced Serum Vitamin A Levels and Recommended SupplementationONPATTRO treatment leads to a decrease in serum vitamin A levels. Supplementation at the recommended daily allowance of vitamin A is advised for patients taking ONPATTRO. Higher doses than the recommended daily allowance of vitamin A should not be given to

try to achieve normal serum vitamin A levels during treatment with ONPATTRO, as serum vitamin A levels do not reflect the total vitamin A in the body.Patients should be referred to an ophthalmologist if they develop ocular symptoms suggestive of vitamin A deficiency (e.g., night blindness).

ADVERSE REACTIONSClinical Trials ExperienceBecause clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of ONPATTRO cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.A total of 224 patients with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) received ONPATTRO in the placebo-controlled and open-label clinical studies, including 186 patients exposed for at least 1 year, 137 patients exposed for at least 2 years, and 52 patients exposed for at least 3 years. In the placebo-controlled study, 148 patients received ONPATTRO for up to 18 months (mean exposure 17.7 months). Upper respiratory tract infections and infusion-related reactions were the most common adverse reactions. One patient (0.7%) discontinued ONPATTRO because of an infusion-related reaction.Table 1: Adverse Reactions from the Placebo-Controlled Trial that Occurred in at Least 5% of ONPATTRO-treated Patients and at Least 3% More Frequently than in Placebo-treated Patients

Adverse ReactionONPATTRO

N=148%

PlaceboN=77

%Upper respiratory tract infectionsa

29 21

Infusion-related reactionb 19 9Dyspepsia 8 4Dyspneac,d 8 0Muscle spasmsc 8 1Arthralgiac 7 0Erythemac 7 3Bronchitise 7 3Vertigo 5 1

a Includes nasopharyngitis, upper respiratory tract infection, respiratory tract infection, pharyngitis, rhinitis, sinusitis, viral upper respiratory tract infection, upper respiratory tract congestion.

b Infusion-related reaction symptoms include, but are not limited to: arthralgia or pain (including back, neck, or musculoskeletal pain), flushing (including erythema of face or skin warm), nausea, abdominal pain, dyspnea or cough, chest discomfort or chest pain, headache, rash, chills, dizziness, fatigue, increased heart rate or palpitations, hypotension, hypertension, facial edema.

cNot part of an infusion-related reaction.dIncludes dyspnea and exertional dyspnea.e Includes bronchitis, bronchiolitis, bronchitis viral, lower respiratory tract infection, lung infection.

Four serious adverse reactions of atrioventricular (AV) heart block (2.7%) occurred in ONPATTRO-treated patients, including 3 cases of complete AV block. No serious adverse reactions of AV block were reported in placebo-treated patients.Ocular adverse reactions that occurred in 5% or less of ONPATTRO-treated patients in the controlled clinical trial, but in at least 2% of ONPATTRO-treated patients, and more frequently than on placebo, include dry eye (5% vs. 3%), blurred vision (3% vs. 1%), and vitreous floaters (2% vs. 1%). Extravasation was observed in less than 0.5% of infusions in clinical studies, including cases that were reported as serious. Signs and symptoms included phlebitis or thrombophlebitis, infusion or injection site swelling, dermatitis (subcutaneous inflammation), cellulitis, erythema or injection site redness, burning sensation, or injection site pain.

USE IN SPECIFIC POPULATIONSPregnancyRisk SummaryThere are no available data on ONPATTRO use in pregnant women to inform a drug-associated risk of adverse developmental outcomes. ONPATTRO treatment leads to a decrease in serum vitamin A levels, and vitamin A supplementation is advised for patients taking ONPATTRO. Vitamin A is essential for normal embryofetal development; however, excessive levels of vitamin A are associated with adverse developmental effects. The effects on the fetus of a reduction in maternal serum TTR caused by ONPATTRO and of vitamin A supplementation are unknown [see Clinical Pharmacology (12.2), Warnings and Precautions (5.2)]. In animal studies, intravenous administration of patisiran lipid complex (patisiran-LC) to pregnant rabbits resulted in developmental toxicity (embryofetal mortality and reduced fetal body weight) at doses that were also associated with maternal toxicity. No adverse

developmental effects were observed when patisiran-LC or a rodent-specific (pharmacologically active) surrogate were administered to pregnant rats (see Data). In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. The background risk of major birth defects and miscarriage for the indicated population is unknown.Data Animal DataIntravenous administration of patisiran-LC (0, 0.15, 0.50, or 1.5 mg/kg) or a rodent-specific (pharmacologically active) surrogate (1.5 mg/kg) to female rats every week for two weeks prior to mating and continuing throughout organogenesis resulted in no adverse effects on fertility or embryofetal development. Intravenous administration of patisiran-LC (0, 0.1, 0.3, or 0.6 mg/kg) to pregnant rabbits every week during the period of organogenesis produced no adverse effects on embryofetal development. In a separate study, patisiran-LC (0, 0.3, 1, or 2 mg/kg), administered to pregnant rabbits every week during the period of organogenesis, resulted in embryofetal mortality and reduced fetal body weight at the mid and high doses, which were associated with maternal toxicity. Intravenous administration of patisiran-LC (0, 0.15, 0.50, or 1.5 mg/kg) or a rodent-specific surrogate (1.5 mg/kg) to pregnant rats every week throughout pregnancy and lactation resulted in no adverse developmental effects on the offspring. Lactation Risk SummaryThere is no information regarding the presence of ONPATTRO in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for ONPATTRO and any potential adverse effects on the breastfed infant from ONPATTRO or from the underlying maternal condition.In lactating rats, patisiran was not detected in milk; however, the lipid components (DLin-MC3-DMA and PEG2000-C-DMG) were present in milk.Pediatric UseSafety and effectiveness in pediatric patients have not been established. Geriatric UseNo dose adjustment is required in patients ≥65 years old [see Clinical Pharmacology (12.3)]. A total of 62 patients ≥65 years of age, including 9 patients ≥75 years of age, received ONPATTRO in the placebo-controlled study. No overall differences in safety or effectiveness were observed between these patients and younger patients, but greater sensitivity of some older individuals cannot be ruled out.Hepatic Impairment No dose adjustment is necessary in patients with mild hepatic impairment (bilirubin ≤1 x ULN and AST >1 x ULN, or bilirubin >1.0 to 1.5 x ULN) [see Clinical Pharmacology (12.3)]. ONPATTRO has not been studied in patients with moderate or severe hepatic impairment.Renal Impairment No dose adjustment is necessary in patients with mild or moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥30 to <90 mL/min/1.73m2) [see Clinical Pharmacology (12.3)]. ONPATTRO has not been studied in patients with severe renal impairment or end-stage renal disease.

Manufactured for: Alnylam Pharmaceuticals, Inc. 300 Third Street, Cambridge, MA 02142 By: Ajinomoto Althea, Inc. 11040 Roselle Street, San Diego, CA 92121ONPATTRO is a trademark of Alnylam Pharmaceuticals, Inc. © 2018 Alnylam Pharmaceuticals, Inc. All rights reserved.

72

AANEM would like to recognize the following organizations for their financial support which was instrumental in making the 2018 AANEM Annual Meeting possible.

Thank you for your commitment to AANEM and this educational initiative. We value your partnership!

THANK YOUAANEM Corporate Supporters

Platinum Plus Support($125,000+)

Gold Support($65,000 - $94,999)

73

Industry Friends (Up to $24,999)

Silver Level Support($45,000 - $64,999)

74

Platinum Gift ($2,500 - $9,999)David Schildmeyer

Gold Gift($1,000 - $2,499)Jitendra Baruah, MDAndrea Boon, MDRandall Braddom, MD, MSMurray Brandstater, MBBS, PhD, FRCP(C)Anthony E. Chiodo, MDHolli Horak, MDJames Leonard, MDJanice Massey, MDJohn Melvin, MD & Carol M. Pate, EdDDianna Quan, MDPerry Richardson, MDYuen So, MD, PhD

Silver Gift($250 - $999)Shawn Bird, MDGregory Carter, MD, MSHarry FendrichRaghav Govindarajan, MDPeter Grant, MDTaylor Harrison, MDLisa Hobson-Webb, MDRobert Irwin, MDJun Kimura, MDMichael Munin, MD

Daniel Phillips, MDDevon Rubin, MDDavid Saperstein, MDZachary Simmons, MDDavid Simpson, DO, MSEric Sorenson, MDChannarayapatna Sridhara, MDJeffrey Statland, MDKathryn Stolp, MD, MSS. Subramony, MDVincent Tranchitella, MDBonnie Weigert, MDFaren Williams, MD

Bronze Gift($50 - $249)Shirlyn Adkins, JDKatharine Alter, MDPrasunamba Amaraneni, MDMaria Arizmendez, MDBassam Bassam, MDBarbara Bess, MDKaren Bontia, MDMilton Calima, MDChing-Chiang (Allen) Chu, MD, PhDBruce Cleeremans, MDPatricia Cook, MDBrian Couri, MDThomas Cowan, MDPhilip Davenport, MSc, MDEduardo De Sousa, MD

Chester Dela Cruz, MDMichael DeMarco, DOJose DeSousa, MDBryan DeSouza, MDUpinder Dhand, MDTimothy Dillingham, MD, MSPeter Donofrio, MDAndrew Dubin, MD, MSRonald Duerksen, MDErik Ensrud, MDEvelia Gomez Wong, MDAndrew Haig, MDSaquib Hanif, MBBS, FCPS(PM&R)Ghazala Hayat, MDSomkiat Hemtasilpa, MDTom and Lynda Henderson James Howard, MDPatrick Huott, MDNelson Hwynn, DOCharles Jablecki, MDShelly JonesShawn Jorgensen, MDVern Juel, MDJeffrey Lemberg, MDKerry Levin, MDTodd Levine, MDCarmen Lopez-Acevedo, MDChristina Marciniak, MDDaniel Menkes, MDDonna Moore, MDMichael Mrochek, MDMatthew Murnane, MD

John Orsini, MDDouglas Pavlak, MDDavid Polston, MDKevin Puzio, MDPatrick Radecki, MDCarlos Rangel, MDMarcel Reischer, MDVeronica Rodriguez, MDMohammad Saeed, MD, MSDonald Sanders, MDMarcy Schlinger, DORobert Smith, MD, PhDMasahiro Sonoo, MD, PhDDavid Sternman, MDRamaswami Sundar, MDJames Teener, MDBryan Tsao, MDSergius TunesLoretta VanEvery, MDJohn Vlattas, MDLouis Weimer, MDJohn Wilson, DOClaire Wolfe, MDNing Yang, MDAmy Zarrin, MD, PhD

Gift (up to $49)Albert Ackil, MDTaimour Alam, MbChb, MRCPIsaac Annan, MD, MPHKenneth Attie, MDRichard Ball, MD, PhD

James Beegan, MDNaoichi Chino, MDLiviu Craciun, MD, PhDGiovanni D’AprileDavid Dickoff, MDDenise DeVitoJose Fernandez, MD, PhDJames Garrison, MDRajesh Gupta, MBBS MSM Faseeh Hadidi, MDKamran Hakimian, MDSusan Hubbell, MD, MSZulfiqar Hussain, MDGoran Jezic, MDPatrick Kortebein, MDSam-Gyu Lee, MD, PhDAaron Levine, MDJose Miro, MDEarnest Murray, MDMichael Polydefkis, MDCaroline Quartly, MD, FRCP(C)Amanda Rabquer, MDPeter Rayis Conor Ryan, MDJenny ShafferBlake Skahan, Rebecca Tanner, MDPierre-Richard Theard, MDGlenn Thomas, MDW. Alaric Van Dam, MDMatthew Wicklund, MDByron Wiley, R.NCS.T, CMA, AATLisa Williams, MD

Donate to the AANEM Foundation at www.aanemfoundation.orgThe AANEM would like to acknowledge the following individuals for their contributions to the AANEM

Foundation in 2018. The AANEM Foundation is a 501(c)(3) nonprofit corporation. Your donation istax-deductible to the extent allowed by law.

Titanium Pledge of $10,000 or greater Francis Lagattuta, MD

THANK YOUAANEM Foundation Contributors(Contributions received between August 1, 2017 - August 17, 2018)Helping advance NM and EDK research and education

Platinum Pledge of $2,500 - $9,999William Pease, MD John Kincaid, MD Kathryn Stolp, MD, MS

Past Board Members Current Board Members Future Board Members

75

The AANEM would like to acknowledge the following individuals for their contributions to the AANEM Advocacy Fund in 2018.

THANK YOUAANEM Advocacy Contributors(Contributions received between August 1, 2017 - August 17, 2018)

Albert A. Ackil, MDIsaac Benjamin Annan, MD, MPHMichele L. Arnold, MDKenneth M Attie, MDRichard D. Ball, MD, PhDJitendra K. Baruah, MDBassam A. Bassam, MDBarbara R. Bess, MDKaren M. Bontia, MDMilton C. Calima, MDNaoichi Chino, MDChing-Chiang (Allen) Chu, MD, PhDThomas B. Cowan, MDLiviu Craciun, MD, PhDGiovanni Antonio D’AprilePhilip A. Davenport, MSc, MDChester R. Dela Cruz, MDMichael DeMarco, DOBryan X. DeSouza, MDJose M. Fernandez, MD, PhDPeter A. Grant, MDRajesh Gupta, MBBS MSHope S. Hacker, MDM Faseeh Hadidi, MDKamran Hakimian, MDGhazala Riaz Hayat, MDSomkiat Hemtasilpa, MDAna M Hess, CNCT, R.NCS.TLisa D. Hobson-Webb, MDMelvin Landon Hughes, R.NCS. T, R. EEG. T.Nelson H. Hwynn, DOShawn Jorgensen, MDJohn C. Kincaid, MDSam-Gyu Lee, MD, PhDJames A. Leonard, MDAaron Martin Levine, MDWilliam J. Litchy, MDLorri J. Lobeck, MDChristina M. Marciniak, MDJoseph H. Mayer, MD

Daniel L. Menkes, MDJose Francisco Miro, MDMichael J. Mrochek, MDMichael C. Munin, MDEarnest Lee Murray, MDPushpa Narayanaswami, MBBS, DMLaura D. Nist, MDThe Neurology Center of Southern California John A. Orsini, MDDouglas M. Pavlak, MDTimothy Pettingell, MDDaniel Phillips, MDKevin J. Puzio, MDAmanda Rabquer, MDPeter RayisVeronica Rodriguez, MDMohammad A. Saeed, MD, MSDavid S. Saperstein, MDDrasko Simovic, MDDavid A. Simpson, DO, MSDavid John Sinclair, MDDavid Sternman, MDBharathi Swaminathan, MDJayson H. Takata, MDFaye Y. Tan, MDVincent J. Tranchitella, MDBryan E. Tsao, MDEroboghene E. Ubogu, MDW. Alaric Van Dam, MDVettaikorumakankav Vedanarayanan, MD, FRCPCJohn S. Vlattas, MDRobert S. Wallach, DOBenjamin S. Warfel, MDDouglas A. Wayne, MDLouis H. Weimer, MDMatthew P. Wicklund, MDByron Alan Wiley, R.NCS.T, CMA, AATJohn E. Wilson, DOAmy R. Zarrin, MD, PhDMark J. Zuckerman, MD

76

Annual Meeting Coordination CommitteeAnthony E. Chiodo, MD, MBA, Co-ChairRobert W. Irwin, MD, Co-ChairIleana Howard, MDMonika Krzesniak-Swinarska, MDRuple S. Laughlin, MDJau-Shin Lou, MD, PhD, MBAWilliam S. Pease, MDGordon Smith, MDEric J. Sorenson, MD

Neuromuscular Update Course CommitteeRuple S. Laughlin, MD, ChairBassam A. Bassam, MDKevin Brenzy, DOJames B. Caress, MDAmtul S. Farheen, MDJustin Y. Kwan, MDTodd D. Levine, MDZachary N. London, MDMargherita Milone, MD, PhDDustin Nowacek, MDAndrew J. Skalsky, MDNizar Souayah, MDVettaikorumakankav Vedanarayanan, MD, FRCPCSumit Verma, MDAmanda L. Witt, MD

Special Interest Group/Symposia CommitteeJau-Shin Lou, MD, PhD, MBA, ChairWilliam Filer, MDE. Matthew Hoffman, DO, PhDStanley Iyadurai, MD, PhD, MScVita G. Kesner, MD, PhDJustin Y. Kwan, MDAmanda C. Peltier, MD, MSDivisha Raheja, MDPerry K. Richardson, MDEricka P. Simpson, MDLoretta M. VanEvery, MD

Technologist Education CommitteeShawn J. Bird, MD, Co- ChairKim B. Butler, CNCT, Co-ChairSamuel M. Bierner, MDArun K. Chandok, MDCandise Dolan, R.EEG.T, R.NCS.T, CNCTMark A. Ferrante, MDJerry Morris, CNCTLynn Sigston, CNCTTeresa Spiegelberg, CNCTLoretta M. VanEvery, MDAgnes Wallbom, MD, MS

Ultrasound CommitteeMonika Krzesniak-Swinarska, MD, ChairAndrea J. Boon, MDLester S. Duplechan, MDLisa D. Hobson-Webb, MDPeter Inkpen, MDShawn Jorgensen, MDJulia Reilly, MDSarada Sakamuri, MDElena Shanina, MDJeffrey A. Strakowski, MD

Workshop CommitteeIleana Howard, MD, ChairKatharine E. Alter, MDSaid R. Beydoun, MDKathleen H. Burgess, MDJeffrey G. Jenkins, MDMohamed Kazamel, MDAnn A. Little, MDDaniel L. Menkes, MDFrancis Renault, MDMary J. Russo, CNCTRenee A. Schwarz, CNCTYedatore S. Venkatesh, MD

Acknowledgments & AppreciationThe AANEM Annual Meeting involves countless hours of planning, coordination, and execution, and takes a variety of people behind the scenes to make it happen. AANEM would like to thank the following committee and staff members for their contributions to the 2018 meeting.

AANEM StaffShirlyn A. Adkins, JD

Executive Director

Mary Kay CostelloAssoc. Executive/HR Support

Scott GerdesFinance Director

Kathleen HaaseEducation & Meeting Director

Shelly JonesCorporate Relations & Foundation

Director

Whitney LuttekeCommunications & Graphic

Designer

Ruth MichelAdministrative/Membership

Specialist

Christy OgdenSr. Project Coordinator, Education

Jay SchwinefusMarketing & Membership Director

Millie Suk, JD, MPPHealth Policy Director

Jacob SokolIT Director

Gwenda TiegenSr. Education Coordinator

Anna Vredenburg Professional Standards Sr.

Coordinator

Gretchen WilliamsonCommunications & Membership Sr.

Coordinator

Carrie Winter, RHIA Health Policy Manager

77

PresidentEric J. Sorenson, MD

Secretary-TreasurerHolli A. Horak, MD

President-ElectAnthony E. Chiodo, MD

Past PresidentWilliam S. Pease, MD

DirectorsMichael C. Munin, MD Dianna Quan, MDDevon I. Rubin, MDYuen T. So, MDFaye Y. Tan, MDBonnie J. Weigert, MD

Resident/Fellow Leadership LiaisonsMegan E. Clark, MDSarah Yang, MD

2017 - 2018Board of Directors The AANEM’s volunteer Board of Directors is responsible for the association’s strategic planning, policy creation, financial oversight, and executive director supervision.

AANEM ANNUAL BUSINESS MEETINGThe AANEM Business Meeting will be held after

the President’s Address, during Plenary 1.

At this meeting, members will have the opportunity to vote and hear about recent

activities of importance to membership including a report on AANEM’s finances. Nominations

for the Board will be presented. AANEM fellow and active members are especially encouraged

to attend.

AANEM’s Ultra EMG ProgramFebruary 13-16, 2019 | San Diego, California

Enhance your knowledge of ultrasound and EMG!

HistorianJohn C. Kincaid, MD

Executive DirectorShirlyn A. Adkins, JD

Learn from Leading Experts

Chair: Jeffrey A. Strakowski, MD Katharine E. Alter, MD

Albert C. Clairmont, MDDaniel Dumitru, MD, PhDLisa D. Hobson-Webb, MD

Jon A. Jacobson, MDJun Kimura, MD

William S. Pease, MD Erik V. Stälberg, MD, PhD

Registration OpensNovember 1

www.aanem.org/ultraemg

Objectives1. Review the fundamentals

and basis of EDX medicine techniques.

2. Determine the best electrophysiologic tests for evaluating peripheral neuropathies and other NM conditions.

3. Review detailed peripheral nerve, MSK, and other relevant anatomy of the upper and lower limbs, including appearance on US.

4. Observe, practice and improve skills with fundamental and advanced techniques in electrophysiology, MSK and NM US, and chemodenervation.

5. Review and practice EMG waveform identification.

6. Learn image optimization with high frequency US.

7. Learn the clinical value of high frequency US with basic and complex MSK and NM conditions.

8. Evaluate and improve report writing.

9. Review and practice appropriate muscle selection for chemodenervation.

10. Review challenging cases incorporating both EDX and US.

11. Review advancements in technology for assessing MSK and NM disorders.

The AANEM is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The AANEM designates this live activity for a maximum of 26 AMA PRA Category 1 Credits TM. Physicians should claim credit commensurate with the extent of their participation in the activity.

78

AANEM: American Association of Neuromuscular & Electrodiagnostic MedicineABMS: American Board of Medical SpecialtiesABPN: American Board of Psychiatry & NeurologyABPMR: American Board of Physical Medicine & PehabilitationALS: Amyotrophic lateral sclerosisATE: Ask the expertsATTR: Amyloid transthyretinCGC: Certified Genetic CounselorCIDP: Chronic inflammatory demyelinating polyradiculoneuropathyCK: Creatine kinaseCMAP: Compound muscle action potentialCNP: Clinical neurophysiologyCTS: Carpal tunnel syndromeED: Erectile dysfunctionEDX: ElectrodiagnosticEMG: ElectromyographyGAA: Acid alpha-glucosidaseGBS: Guillain-Barré syndromeHRDB: Heart rate variation during deep breathingHIV: Human immunodeficiency virusIOM: Intraoperative monitoringLGMD: Limb-girdle muscular dystrophyMEP: Motor evoked potentialMG: Myasthenia gravisMGFA: Myasthenia Gravis Foundation of AmericaMND: Motor neuron disorderMRI: Magnetic resonance imagingMSK: MusculoskeletalMUAP: Motor unit action potentialMUNE: Motor unit number estimatesNAP: Nerve action potentialNCS: Nerve conduction studyNM: NeuromuscularNMDs: Neuromuscular disordersNMJ: Neuromuscular junctionPMR: Physical medicine & rehabilitationQ-SART: Quantitative sudomotor axon reflex testQST: Quantitative sensory testRNS: Repetitive nerve stimulationSCS: Sports Certified SpecialistSEP: Somatosensory evoked potentialSFEMG: Single-fiber electromyographySIG: Special interest groupSSR: Sympathetic skin responseTOS: Thoracic outlet syndromeTST: Thermoregulatory sweat testTTS: Tarsal tunnel syndromeUS: Ultrasound

InitialismsAbraham, Alon, 20Abu Rub, Mohammad, 44Allen, Jeffrey A., 38, 45Amato, Anthony A., 27Andary, Michael T., 24Annaswamy, Thiru M., 42Avila, Jose David, 23Barkhaus, Paul E., 21Bassam, Bassam A., 25, 41, 47 Baute, Vanessa, 25, 46 Beydoun, Said R., 28, 41, 44Bierner, Samuel M., 42Biliciler, Suur, 30, 32 Bird, Shawn J., 32Boon, Andrea J., 17Boulis, Nicholas M., 46Bromberg, Mark B., 32Bryan, Wilson W., 14, 40 Bullock, Melody, 45Cartwright, Michael S., 17, 23, 30, 33 Chawla, Jasvinder P., 20, 46 Chiodo, Anthony E., 48Choi, Joseph M., 16Christiansen, Dane, 45Clifford, Katherine, 20Crawford, Thomas O., 43Dastgir, Jahannaz, 39Dawodu, Segun T., 23De Sousa, Eduardo A., 23Del Toro, David R., 25, 36 Dillingham, Timothy R., 29Dimachkie, Mazen M., 20Dimitrova, Alexandra K., 39Dolan, Candise, 32Donofrio, Peter D., 37Doss, William L., 19Doughty, Christopher, 20Dubin, Andrew H., 24Dumitru, Daniel, 18Duplechan, Lester S., 22Dyck, P James B., 19Edinger, Jason M., 23Edmundson, Christyn, 32Ensrud, Erik R., 35, 38, 43Ferrante, Mark A., 37, 43, 47 Filer, William, 43Forrest, Elizabeth G., 17Ganguly, Karunesh, 33Gilchrist, James M., 21

Speaker Index

79

Speaker Index continued

Gonzalez-Duarte, Alejandra, 27Govindarajan, Raghav, 34Grant, Peter A., 28Gronseth, Gary S., 28, 34 Guidon, Amanda C., 20, 38 Guptill, Jeffrey, 31Gwathmey, Kelly G., 16Haig, Andrew J., 18Han, Jay J., 20Hanna, Mazen, 27Harms, Matthew B., 14, 31, 34, 36 Harrison, Taylor B., 33Hayat, Ghazala R., 21, 25 Heiman-Patterson, Terry, 23Helkowski, Wendy M., 33Hobson-Webb, Lisa D., 23, 30, 37 Hochberg, Leigh R., 33Hoffman, E. Matthew, 21, 45 Holland, Venessa, 43, 44Howard, Ileana, 35Howard, Jr., James F., 31Irwin, Robert W., 26Izenberg, Aaron, 16Janssen, Mariska, 20Johnson, Nicholas E., 32Jorgensen, Shawn, 19, 30, 33 Kaminski, Henry J., 20Kassardjian, Charles D., 20Katirji, Bashar, 17, 43 Kazamel, Mohamed, 22, 23, 32, 41 Kersey, Cameron, 22Kesner, Vita G., 46Khanna, Ashish, 18Kimura, Jun, 22, 33, 35, 38, 46 Kincaid, John C., 23Klein, Christopher J., 32, 42 Kolb, Noah A., 32Krzesniak-Swinarska, Monika, 47Kusner, Linda L., 20Kwan, Justin Y., 30, 32 Lagattuta, Francis P., 24, 47 Lancaster, Eric, 26Larkin, Mark, 39Laughlin, Ruple S., 17Law, Nancy, 19Levin, Kerry H., 29, 33 Levine, Todd D., 41

Li, Yingkai, 20Liewluck, Teerin, 32Little, Ann A., 19Liu, Weibin, 20London, Zachary N., 17Lou, Jau-Shin, 28, 44 Lugo, Estela, 39Massey, Janice M., 27, 39 McDonald, Craig M., 14, 48 Medne, Livija, 36Mercelis, Rudolf, 20Miller, Matthew E., 48Miller, Timothy M., 14, 31 Milone, Margherita, 17, 32, 42 Mnatsakanova, Diana, 23Moore, Allison, 39Morris, Jerry, 23, 42 Munin, Michael C., 21, 25 Muppidi, Srikanth, 20Naddaf, Elie, 21, 44 Narayanaswami, Pushpa, 34Nicholson, Katharine, 17Niu, Zhiyv (Neal), 42Norbury, John W., 19, 22, 24, 33, 35 Nussbaum, James, 39O’Connor, Kevin, 20Pal, Andrea, 39Pasnoor, Mamatha, 34Pasquina, Paul F., 43Patel, Atul T., 23, 29, 48 Pearson, Steven D., 14, 40 Pease, William S., 21Peltier, Amanda C., 24, 27, 34, 35 Phan, Cecile L., 30Polston, David W., 24Polydefkis, Michael J., 26Preston, David C., 23Punga, Anna R., 19Quan, Dianna, 33, 39 Raabe, Winfried A., 29Raheja, Divisha, 46Raja, Shruti, 20Reece, David, 48Rezania, Kourosh, 46Richardson, Perry K., 44Robinson, Lawrence R., 25, 30, 35, 36

Rosenfeld, Jeffrey, 23Rowin, Julie, 39Rubin, Devon I., 18, 29 Sakamuri, Sarada, 22Salajegheh, Mohammad K., 16, 44 Saporta, Mario, 34Shaibani, Aziz, 37Shanina, Elena, 19, 25 Shieh, Perry B., 41, 43 Shook, Steven J., 18, 47 Simmons, Zachary, 30Simpson, Ericka P., 34, 43, 44 Singer, Adam, 46Singleton, John R., 34Smith, A. Gordon, 14, 17, 26 Smith, Edward C., 43Smith, Jonathan K., 48Sorenson, Eric J., 26, 31, 40, 48 Spiegelberg, Teresa, 19, 38 Strakowski, Jeffrey A., 17, 21, 25, 33, 42, 47 Strommen, Jeffrey A., 45Suk, Millie, 27, 35, 45 Sumner, Charlotte J., 26Tan, Faye Y., 17Tavee, Jinny, 39Teener, James W., 19Thomas, Florian, 39Tsao, Bryan E., 43Tyler, Dustin, 43VanEvery, Loretta M., 29Varadhachary, Arun, 22Vedanarayanan, Vettaikorumakankav, 18Verma, Aparajitha K., 43, 44 Vernino, Steven, 46Vu, Tuan H., 45Walker, Francis O., 24, 27 Walsh, Edward, 19Weigert, Bonnie J., 25, 39 Witt, Amanda L., 41Wolfe, Gil I., 20Zhou, Lan, 28

80

Through cutting-edge science, Biogen discovers, develops and delivers to patients worldwide therapies for the treatment of neurodegenerative and rare diseases.

We’re proud to sponsor AANEM

WWW.BIOGEN.COM

©2017 Biogen. All rights reserved • 10/17 SMA-US-0259 • 225 Binney Street, Cambridge, MA 02142

2301_SMA Ad Template v0.2.indd 1 8/20/18 5:17 PM

81

IGI-0108-AUG18

This symposium is organized and sponsored by CSL Behring. Biotherapies for Life® is a registered trademark of CSL Behring LLC.

This activity is not part of the official scientific program of the AANEM

CIDP Treatment:Patients, Practicalities, and Perspectives

Saturday, October 13, 2018, (7:00 AM – 8:00 AM)AANEM 2018Gaylord National Resort & Convention Center, National Harbor, MDPotomac Ballroom ASecond level in the Gaylord Conference SpaceChair: Dr. Jeffrey A. Allen

Agenda6:45‒7:00 Arrival

7:00‒7:05 Welcome Jeffrey A. Allen

7:05‒7:30 Update on the Diagnosis and Jeffrey A. Allen Treatment of CIDP

7:30‒7:40 A Patient’s Perspective Tuan H. Vu and Appolos L.

7:40–7:50 Subcutaneous Immunoglobulin Melody Bullock Administration: Practicalities

7:50–8:00 Q&A and Closing Remarks Jeffrey A. Allen and all speakers

8:00 Close of Symposium

Meeting ObjectivesThe 2018 annual meeting will focus on improving patient care, medical knowledge, interpersonal communication, professionalism, and systems-based practices and attendees will (1) explain the pathophysiology of NM diseases in reference to new and novel therapeutic targets; (2) describe the drug development pathway leading to the present day novel therapies; (3) identify the impact on EDX testing on achieving proper NM diagnoses; (4) relate the social and societal impact of expensive novel therapies for rare NM diseases; and (5) differentiate the emerging rehabilitative challenges of progressive and fatal diseases as they transition to chronic conditions.

Accreditation StatementThe AANEM is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA Credit Designation StatementThe AANEM designates this live activity for a maximum of 22.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The Royal College of Physicians & Surgeons of CanadaActivities held outside of Canada developed by a university, academy, specialty society or other physician organization can be recorded as accredited group learning activities under Section 1 of the Royal College of Physicians and Surgeons of Canada’s Maintenance of Certification (MOC) Program. The AANEM is a physician organization accredited by the ACCME at the end of December.

Self-Assessment CreditFive courses at the 2018 annual meeting will be designated to offer Part II MOC Self-Assessment credit for physicians. AANEM will report completion of this self-assessment activity to ABPN and ABPMR.

Disclaimer StatementAANEM will disclose to learners the relevant financial relationships for those in control of CME content prior to the educational activity or disclose that there were no relevant financial relationships. Information will be provided through print and verbal disclosures.

AANEM Annual Meeting Refund PolicyThe association dedicates a significant amount of time and expense to deliver a great annual meeting each year. While we hope everyone who registers for the annual meeting will be able to attend, we understand that circumstances may sometimes prevent this from happening. AANEM has established the following refund policy for those who request a refund.

Refund requests received from 13 days, through the start of onsite registration, will be subject to a $150 cancellation fee and any remaining amount will be credited toward future AANEM purchases (credit expires 2 years after the first day of the annual meeting). Registration fees will not be refunded after the start of onsite registration*.

*Individual workshops, events, or sessions that were purchased in addition to the standard registration fee may be cancelled during the meeting, as long as the attendee has not cancelled their standard meeting registration. A refund of 50% of the purchase price will be provided. The ticket must be returned to the registration desk to receive a refund.

AANEM CME ProgrammingIt is the policy of the AANEM to ensure balance, independence, objectivity and scientific rigor in all of its educational activities. This program is for scientific and educational purposes only and will not, directly or indirectly, promote the interests of any commercial interest. All CME sessions that are offered as part of the official AANEM Annual Meeting program are developed and implemented solely by the AANEM Annual Meeting education planning committees and the AANEM staff. Education planning committees are responsible for: identifying educational needs and gaps between current and ideal performance, competencies and patient outcomes; determining teaching methods; selecting presentation topics, choosing faculty, establishing objectives; and determining format for the presentation of content. Educational materials cannot contain any advertising, corporate logo, trade name, or product-group message. All scientific research referred to, reported or used in support of justification of a patient care recommendation will conform to generally accepted standards of experimental design, data collection and analysis. Speakers are requested to provide a balanced view of therapeutic options, using generic names in presentations to contribute to impartiality. If content includes trade names, speakers are instructed to incorporate the trade names from several companies.

Specific disclosure information for all speakers, planning committee members and course chairs participating in the 2018 Annual Meeting is provided in the Disclosure Index at the registration desk or online at www.aanem.org/disclosures.

Industry ForumsIndustry Forums are commercially supported educational activities held in conjunction with the AANEM Annual Meeting. These satellite symposia sessions are not part of the AANEM’s official annual meeting program and are planned by an outside company or party. These sessions are clearly labeled as Industry Forums to allow the participant to be fully aware of any bias in the presentations. Seating at sessions is limited, and food is provided by the AANEM to Industry Forum attendees on a first-come, first-served basis.

TreatingCIDP?

© 2018 Grifols All rights reserved October 2018 US/GX/0716/0343(1)a(1)

Visit Grifols booth #220 to learn more

As a fellow, you can become a

CIDP AMBASSADORCome to the Grifols booth #220 or visit rrnmf.com to learn about our fellows Ambassador Program that takes place in January 2019 and see the diff erence we’re making in the treatment of CIDP.

GM-9967_AANEM_Full_Page_Ad_v5DR.indd 1 8/10/18 11:30 AM

Documents

WE’VE COME SINCE MENDEL - AANEM